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IntroductIon:
Molecular subtypes of glIoMas
Lonneke A.M. Gravendeel1 and Pim J. French1
1Department of neurology, Erasmus Medical Center, 
Rotterdam, The Netherlands.
Tumors of the central nervous system part II (book). 
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Gliomas are the most common type of primary brain tumors in adults with an incidence 
rate of 5.27 per 100.000 patients every year 1-2. In 1926, Bailey and Cushing suggested a 
classification model based on distinct histological morphologies 3, which forms the basis of 
the currently used WHO classification 1. Two major subtypes are recognized: Astrocytic (A) and 
oligodendrocytic (OD) tumors, the latter including pure OD tumors and mixed oligoastrocytic 
(MOA) tumors. Astrocytic tumors are further separated into grades I (pilocytic astrocytomas 
[PA]), II (low grade), III (anaplastic), and IV (glioblastoma [GBM]). Oligodendrocytic tumors 
are further separated into grades II (low grade) and III (anaplastic). Patient survival, time to 
tumor progression, and response to therapy are all associated with subtype and grade of the 
tumor 1. This classification model, combined with the patients’ prognostic features (e.g. age 
and Karnofsky Performance Score [KPS]), guides treatment decisions. 
Differences between histological subtypes are very subtle, and classifying gliomas is subject 
to a large interobserver variability 4-7. Clearly, this variability can result in misdiagnosis of gliomas, 
for example by assigning a prognostically favorable lower-grade glioma into a poor prognostic 
glioma (e.g. “false-positive GBM”), and in assigning a prognostically less favorable higher-grade 
glioma into a good prognostic glioma (e.g. “false-negative GBM”). Since treatment protocols 
often dependon the diagnosed histological subtype, accuracy in diagnosis is very important 
for patients in order to get optimal treatment 6. Therefore, more accurate methods to diagnose 
gliomas are urgently required.
The molecular characteristics of gliomas have been studied extensively over the last years, in 
order to provide more objective and accurate methods of identifying distinct molecular tumor 
subgroups, and to identify specific molecular tumor markers that can help diagnosis. In the 
future, these molecular features may also be used to develop personalized targeted therapy.
SINGLE MOLECULAR MARKERS IN GLIOMAS
LOH 1p19q
Loss of heterozygosity (LOH) of 1p19q is a chromosomal aberration that is strongly associated 
with classical ODs 8-10. Determination of the 1p19 status in gliomas is clinically relevant because of 
two important features. First, gliomas with LOH of 1p19q generally grow more slowly than most 
other gliomas and therefore have a better prognosis. Second, the presence of this mutation 
is predictive for response to treatment with alkylating agents such as PCV (procarbazine, 
lomustine, and vincristine) 11-12. However, many glial tumors benefit from alkylating agents at 
some level. Nevertheless, 1p19q status is a strong prognostic factor, and the presence or absence 
of 1p and 19q is currently tested for in patients with a tumor containing oligodendroglial features.
IDH1
Recently, somatic mutations in the gene encoding isocitrate dehydrogenase 1 (IDH1) have been 
identified in gliomas 13. IDH1 mutations occur mainly in lower grade gliomas and in secondary 
GBMs and are therefore thought to be early events in glioma genesis 14. Interestingly, glioma-
specific mutations in IDH1 always affect the amino acid arginine in position 132 of the amino 
acid sequence, which belongs to an evolutionary highly conserved region located at the 
binding site for isocitrate 13,15. The most frequent mutation occurring in this region is the R132H 
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mutation (>90%), but other variants also have been found (R132S, R132C, R132G, and R132L) 15-16. 
Interestingly, non-R132H mutations segregate in distinct histological and molecular subtypes of 
glioma 14,16. Histologically, non-R132H mutations occur sporadically in classic oligodendrogliomas 
and at significantly higher frequency in other grade II and III gliomas. Genetically, non-p.R132H 
mutations occur in tumors with TP53 mutation, are virtually absent in tumors with LOH on 1p and 
19q and accumulate in distinct (gene-expression profiling based) intrinsic molecular subtypes 16-17. 
Importantly, IDH1 mutations are associated with improved prognosis 13,18. Therefore 
IDH1 mutation status is likely to be used as a prognostic molecular marker in the near 
future. Additionally, two studies have examined whether IDH1 mutation status can predict 
response to treatment in gliomas. In a group of patients with dedifferentiated low-grade 
astrocytomas progressive after radiotherapy response to TMZ did not differ between IDH1 
mutant and wild-type tumors 19. In patients with anaplastic oligodendroglial tumors treated 
with radiotherapy alone or radiotherapy with adjuvant PCV, IDH1 mutations reported had no 
predictive value for response 20.
MGMT
The O6-methylguanine-DNA methyltransferase (MGMT) gene encodes for the nuclear repair 
enzyme alkyltransferase, which removes alkylating adducts from the O6 position of thymine. By 
doing this, the enzyme is involved in maintaining the integrity of the DNA. More specifically, 
the product of the MGMT gene protects the cells from being damaged by alkylating and 
methylating agents (e.g. BCNU [N,N[prime]-bis(2-chloroethyl)-N-nitrosourea], procarbazine 
and TMZ).
In gliomas, the CpG islands located in the promotor of the MGMT gene are frequently 
methylated, causing “epigenetic” silencing of this gene. Theoretically, this methylation would 
result in a greater susceptibility for alkylating and methylating agents. In daily practice, the 
meaning and implications of the MGMT status are more difficult to interpret. Several studies 
showed that the epigenetic silencing of the MGMT gene is of clinical importance, because 
its association with increased survival and better response to combined chemo-irradiation in 
GBMs 21-22. It was shown that the effect of the MGMT silencing was especially present when TMZ 
was used as chemotherapy 22. Other studies showed that the time of administering the TMZ 
seemed to be crucial. One study showed that a positive effect of the methylated MGMT gene on 
survival was only seen if TMZ was administered at the time of radiation, while other studies showed 
positive effects when administering TMZ before or after irradiation 23-25. Interestingly, a recent 
study showed that MGMT promotor methylation in GBMs was a predictor for better response 
to radiotherapy, and a prognostic marker even in patients not receiving adjuvant alkylating 
chemotherapy 26. This study suggests that MGMT might be a general favorable prognostic factor 
in GBMs, instead of being a predictive marker for response to alkylating chemotherapy. 
Another issue that makes it difficult to interpret the role of MGMT, is that there are several 
different approaches in the assays for measuring the MGMT promotor methylation. These 
different approaches cause variable results, which are difficult to compare. MGMT activity can 
be measured using immunohistochemistry, but also using Q-pcr, or promotor methylation 
assays. Also, differences in outcome arise using assays on frozen tissue as well as on paraffin 
samples, as well as by possible interobserver-variability. In conclusion, MGMT status is thought 
to be an important biomarker in gliomas.
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GENOME WIDE MOLECULAR MARKERS IN GLIOMAS
Several techniques have been developed to perform genome wide analysis of the tumors’ 
epigenome, genome or transcriptome. Whilst markers for glioma have been identified on all 
levels 27, this review will discuss the molecular markers identified by the tumor’s transcriptome, that 
are currently used (or show promise to aid) in clinical decision making. Gene expression profiling 
involves the measurement of the activity (the expression) of thousands of genes at once. In general, 
gene expression profiling is performed using microarrays; chips that containthe complementary 
sequence to thousands of target mRNA sequences. mRNA isolated from tumor samples is 
processed and labeled and subsequently hybridized to the microarray. The signal extracted from 
the microarray is a measure of gene expression levels, which is visualized using fluorescence. 
Expression profiling can be used to identify molecular subtypes of tumors roughly by 
two methods: Supervised and unsupervised. Supervised clustering uses external information 
to separate tumors into predefined subgroups (e.g. responders vs. non-responders; long 
vs. short-survivors), and then specifically screens for genes that are differentially expressed 
between these groups. In contrast, unsupervised clustering does not use external information 
and thus classifies tumors based on homologies in gene expression profiles. 
One of the first large studies that used supervised clustering (on survival) has identified three 
large subtypes of glioma with distinct prognosis. Subtypes were named according to the signature 
of the genes they predominantly expressed: Proneural, Mesenchymal and Proliferative subtypes 28. 
These subtypes have also been identified in GBM using unsupervised methods 29. A different 
supervised study identified genes associated with response to treatment 30. Most often however, 
supervised clustering has been used to define gene expression signatures based on histological 
subtypes 31. 
Thusfar, only threegroups have performed unsupervised analysis to define “intrinsic” 
molecular subgroups of gliomas  17,29,32. In all cases, the unsupervised clusters identified more 
subtypes of gliomas than histology. The molecular clusters correlate better with survival than 
histology 17,31-32. Therefore, molecular clustering provides an objective and more accurate method 
to classify gliomas, and may even be used to predict patients’ prognosis. The molecular clusters 
all contained a wide variety of histological subtypes. The fact that different histological subtypes 
were assigned to the same molecular cluster means that these phenotypically different tumors 
have a similar genetic composition. Indeed, two independent studies have demonstrated that 
genetic changes segregate into distinct molecular subtypes indicating that causal genetic change 
drives a distinct pattern of gene expression 16-17,29.
For example, gliomas of different histological subtypes with LOH of 1p19q are accumulating 
within one distinct molecular profile, regardless of their histological appearance, showing 
significant longer survival times than other molecular subgroups 17. These findings imply that 1p19q 
status should be determined in all histological subtypes of gliomas, instead of testing this mutation 
in oligodendroglial-like tumors only. 
In the future, the specific genetic features of molecular glioma subgroups can be used to 
improve diagnosis, to give a more accurate prognosis, as well as todevelop personalized therapies. 
It is likely that each molecular glioma subgroup will benefit from its own specific treatment based on 
the specific underlying molecular pathways and markers. Novel randomized controlled trials should 
take these molecular clusters into account when comparing different therapy regimens in gliomas. 
11
REFERENCES
1. Louis DN, Ohgaki H, Wiestler OD, et al: WHO 
Classification of Tumours of the Central 
Nervous System, in Bosman FT, Jaffe ES, La-
khani SR, et al (eds): (ed 4th). Lyon, 2007
2. Ohgaki H, Dessen P, Jourde B, et al: Genet-
ic pathways to glioblastoma: a population-
based study. Cancer Res 64:6892-9, 2004
3. Bailey P, Cushing HW: A Classification of the 
Tumors of the Glioma Group on a Histoge-
netic Basis with a Correlated Study of Prog-
nosis. Philadelphia, J. B. Lippincott, 1926
4. Hildebrand J, Gorlia T, Kros JM, et al: Adju-
vant dibromodulcitol and BCNU chemo-
therapy in anaplastic astrocytoma: results 
of a randomised European Organisation for 
Research and Treatment of Cancer phase 
III study (EORTC study 26882). Eur J Cancer 
44:1210-6, 2008
5. Kros JM, Gorlia T, Kouwenhoven MC, et al: 
Panel review of anaplastic oligodendrog-
lioma from European Organization For Re-
search and Treatment of Cancer Trial 26951: 
assessment of consensus in diagnosis, in-
fluence of 1p/19q loss, and correlations with 
outcome. J NeuropatholExpNeurol 66:545-
51, 2007
6. Murphy M, Loosemore A, Ferrer I, et al: Neu-
ropathological diagnostic accuracy. Br J 
Neurosurg 16:461-4, 2002
7. Scott CB, Nelson JS, Farnan NC, et al: Central 
pathology review in clinical trials for patients 
with malignant glioma. A Report of Radia-
tion Therapy Oncology Group 83-02. Cancer 
76:307-13, 1995
8. Jenkins RB, Blair H, Ballman KV, et al: A t(1;19)
(q10;p10) mediates the combined deletions 
of 1p and 19q and predicts a better prognosis 
of patients with oligodendroglioma. Cancer 
Res 66:9852-61, 2006
9. Griffin CA, Burger P, Morsberger L, et al: 
Identification of der(1;19)(q10;p10) in five oli-
godendrogliomas suggests mechanism of 
concurrent 1p and 19q loss. J NeuropatholEx-
pNeurol 65:988-94, 2006
10. Cairncross G, Jenkins R: Gliomas with 1p/19q 
codeletion: a.k.a. oligodendroglioma. Can-
cer J 14:352-7, 2008
11. Kouwenhoven MC, Kros JM, French PJ, et al: 
1p/19q loss within oligodendroglioma is pre-
dictive for response to first line temozolo-
mide but not to salvage treatment. Eur J Can-
cer 42:2499-503, 2006
12. Cairncross JG, Ueki K, Zlatescu MC, et al: Spe-
cific genetic predictors of chemotherapeu-
tic response and survival in patients with an-
aplastic oligodendrogliomas. J Natl Cancer 
Inst 90:1473-9, 1998
13. Parsons DW, Jones S, Zhang X, et al: An inte-
grated genomic analysis of human glioblas-
tomamultiforme. Science 321:1807-12, 2008
14. Hartmann C, Meyer J, Balss J, et al: Type and 
frequency of IDH1 and IDH2 mutations are 
related to astrocytic and oligodendroglial 
differentiation and age: a study of 1,010 dif-
fuse gliomas. ActaNeuropathol 118:469-74, 
2009
15. Bleeker FE, Lamba S, Leenstra S, et al: IDH1 
mutations at residue p.R132 (IDH1(R132)) 
occur frequently in high-grade gliomas but 
not in other solid tumors. Hum Mutat 30:7-
11, 2009
16. Gravendeel LA, Kloosterhof NK, Bralten LB, 
et al: Segregation of non-p.R132H mutations 
in IDH1 in distinct molecular subtypes of glio-
ma. Hum Mutat 31:E1186-99, 2010
17. Gravendeel LA, Kouwenhoven MC, Gevaert 
O, et al: Intrinsic gene expression profiles 
of gliomas are a better predictor of survival 
than histology. Cancer Res 69:9065-72, 2009
18. Kloosterhof NK, Bralten LB, Dubbink HJ, et 
al: Isocitrate dehydrogenase-1 mutations: a 
fundamentally new understanding of diffuse 
glioma? Lancet Oncol 12:83-91, 2011
19. Dubbink HJ, Taal W, van Marion R, et al: IDH1 
mutations in low-grade astrocytomas pre-
dict survival but not response to temozolo-
mide. Neurology 73:1792-1795, 2009
20. van den Bent MJ, Dubbink HJ, Marie Y, et al: 
IDH1 and IDH2 mutations are prognostic but 
not predictive for outcome in anaplastic oli-
godendroglial tumors: a report of the Euro-
pean Organization for Research and Treat-
ment of Cancer Brain Tumor Group. Clin Can-
cer Res 16:1597-604, 2010
21. Gerson SL: MGMT: its role in cancer aetiolo-
gy and cancer therapeutics. Nat Rev Cancer 
4:296-307, 2004
22. Hegi ME, Diserens AC, Gorlia T, et al: MGMT 
gene silencing and benefit from temozolo-
mide in glioblastoma. N Engl J Med 352:997-
1003, 2005
23. Chakravarti A, Erkkinen MG, Nestler U, et 
al: Temozolomide-mediated radiation en-
hancement in glioblastoma: a report on 
underlying mechanisms. Clin Cancer Res 
12:4738-46, 2006
24. Criniere E, Kaloshi G, Laigle-Donadey F, et al: 
MGMT prognostic impact on glioblastoma is 
dependent on therapeutic modalities. J Neu-
rooncol 83:173-9, 2007
12
IN
TRO
D
U
C
TIO
N
25. Everhard S, Kaloshi G, Criniere E, et al: MGMT 
methylation: a marker of response to temo-
zolomide in low-grade gliomas. Ann Neurol 
60:740-3, 2006
26. Rivera AL, Pelloski CE, Gilbert MR, et al: 
MGMT promoter methylation is predictive 
of response to radiotherapy and prognostic 
in the absence of adjuvant alkylating chem-
otherapy for glioblastoma. NeuroOncol 
12:116-21, 2010
27. TCGARN: Comprehensive genomic char-
acterization defines human glioblastoma 
genes and core pathways. Nature 455:1061-
8, 2008
28. Phillips HS, Kharbanda S, Chen R, et al: Mo-
lecular subclasses of high-grade glioma pre-
dict prognosis, delineate a pattern of disease 
progression, and resemble stages in neuro-
genesis. Cancer Cell 9:157-73, 2006
29. Verhaak RG, Hoadley KA, Purdom E, et al: 
Integrated genomic analysis identifies clini-
cally relevant subtypes of glioblastoma char-
acterized by abnormalities in PDGFRA, IDH1, 
EGFR, and NF1. Cancer Cell 17:98-110, 2010
30. French PJ, Swagemakers SM, Nagel JH, et 
al: Gene expression profiles associated with 
treatment response in oligodendrogliomas. 
Cancer Res 65:11335-44, 2005
31. Nutt CL, Mani DR, Betensky RA, et al: Gene 
expression-based classification of malig-
nant gliomas correlates better with survival 
than histological classification. Cancer Res 
63:1602-7, 2003
32. Li A, Walling J, Ahn S, et al: Unsupervised 
analysis of transcriptomic profiles reveals six 
glioma subtypes. Cancer Res 69:2091-9, 2009
13

IntrInsIc gene expressIon profIles 
of glIoMas are a better predIctor 
of survIval than hIstology 
Lonneke A.M. Gravendeel1*, Mathilde C.M. Kouwenhoven1*, 
Olivier Gevaert2, Johan J. de Rooi3,4, Andrew P. Stubbs3, 
J. Elza Duijm1, Anneleen Daemen2, Fonnet E. Bleeker5, Linda 
B.C. Bralten1, Nanne K. Kloosterhof1,6, Bart De Moor2, Paul 
H.C. Eilers4, Peter J. van der Spek3, Johan M. Kros7, Peter A.E. 
Sillevis Smitt1, Martin J. van den Bent1 and Pim J. French1
 1Depts. Neurology, 3Bioinformatics, 4Biostatistics, 7Pathology, 
Erasmus University Medical Center, Rotterdam, the Netherlands 
2Dept. Electrical Engineering (ESAT-SCD), Katholieke 
Universiteit Leuven, Leuven, Belgium 
 5Dept. Neurosurgery, Amsterdam Medical Center, 
Amsterdam, the Netherlands 
6Dept. Pediatric Oncology and Hematology, Erasmus 
MC-Sophia Children’s Hospital, Rotterdam, the Netherlands
Cancer Res. 2009 Dec 1;69(23):9065-72.
1
ABStRACt
Gliomas are the most common primary brain tumors with heterogeneous morphology and 
variable prognosis. Treatment decisions in patients rely mainly on histologic classification 
and clinical parameters. However, differences between histologic subclasses and grades 
are subtle, and classifying gliomas is subject to a large interobserver variability. To improve 
current classification standards, we have performed gene expression profiling on a large 
cohort of glioma samples of all histologic subtypes and grades. We identified seven distinct 
molecular subgroups that correlate with survival. These include two favorable prognostic 
subgroups (median survival, >4.7 years), two with intermediate prognosis (median survival, 
1–4 years), two with poor prognosis (median survival, <1 year), and one control group. The 
intrinsic molecular subtypes of glioma are different from histologic subgroups and correlate 
better to patient survival. The prognostic value of molecular subgroups was validated on 
five independent sample cohorts (The Cancer Genome Atlas, Repository for Molecular Brain 
Neoplasia Data, GSE12907, GSE4271, and Li and colleagues). The power of intrinsic subtyping 
is shown by its ability to identify a subset of prognostically favorable tumors within an external 
data set that contains only histologically confirmed glioblastomas (GBM). Specific genetic 
changes (epidermal growth factor receptor amplification, IDH1 mutation, and 1p/19q loss of 
heterozygosity) segregate in distinct molecular subgroups. We identified a subgroup with 
molecular features associated with secondary GBM, suggesting that different genetic changes 
drive gene expression profiles. Finally, we assessed response to treatment in molecular 
subgroups. Our data provide compelling evidence that expression profiling is a more accurate 
and objective method to classify gliomas than histologic classification. Molecular classification 
therefore may aid diagnosis and can guide clinical decision making. 
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INtRODUCtION
Gliomas are the most common type of primary brain tumor in adults (1, 2). Despite advances 
in therapy, the prognosis for most glioma patients remains dismal. Based on their histologic 
appearance, gliomas can be divided into two major subtypes according to the 2007 WHO 
classification (1): astrocytic tumors, including pilocytic astrocytomas (PA), astrocytomas, and 
glioblastomas (GBM), and oligodendroglial (OD) tumors, including pure OD tumors and mixed 
oligoastrocytic (MOA) tumors. Tumors are further divided into grades I (PA), II (low grade), 
III  (anaplastic), and IV (GBM) depending on the presence of anaplasticfeatures (1). Patient 
survival, time to tumor progression, and response to therapy are all associated with subtype 
and grade of the tumor (1). In glioma patients, the histologic classification of tumors, often 
combined with perceived clinical prognostic features, guides treatment decisions. However, 
histologic classification of gliomas is troublesome and subject to interobserver variation (3).
Expression profiling provides an objective method to classify tumors (4, 5). Thus far, 
previous studies have shown that expression profiling correlates better with prognosis than 
histology (6) and may even be used to predict patients’ prognosis (7–11). However, these 
studies have used external information (histology or clinical parameters) to build molecular 
classifiers. Furthermore, many studies were performed on a more restricted number of 
histologic diagnoses and/or tumor grades, contained incomplete clinical annotation, or 
included a relatively small number of patients (6–9, 12–19). Although these studies show that 
expression profiling can predict outcome based on supervised analysis, thus far only one study 
has identified intrinsic (unsupervised) subtypes of glioma and correlated them with patients’ 
prognosis (20). However, no study has compared the prognostic and predictive value of 
molecular classification methods with that of histologic subtyping in glioma.
In this study, we therefore performed expression profiling on a large cohort of clinically 
annotated glioma samples of all histologic subtypes and grades. We provide strong evidence 
that the intrinsic molecular subtypes of gliomas correlate better with survival than histologic 
diagnosis. Furthermore, our data indicate that certain molecular subgroups clearly benefit 
from treatment. Our results were validated on several large independent external data 
sets. Molecular classification therefore may aid diagnosis and may be used to guide clinical 
decision making.
MAtERIALS AND MEtHODS
Patients and tumor samples
Glioma samples were collected from the Erasmus University Medical Center tumor archive 
(n = 276) from patients (1989–2005), including seven repeat samples. Samples were collected 
immediately after surgical resection, snap frozen, and stored at −80°C. Use of patient material 
was approved by the Institutional Review Board. Medical history is stated in Supplementary 
Table S1. Survival time was defined as the period from date of surgery to date of death. If 
unavailable, date of last follow-up was used. Repeat samples were not included in survival 
analysis. All samples were visually inspected at the time of this study on their extent of tumor 
(J.M.K.). All histologic diagnoses were made on formalin fixed, paraffin-embedded H&E 
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sections and were reviewed (J.M.K.) blinded to the original diagnosis according to the 2007 
WHO classification (1). GBMs were defined as secondary when symptoms occurred more than 
1.5 y before histologic diagnosis or following relapse of a lower-grade glioma. Eight additional 
control samples (normal adult brain) were obtained from the Erasmus University Medical 
Center (n = 4) and the Dutch Brain Bank (n = 3) or purchased (n = 1; Qiagen).
Nucleic acid isolation, cDNA synthesis, and array hybridization
Total RNA and genomic DNA were isolated from 20 to 40 cryostat sections of 40-μm thickness 
using Trizol (Invitrogen) according to the manufacturer’s instructions (14) and further purified 
on RNeasy mini columns (Qiagen). RNA quality was assessed on a Bioanalyzer (Agilent). One 
to two micrograms of high-quality RNA [i.e., RNA integrity number >6.5 (21)] was used for our 
experiments. Double-stranded cDNA synthesis and labeled cRNA synthesis were performed 
according to the Affymetrix Eukaryotic One-cycle cDNA synthesis protocol. Affymetrix 
HU133 Plus 2.0 microarrays were hybridized overnight with 10 μg of biotin-labeled cRNA. 
Genechips with a glyceraldehyde-3-phosphate dehydrogenase 5′/3′ ratio >4, present calls 
<30%, unsuccessful RT controls, or a background >200 were excluded. Robustness of sample 
processing was assessed using eight biological replicates and three technical replicates. 
Replicates were not included in any analysis. Sample labeling and array hybridization on 
250K NspI arrays was performed using high-quality genomic DNA according to the Genechip 
Mapping 500K Assay Manual (n = 40). Sample labeling and array hybridization on single-
nucleotide polymorphism (SNP) 6.0 arrays were performed using Trizol-extracted, Repli-G 
(Qiagen)–amplified genomic DNA by AROS Applied Biotechnology AS according to standard 
Affymetrix protocols (n = 15).
Genetic aberrations
Loss of heterozygosity (LOH) of 1p19q was determined by microsatellite analysis or inferred 
from genotyping arrays. Microsatellites were amplified by PCR and analyzed as described (14). 
Allelic losses were statistically determined as described (22). Mutations in exon 4 of IDH1 
were determined by direct sequencing (Supplementary Table S2). Apart from experiments on 
250K NspI arrays, all experiments used Trizol extracted, Repli-G–amplified genomic DNA as 
starting material. 
Amplification of EGFR was determined by semiquantitative PCR as described (14).
Unsupervised clustering analysis
Expression levels of 17,527 genes were extracted from Affymetrix HU133 Plus 2.0 arrays using 
updated array annotation (23). Next, hierarchical ordered partitioning and collapsing hybrid 
(HOPACH) clustering was used to identify molecular subgroups in gliomas on 5,000 genes with 
highest variance (24). Nonparametric bootstrapping was used to estimate the probability that 
each sample belongs to a cluster (i.e., fuzzy clustering) and thus determine cluster stability. 
Samples were assigned to a cluster when at least 50% of bootstraps allocated the sample to 
that specific cluster. 
The Cancer Genome Atlas (TCGA) and GSE4271 data sets used HU133A microarrays; thus, 
the actual probes used to define a probe set may differ between this and our data set. Cluster 
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validation was performed by representing each of the molecular clusters in our data set by 
its centroid and classifying external samples to their nearest centroid. Samples belonging to 
the original data set that were not assigned to a cluster were similarly assigned to the nearest 
centroid. Robustness of external validation was estimated with the in-group proportion (IGP) 
cluster quality measure (25). To validate the groups, the IGP scores are compared with a null 
distribution of IGPs. A P value for each IGP was calculated based on permutation tests. Both 
HOPACH and IGP were available as R packages.
Gene set enrichment analysis
Gene set enrichment analysis (GSEA) was done for each cluster versus the remaining samples 
against the MSigDB gene ontology gene sets (26, 27). Gene sets that are over expressed or 
under expressed in at least one cluster with P value of <0.01 and false discovery rate (FDR) q 
value of <0.05 were selected. Enrichment scores were calculated by the negative and positive 
logarithm (base 10) of the FDR q values for the over expressed and under expressed gene 
sets, respectively, such that over expressed gene sets are scored on a positive scale and under 
expressed gene sets on a negative scale.
Data analysis
Statistical processing of data was performed using Excel, Access, Stata 10.0, and Prism 5.02 
(GraphPad). The significance of prognostic factors was determined with a multivariate analysis 
using Cox regression. Differences between Kaplan-Meier survival curves were calculated by 
the log-rank (Mantel-Cox) test. Comparisons between mean survivals of different groups were 
assessed by unpaired t tests, and comparisons between frequencies by the Fisher’s exact test.
RESULtS
Patient characteristics
A total of 276 glioma samples of following histology were included in this study: 8 astrocytomas 
grade 1 (PAs), 13 astrocytomas grade 2 (AII), 16 astrocytomas grade 3 (AIII), 159 astrocytomas 
grade 4 (GBM; 106 primary and 53 secondary), 28 MOAs (3 grade 2 and 25 grade  3), and 52 
ODs (8 grade 2 and 44 grade 3). Male-to-female ratio was 2.1:1, median age at diagnosis was 
50.2 years (range, 11.7–81.2), and mean Karnofsky Performance Score (KPS) was 78.9. Molecular 
clustering is an independent prognostic factor (Table 1) and remains independent when the 
analysis is performed on GBMs only (Supplementary Table S3). Age at time of diagnosis and 
KPS are well-documented prognostic factors in glioma (28–31). However, age at diagnosis does 
not remain an independent factor when taking molecular markers into account, as they mostly 
occur in tumor types associated with lower age at onset (IDH1, 1p19q). Due to the long period 
of inclusion, patients did not receive uniform treatment. One hundred and seventy-four (63%) 
patients were treated with radiotherapy and 24 (8.5%) with combined chemoradiation therapy, 
and a “wait and see” policy was applied to 11 (4%) patients until disease progression. Sixty-
eight (24.5%) patients only received supportive treatment after diagnosis because of poor 
performance status, high age at diagnosis, rapid disease progression, or refusal of any other 
treatment by the patient. Detailed patient characteristics are listed in Supplementary Table S1.
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table 1. Multivariate analysis. Multivariate analysis (Cox regression analysis) on all samples included in the study.
  Haz. ratio std. err. z P>|z| [95% conf. interval]
Histological diagnosis 0,6737357 0,6098470 -4,36 0,000 0,5642105 0,8045220
Histological grade 0,8869178 0,1263290 -0,84 0,400 0,6708751 1,1725330
Age 1,0349960 0,0056765 6,27 0,000 1,0239300 1,0461820
sex 0,7155355 0,0976483 -2,45 0,014 0,5476066 0,9349614
KPs 0,9867135 0,0025791 -5,12 0,000 0,9816714 0,9917815
extent of surgery 0,7946357 0,0726748 -2,51 0,012 0,6642323 0,9506402
radiotherapy 0,7811229 0,0617660 -3,12 0,002 0,6689783 0,9120669
chemotherapy 0,8947309 0,1903937 -0,52 0,601 0,5896056 1,3577610
Molecular cluster 1,3198160 0,0543694 6,74 0,000 1,2174420 1,4307980
Molecular clusters differ from histologic subgroups
Principle components analysis based on the 5,000 most variable genes in the data set  highlights 
the relative difference and similarity between samples (Supplementary Fig. S1). Similar clustering 
results were obtained using all genes, half of the genes, or 1,000 genes. We then identified molecular 
subgroups in our data set based on similarities in gene expression levels between samples using 
the HOPACH algorithm. Twenty-four distinct molecular clusters were identified. Nonparametric 
bootstrapping confirmed that most samples indeed belong to a defined cluster (fuzzy clustering). 
Only 17 samples were assigned to a cluster different from the original after bootstrapping, indicating 
the high stability of the clusters (see Materials and Methods). More specifically, all of these samples 
had very sparse cluster memberships, meaning that for most of these samples the remaining 
cluster membership was to one or very few clusters. Clustering of samples and bootstrapping 
results are shown in Supplementary Fig. S2 and Supplementary Table S4.
We then focused our analysis on the five largest clusters containing >10 samples each 
(clusters 9, 17, 18, 22, and 23) and two smaller subgroups that are molecularly (Supplementary 
Fig. S1) and histologically distinct: a control sample cluster 0 (n = 8; a merge of clusters 0, 1, 
and 3) and cluster 16 that contains PAs (n = 6; a merge of clusters 14, 15, and 16) and 3 recurrences 
of PAs. All samples were then reassigned to one of these seven clusters. After reassignment, 
clusters 0, 9, 16, 17, 18, 22, and 23 contained 23, 44, 10, 38, 64, 26, and 79 samples, respectively. 
All clusters contain a wide variety of histologic diagnosis and malignancy grades. However, 
distinct histologic subtypes segregate into different molecular clusters. For example, clusters 
18, 22, and 23 predominantly contain GBMs; cluster 9 contains most of the ODs (grade 2 and 3); 
and six of eight PAs cluster in group 16. Cluster 17 is the most histologically diverse cluster. The 
histologic composition of all molecular subgroups is shown in Fig. 1A.
Because control brain samples are markedly different in gene expression profile from the 
large majority of glioma samples (Supplementary Fig. S1), we were surprised that cluster 0 
contained 15 glioma samples in addition to the 8 control brain samples. We hypothesized that 
the tumor samples in cluster 0 might contain a large amount of nonneoplastic tissue. Indeed, 
histologic reexamination of all samples by a blinded experienced neuropathologist (J.M.K.) 
confirmed that all 15 samples that were reassigned to cluster 0, but none of the other samples, 
contained a substantial (>50%) amount of nonneoplastic brain tissue. Because of the high amount 
of nonneoplastic tissue in the samples in this cluster, we were unable to extract a clear glioma-
derived expression profile and, therefore, did not involve cluster 0 in the survival analysis.
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Molecular clusters correlate with survival
Kaplan-Meier survival analysis highlighted that the molecular clusters differ significantly 
with respect to their survival (P < 0.0001). As illustrated in Fig. 1B, molecular clusters are 
separated in two favorable prognostic subgroups (9 and 16; median survival of 6.06 and >4.7 
years, respectively), two subgroups with intermediate prognosis (17 and 22; median survival 
of 1.1 and 3.32 years, respectively), and two subgroups with poor prognosis (18 and 23; median 
survival of 0.68 and 0.67 years, respectively). Cluster 16 has a median survival of >4.7 years, 
as 6 of 10 patients were still alive at the time of last follow-up. Clinical characteristics of 
the molecular subgroups are summarized in Table 2. In repeat samples, cluster assignment 
either remained identical or changed to a molecular subgroup with poorer prognosis 
(Supplementary Table S5). 
Figure 1. Molecular subgroups are distinct from histological subgroups and correlate with survival. 
A: Pie charts show the composition of individual molecular subgroups by their histological subtypes. 
Each molecular subgroup is composed of a variety of different histological subtypes, although distinct 
histological subtypes predominate distinct molecular subgroups. B: Kaplan Meijer survival analysis of 
molecular clusters. Intrinsic gene expression profiles identify two molecular clusters with poor prognosis 
(18 and 23), two clusters that have intermediate prognosis (17 and 22), and two clusters with relatively 
favorable prognosis (9 and 16). 
table 2. Clinical characteristics of the molecular subgroups. Median age at diagnosis, median survival, and mean 
KPS per molecular cluster. Median survival of cluster 16 could not be defined since 6/10 patients were still alive 
at time of last follow-up.
cl 9 cl 16 cl 17 cl 18 cl 22 cl 23
Median Age at Diagnosis (yrs) 48,50 36,50 38,30 58,00 46,00 54,70
Median survival (yrs) 6,06 Undefined 3,32 0,68 1,12 0,67
Mean Karnofsky Performance score 82,9 70,9 89,2 77,0 79,2 79,7
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Cox regression analysis showed that molecular clustering is an independent significant 
prognostic variable in survival (P < 0.012; Table 1). Other factors in survival are age at diagnosis, 
KPS, and sex (28–31). These results are illustrated by Supplementary Fig. S3 and show that 
additional prognostic factors can help estimate prognosis.
Molecular clusters correlate better with patient survival than 
histologic subgroups 
Because histology also correlates with patient survival, we compared the accuracy of survival 
prediction by the two classification methods. To this end, we separated samples of the same 
histologic diagnosis by their molecular profile. Conversely, samples of the same molecular 
subgroup were further separated by their histologic appearance. The median survival of all 
GBMs used in our study was 0.73 years (range, 0.02–9.8). However, GBMs in the three poorest 
prognostic molecular subgroups (18, 22, and 23) have a significantly shorter median survival 
compared with GBM sin the three most favorable molecular clusters (9, 16, and 17; 0.70 versus 
2.05 years; P = 0.0024; Fig. 2A). Conversely, within the poor prognostic subgroups (18, 22, and 
23), no significant difference was observed in median survival between samples with poorest 
histologic diagnosis (GBM) versus those with a histologically more favorable prognosis (all 
Figure 2. Molecular subgroups correlate better with survival than histological subgroups. Comparison 
between molecular and histological classification: A: Samples of the same histological diagnosis (GBM) 
were separated by their molecular profile into those present in poorest prognostic molecular subgroups 
(18, 22 and 23) and those present in relatively favorable prognostic molecular subgroups (9, 16 and 17). The 
median survival of all GBMs was 0.73 years, but patients with a GBM in a poor molecular subgroup perform 
worse than patients with a GBM in a relatively favorable subgroup (0.70 vs. 2.1 years, P<0.01). B Samples 
present in poor molecular subgroups (median survival 0.82 years) cannot be further separated by their 
histological appearance into those of poor (GBMs) and less poor (all other tumors) prognostic subgroups 
(median survival 0.71 and 1.04 years). C: Similar to A, but using ODIIs and ODIIIs as histological subgroup 
(median survival 6.04 years) further separated by their poor and relatively favorable molecular subgroup 
(median survival 6.87 and 1.78 years, P<0.023). These results demonstrate that molecular clustering 
has additional prognostic value to histological diagnosis whereas histological diagnosis does not have 
additional prognostic value to molecular subgroups. 
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non-GBM; Fig. 2B). Similar to GBMs, ODs in the favorable molecular cluster 9 have a significantly 
better prognosis than the ODs in the poor prognostic subgroups (P = 0.02; Fig. 2C). Our data 
show that unsupervised molecular clustering has additional prognostic value to histologic 
diagnosis, whereas histologic diagnosis does not add prognostic value to molecular subgroups. 
The intrinsic molecular subtypes of glioma therefore predict survival more accurately than 
histology in our data set.
Molecular analysis
We next evaluated the frequencies of known molecular markers in gliomas within the 
subgroups. LOH of 1p19q was determined in 149 of 276 (54%) samples. Virtually all samples in 
cluster 9 have LOH on 1p (85%) or on 19q (85%; regardless of histology), with 82% of samples 
showing combined loss. 1p/19q LOH was observed at significantly lower frequencies in samples 
not associated with cluster 9, with 11% showing combined loss (P < 0.0001, Fisher’s exact test). 
Epidermal growth factor receptor (EGFR) status was determined in 151 (55%) samples (unbiased 
toward histologic diagnosis). EGFR amplification was predominantly observed in clusters 18 and 
23 (71%; 27%); no amplification was seen in clusters 9, 17, and 22. Sequencing of IDH1 exon 4 
was successfully evaluated in 226 (82%) cases. Mutations in the highly conserved Arg132 were 
predominantly identified in clusters 9 (69%) and 17 (70%). Clusters 16, 18, 22, and 23 contained 
13%, 16%, 45%, and 22% R132 mutations, respectively. A complete overview of genetic changes 
is stated in Fig. 3A and Supplementary Table S6. Figure 3B shows the clustering of the GSEA 
enrichment scores using average linkage hierarchical clustering using cosine similarity. Our 
data show that each molecular subgroup has a distinct pattern of genetic changes.
Cluster validation
Five independent external data sets were used to validate our clustering results: The Cancer 
Genome Atlas data set (n = 236; ref. 12), the Repository for Molecular Brain Neoplasia Data 9 
data set [REMBRANDT; n = 296; National Cancer Institute (2005), assessed 2008 December; 
ref. 32), a data set containing 21 PAs (GSE12907; ref. 33), data set GSE4271 (8), and a data set froma 
recent study (20). In all cases, the molecular clustering results correlate with the composition 
of the data set. For example, the TCGA data set only consists of GBMs, which is reflected by the 
predominance of clusters 18, 22, and 23. The REMBRANDT data set has a more diverse histologic 
makeup (ODs, MOAs, astrocytomas, and GBMs), which is reflected by the recurrence of all 
molecular clusters (Fig. 4A). Finally, GEO data set GSE12907 contains 21 PAs, which is reflected by 
20 of 21 samples being grouped in cluster 16. When comparing the survival of molecular clusters 
in both the TCGA and REMBRANDT data sets, the relative differences between molecular 
subgroups are virtually identical to those identified inour data set (Fig. 4B). For example, clusters 
9 and 17 have significantly longer median survival in the REMBRANDT data set compared with 
clusters 18, 22, and 23 (P < 0.0001). Eighteen of the GBM samples in the TCGA data set were 
assigned to the relatively more favorable molecular cluster 17. These patients indeed had 
significantly longer survival (799 days) compared with those of clusters 18, 22, and 23 (420 days; 
P = 0.0002). Only one GBM sample of the TCGA data set was assigned to cluster 9. This patient 
had the longest survival in the entire data set (9.7 years). The identification of prognostically 
favorable samples in a data set that contains only GBMs highlights the prognostic power of 
intrinsic expression profiles. Analysis of genetic changes in the TCGA data set showed that both 
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1Figure 3. Genetic and pathway differences between molecular subgroups. A: distinct genetic changes 
are associated with distinct molecular clusters. Amplification of EGFR is predominantly observed in clusters 
18 and 23, whereas mutations in IDH1 are more prevalent in clusters 9 and 17. These data strongly suggest 
that distinct molecular subtypes have different underlying causal genetic changes. B: clustering of GSEA 
scores. A to O correspond to gene set clusters that are differentially expressed in at least one subtype. 
These functional categories were investigated by extracting overlapping genes in >10% of all gene sets in a 
particular cluster. Functional categories: A, cyclic AMP binding, neurogenesis, GnRH signaling, long-term 
potentiation; B, protein transport and regulation; C, no significant functional categories; D,  ribosome, 
metabolic processes, histone and chromatin modification, RNA transcription; E, fatty acid metabolism; 
F, oxidative phosphorylation, transport; G, no significant functional categories; H, G-protein coupled 
receptor, neuropeptide binding; I, RNA polymerase and transcription; J, amino acid transport; K, ribosome, 
mitochondrion; L, cell-cellsignaling, nervous system development, ion channel activity; M,  immune 
response; N, Janus-activatedkinase–signal transducer and activator of transcription signaling, response to 
stress and wounding, apoptosis, immune response; O, cell cycle, mitosis, response to DNA damage.
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EGFR amplification and IDH1 mutation frequencies have virtually identical distribution across 
the different subgroups (Supplementary Fig. S4; refs. 12, 34). Distributions of other frequently 
mutated genes (NF1 and P53) are shown in Supplementary Fig. S5.
Furthermore, the single patient assigned to cluster 9 in the TCGA data set indeed showed 
LOH on 1p19q (34), as did one of the samples from the REMBRANDT data set assigned to 
cluster  9. SNP chip data were not available for other samples of the REMBRANDT data set 
assigned to cluster 9. In summary, the intrinsic glioma subgroups identified in our study can be 
validated in external data sets with respect to histologic, molecular, and clinical features.
We overlaid our clustering results onto GSE4271 (8), which again resulted in similar survival 
between molecular subgroups (Supplementary Fig. S6). The three different signatures 
identified by Phillips and colleagues (proneural, proliferative, and mesenchymal; see also 
ref.  35) segregated into specific molecular subgroups. For example, the proneural signature 
was predominantly found in clusters 16 and 17, whereas the proliferative and the mesenchymal 
signatures were mostly found in clusters 18, 22, and 23 (Supplementary Fig. S7A). Conversely, 
these results are confirmed when imposing these signatures onto our data set (Supplementary 
Fig. S7B). However, one of our best prognostic groups (cluster 9) is classified as poor prognostic 
group (proliferative) by Phillips and colleagues. This shows that, at least for some molecular 
subtypes, our clustering method predicts prognosis more specifically. Li and colleagues (20) 
also identified intrinsic molecular subtypes of gliomas by expression profiling. These subgroups 
can be confirmed in our data set, with similar survival to reported (Supplementary Fig. S8A). 
However, samples in the poor prognostic subgroup identified by Li and colleagues (G-groups) 
can be further separated based on our molecular classification into a poor prognostic 
Figure 4. Molecular subgroups can be confirmed in external data sets. A: composition of individual 
molecular subgroups by their histologic subtype. Each molecular subgroup is composed of a variety 
of different histologic subtypes in the REMBRANDT data set. Similar to our set, histologic subtypes 
predominate distinct molecular subgroups. B: Kaplan-Meier survival analysis of molecular clusters in 
the REMBRANDT data set (left) and the TCGA data set (right). Both sets show similar trends in survival 
compared with our data. Distinct genetic changes are associated with distinct molecular clusters. 
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group (n = 132) and a more favorable prognostic group (n = 18) with significantly better survival 
(P = 0.03; Supplementary Fig. S8B). Similarly, samples that cluster in good prognostic subgroups 
of Li and colleagues (OA and OB group) can be separated by our profiles into a poor prognostic 
group (n = 13) and a favorable prognostic group (n = 67; P = 0.009; Supplementary Fig. S8C). 
The reverse analysis is shown in Supplementary Fig. S9. GSEA shows that some of the pathways 
identified by Li and colleagues show differential distribution in our subgroups (Supplementary 
Fig. S10). This indicates that the different clustering methods show some overlap.
Molecular clusters and treatment response
Finally, we examined whether there are differences in treatment response between molecular 
subgroups. The efficacy of treatment in molecular subgroups could be assessed in our sample 
cohort as patients were treated heterogeneously. A clear effect of radiotherapy was observed 
in clusters 18 and 23 (P < 0.001 and P = 0.01, respectively). In other clusters, the effects were 
either less pronounced or contained too few samples to reach statistical significance. However, 
to eliminate potential effects of sample bias, we used an external data set (GSE7696; ref. 16) that 
consisted of 80 GBM patients from a randomized controlled trial in which patients were treated 
with radiotherapy versus combined chemoradiation. We identified the following molecular 
clusters in this data set: clusters 0 (n = 4), 16 (n = 3), 17 (n = 10), 18 (n = 52), 22 (n = 4), and 23 
(n = 11; Supplementary Fig. S11A). Results showed that both clusters 18 and 23 seem to benefit 
from combined chemoradiation therapy (Supplementary Fig. S11B) compared with radiotherapy 
only. Other clusters contain too few samples to assess effect of treatment.
DISCUSSION
In this study, we have examined whether expression profiling can serve as a more objective 
method to classify gliomas than histology. Our data show that expression profiling identifies 
molecular subgroups that are distinct from histologic subgroups and that these molecular 
subgroups correlate better with patient survival. In addition, our data indicate that distinct 
molecular subgroups benefit from treatment. As a confirmatory step, the molecular subgroups 
and their prognostic values were validated on five independent sample cohorts. Finally, specific 
genetic changes (EGFR amplification, IDH1 mutation, and 1p19q LOH) segregate in distinct 
molecular subgroups.
At present, the treatment pathway for glioma patients has been optimized for the different 
histologic subtypes. However, classification based on histologic appearance has a high degree 
of interobserver variability (3). The intrinsic subtypes of glioma identified in our study therefore 
provide a robust and objective alternative to histologic classification. The power of intrinsic 
subtyping was shown by its ability to identify a subset of prognostically favorable tumors within 
an external data set that contains only histologically confirmed GBMs (TCGA).
Distinct genetic changes segregate into different intrinsic molecular clusters. For example, 
amplification of EGFR is predominantly observed in clusters 18 and 23, whereas mutations in 
IDH1 are significantly more prevalent in clusters 9 and 17. All but four samples in cluster 9 have 
LOH on 1p19q regardless of histologic subtype. This observation is confirmed in external data 
sets. Interestingly, the molecular changes and clinical features associated with secondary GBMs 
(high mutation rate of IDH1, absent EGFR amplification, and lower age at time of diagnosis) are 
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reflected in a distinct molecular subgroup (cluster 22) that indeed is enriched in the number 
of secondary GBMs. Differences in genetic changes between molecular subtypes can indicate 
that novel targeted agents may only be effective in distinct molecular subtypes (Supplementary 
Fig. S12).
Cluster 0 contains all nonneoplastic tissue samples in our study (n = 8), in the REMBRANDT 
data set (n = 21), and in GSE7696 (n = 4). However, cluster 0 also contains several glioma 
samples in our dataset (n = 15), in the TCGA data set (n = 3), and in the REMBRANDT data set 
(n = 20). In our data set, samples that are associated with cluster 0 have significant amounts 
of nonneoplastic tissue (>50%). Similarly, two of three samples of the TCGA data set contained 
>90% nonneoplastic tissue (data on other sample not available) and have virtually no genetic 
aberrations. The samples of the REMBRANDT data set that associate with cluster 0 might 
therefore also contain substantial amounts of non tumor tissue.
Our data indicate that both clusters 18 and 23 benefit from chemoradiation. This benefit 
seems to be reflected by an increase in overall survival between our data set, in which few samples 
received chemoradiation, and the TCGA, in which most samples received chemoradiation (0.68 
versus 0.89 years and 0.67 versus 1.02 years in clusters 18 and 23, respectively). However, in 
the TCGA data set, cluster 22 does not show improved survival (1.1 versus 0.98 years), and it 
is possible that current treatment standards do not affect this specific molecular subgroup. 
Unfortunately, too few samples from this chemoradiotherapy (16) were assigned to cluster 22 
to assess treatment efficacy.
Another study also identified intrinsic molecular subtypes of gliomas by expression profiling 
(20). Although these molecular clusters also correlate with patient survival, a comparison with 
histologic diagnosis and molecular markers was not attempted. In addition, several histologic 
subtypes were not included (control tissue, MOAs, and PAs) in building molecular glioma 
classifiers. Our data show that our molecular clustering has additional prognostic value both 
to histologic diagnosis (20) and to alternative clustering methods (8, 20). There are several 
limitations using unsupervised hierarchical clustering for subclassification based on mRNA 
expression profiles. For example, tumor types that are not included in present study (e.g., brain 
metastasis) and rare tumor types with insufficient sample size to form a separate molecular 
cluster will be incorrectly classified. Histologic examination to detect such histologies therefore 
remains required. To some extent, molecular cluster definition also depends on the algorithms 
used (both for clustering and data extraction) so that individual samples may switch between 
molecular subgroups.
In conclusion, our data indicate that the intrinsic subtypes identified improve on histologic 
classification of gliomas and are an accurate predictor of prognosis. Molecular classification 
can contribute to diagnosis and may form a rationale for clinical decision making and novel 
targeted therapies.
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2ABStRACt
Background: We have recently demonstrated that expression profiling is a more accurate 
and objective method to classify gliomas than histology. Similar to most expression profiling 
studies, our experiments were performed using fresh frozen (FF) glioma samples whereas most 
archival samples are fixed in formalin and embedded in paraffin (FFPE). Identification of the 
same, expression-based intrinsic subtypes in FFPE stored samples would enable validation of the 
prognostic value of these subtypes on these archival samples. In this study, we have therefore 
determined whether the intrinsic subtypes identified using FF material can be reproduced in 
FFPE stored samples.
Methods: We have performed expression profiling on 55 paired FF-FFPE glioma samples 
using HU133 plus 2.0 arrays (FF) and Exon 1.0 ST arrays (FFPE). The median time in paraffin of the 
FFPE samples was 14.1 years (range 6.6 - 26.4 years).
Results: In general, the correlation between FF and FFPE expression in a single sample was 
poor. We then selected the most variable probe sets per gene (n=17,583), and of these, the 5,000 
most variable probe sets on FFPE expression profiles. This unsupervised selection resulted in a 
better concordance (R2= 0.54) between expression of FF and FFPE samples. Importantly, this 
probe set selection resulted in a correct assignment of 87% of FFPE samples into one of seven 
intrinsic subtypes identified using FF samples. Assignment to the same molecular cluster as the 
paired FF tissue was not correlated to time in paraffin.
Conclusion: We are the first to examine a large cohort of paired FF and FFPE samples. 
We show that expression data from FFPE material can be used to assign samples to intrinsic 
molecular subtypes identified using FF material. This assignment allows the use archival 
material, including material derived from large- randomized clinical trials, to determine the 
predictive and/or prognostic value of “intrinsic glioma subtypes” on Exon arrays. This would 
enable clinicians to provide patients with an objective and accurate diagnosis and prognosis, 
and a personalized treatment strategy.
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INtRODUCtION
Classification of tumor subtypes influences treatment decisions for many types of cancer. 
Accuracy in classifying cancer subtypes is therefore necessary to provide patients with correct 
diagnosis, prognosis and an optimal treatment strategy. Since histological classification is 
often difficult in poorly differentiated tumors, this classification method urgently needs 
improvement. Gene expression profiling of cancer offers an accurate and objective method for 
classifying cancer subtypes (Sorlie et al., 2001; Valk et al., 2004). For example, in gliomas, the 
most common primary brain tumor in adults, gene expression profiling has identified distinct 
intrinsic subtypes of gliomas (Freije et al., 2004; Gravendeel et al., 2009; Li et al., 2009; Louis 
et al., 2007; Madhavan et al., 2009; Nutt et al., 2003; Phillips et al., 2006; Shirahata et al., 2007; 
Shirahata et al., 2009; Verhaak et al., 2010). We have performed unsupervised gene expression 
profiling in a cohort of 276 gliomas of all histological subtypes (Gravendeel et al., 2009). In 
this largest single-institution study conducted to date, we identified seven molecular glioma 
clusters. The molecular clusters were a significantly better predictor of survival than histology, 
and were characterized by specific genetic changes. Data were validated and confirmed on six 
large external datasets. When validated in prospective studies these molecular clusters could 
contribute to clinical decision making. However, this study was conducted using RNA isolated 
from fresh frozen (FF) tissue. Unfortunately, FF tissue is scarce; most of the tissue archives 
with matched clinical outcome data are fixed in formalin and embedded in paraffin (FFPE). 
RNA isolated from FFPE material is often degraded and chemically modified as a result of the 
archiving method (Farragher et al., 2008; Masuda et al., 1999). However, new techniques have 
shown promising results in genome wide expression profiling of RNA isolated from FFPE (Hall et 
al., 2011; Hoshida et al., 2008; Linton et al., 2009; Linton et al., 2008; Mittempergher et al., 2011). 
Techniques used to study gene expression with FFPE material thus far have mostly been 
limited to single gene analysis with RT-qPCR. Such techniques have demonstrated to be clinical 
relevant on a limited set of “classifier” genes (Colman et al., 2010; Ma et al., 2006). Other 
multiplex assays (DASL, Quantigene, Nanostring, Fluidigm) have also shown promising results 
using distinct classifier genes (Canales et al., 2006; Geiss et al., 2008; Hall et al., 2011; Hoshida 
et al., 2008; Linton et al., 2009; Linton et al., 2008; Mittempergher et al., 2011; Spurgeon et al., 
2008). Although whole genome approaches for degraded RNA samples have improved over 
the last few years, the performance of current techniques to detect more subtle differences 
between cancer subtypes remains to be confirmed. 
In this study we therefore have performed expression analysis using a large cohort paired 
FF-FFPE glioma tissue using Exon 1.0 ST “exon” arrays (Affymetrix). Expression profiling using 
such a cohort has thus far not been performed. Most expression profiling studies using FF 
tissues have been performed on HU133 –type arrays (A, A+B or the +2.0 version), whereas best 
results using FFPE samples have been obtained using the Exon 1.0 ST arrays. In this study we 
therefore compare expression of FF samples on HU133 plus 2.0 arrays with FFPE samples on 
Exon 1.0 ST arrays. Previous studies have demonstrated an good overall correlation of HU133 
Plus 2.0 with Exon 1.0 ST arrays (Okoniewski et al., 2007) (supplementary figure 1). We show that 
expression data from FFPE glioma material is concordant with expression data from matched FF 
tissue, and can be used for molecular profiling in gliomas. Furthermore, this molecular profiling 
is able to identify the subtle differences between the molecular glioma subtypes. 
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Patient samples
We selected 55 paired FF-FFPE samples from the Erasmus University Medical center glioma 
tumor archive. The FF and the FFPE samples were taken simultaneously from the tumor as 
parallel biopsies. All samples were visually inspected at the time of this study for tumor content 
by the neuropathologist (J.M.K.) so that samples containing at least 80% of tumor tissue were 
selected. The FF samples selected were used in a previous study in which seven molecular 
clusters were identified (Gravendeel et al., 2009). The selection contained ~10 samples from 
each molecular cluster. FF expression profiling results were reported previously (Gravendeel 
et al., 2009). The RNA from the FF tissue was extracted and hybridized in 2008. The RNA from 
the FFPE tissue was extracted and hybridized in 2010. Clinical and molecular data from the 
glioma samples included were reported previously (Gravendeel et al., 2009). The use of patient 
material was approved of by the Institutional Review Board of the ErasmusMC, Rotterdam, 
the Netherlands (nr MEC 221.520/2002/262; date of approval July 22, 2003, and MEC-2005-
057, date of approval February 14, 2005). For this use, patients gave written informed consent 
according to institutional and national guidelines. The fixation method of tissue in the Erasmus 
MC did not change over the last 25 years.
RNA from FFPE extraction
Five sections of 10 μm thick were cut from each tissue block. The High Pure RNA Paraffin Kit 
(Roche Applied Science, Mannheim, Germany) was used to isolate the RNA from the paraffin. 
After isolation the RNA was purified by ethanol precipitation (supplementary table  1). The 
quantity and integrity of the RNA was measured using a Nanodrop, and an Agilent 2100 
BioAnalyzer RNA 6000 Nano Assay (Agilent Technologies). After total RNA isolation and 
purification, samples were diluted to 50 ng/ml and stored at -80°C until use.
qPCR
We randomly selected eleven samples that were assigned to two molecular clusters based 
on the fresh frozen expression data (Cluster 9 (n=5) and Cluster 18 (n=6)) (Gravendeel et al., 
2009). Four genes (two up-regulated, two down-regulated) that discriminate between the two 
subtypes were examined for differential gene expression (EMP3, SLC2A10, SUSD5, and CSMD3). 
These genes were identified using a t-test in combination with fold change. ACTB, GAPDH 
were used as control. All reactions were performed in duplicate. Primers and conditions are 
described in supplementary table 2.
Arrays
A total of 150 ng per sample of the extracted RNA (FFPE) was used for the Exon 1.0 ST arrays 
(Affymetrix). Sample labeling and array hybridization were performed by AROS Applied 
Biotechnology AS (Arhus, Denmark) according to standard Affymetrix protocols in combination 
with Nugen WT-Ovation technology (FFPE V2 and Exon modules) (San Carlos, CA, USA) (n=55). 
Expression arrays (HU 133 plus 2.0 (Affymetrix) using FF material was reported previously 
(Gravendeel et al., 2009).
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Quantile normalized RMA expression levels of 22,011 genes and 287,329 exons were extracted 
from Affymetrix Exon 1.0 ST arrays using Expression Console (Affymetrix). ClusterRepro (an R 
package) was used to assign a sample to a defined molecular subtype (Kapp & Tibshirani, 2007). 
Statistics
Differences between Kaplan-Meier survival curves were calculated by the log-rank (Mantel-
Cox) test. Differences in age and RIN-scores of the tissue blocks were calculated using a t-test 
and a Mann-Whitney test. Significance of correlation coefficients was calculated using the 
p-value calculator for correlation coefficients (www.danielsoper.com/statcalc3).
RESULtS
Sample characteristics
At total of 55 FFPE samples was included in the study. These samples included 29 glioblastomas 
(GBMs), 5 astrocytomas grade III (A III), 5 As grade II, 4 mixed oligoastrocytoma grade III (OA II), 
2 OAs grade II, 8 oligodendrogliomas grade III (OD III), and 2 pilocytic astrocytoma (PA). The 
median time in paraffin of the FFPE samples was 14.1 years (range 6.6 - 26.4 years). The median 
RIN score of the RNA was 2.4 (range 1.1-2.7). Sample characteristics are listed in table 1. 
Db no
survival 
(yrs) status PA diagnosis
Age FFPe 
material 
(yrs) riN score
correlation 
(r2) FF and 
FFPe
P-value 
correlation 
FF and FFPe
8 9.82 dead OD III 15.3 1.90 0.24 <0.001
40 10.28 dead OD III 18.9 2.20 0.29 <0.001
55 17.49 dead OD III 23.9 2.30 0.30 <0.001
63 3.28 dead GBM 9.9 2.40 0.12 <0.001
77 1.30 dead GBM 12.2 2.60 0.03 0.02
92 1.26 dead GBM 11.3 1.10 0.20 <0.001
98 0.98 dead GBM 12.1 2.30 0.13 <0.001
99 0.86 dead GBM 13.3 N/A 0.03 0.024
104 0.21 dead GBM 10.4 N/A 0.15 0.024
105 1.03 dead GBM 16.0 N/A 0.08 <0.001
112 0.59 dead GBM 16.0 N/A 0.10 <0.001
119 0.18 dead GBM 13.1 2.30 0.15 <0.001
123 2.05 dead GBM 13.9 2.50 0.15 <0.001
130 6.31 dead GBM 15.1 1.40 0.08 <0.001
134 1.48 dead A II 13.9 N/A 0.06 <0.001
143 4.79 dead A II 13.4 2.70 0.10 <0.001
174 0.28 dead GBM 19.3 N/A 0.05 <0.001
183 0.12 dead GBM 12.3 N/A 0.14 <0.001
194 0.19 dead A III 20.8 1.90 0.13 <0.001
table 1. Patient and sample characteristics. GBM = Glioblastoma; A III = Astrocytoma grade III; A II = Astrocytoma 
grade II; PA = Pilocytic Astrocytoma; OA III = Oligoastrocytoma grade III; OA II = Oligoastrocytoma grade II; 
OD III = Oligodendroglioma grade III; OD II; Oligodendroglioma grade II.
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Db no
survival 
(yrs) status PA diagnosis
Age FFPe 
material 
(yrs) riN score
correlation 
(r2) FF and 
FFPe
P-value 
correlation 
FF and FFPe
198 6.27 dead A III 21.8 2.40 0.11 <0.001
199 1.11 dead GBM 20.2 2.10 0.14 <0.001
206 0.29 dead GBM 11.7 2.50 0.03 0.028
209 1.96 dead OA III 11.0 2.50 0.09 <0.001
227 3.10 lost to follow up GBM 10.9 N/A 0.01 p=0.22
253 0.62 dead GBM 9.3 2.20 0.32 <0.001
256 0.27 dead GBM 14.1 2.40 0.15 <0.001
257 3.30 dead OD III 17.9 2.50 0.23 <0.001
258 2.26 dead GBM 18.4 2.50 0.12 <0.001
259 5.02 dead OD III 13.5 2.40 0.02 0.087
286 5.56 lost to follow up GBM 24.6 2.30 0.13 <0.001
291 0.63 dead OA III 20.3 2.10 0.24 <0.001
293 2.99 dead OD III 22.7 2.50 0.10 <0.001
315 0.61 dead GBM 15.4 N/A 0.14 <0.001
336 1.19 dead A II 11.9 2.40 0.15 <0.001
353 9.79 dead GBM 26.0 2.10 0.10 <0.001
380 1.61 dead GBM 7.5 2.20 0.04 p=0.002
387 3.32 dead GBM 17.0 N/A 0.12 <0.001
393 0.06 dead GBM 14.2 2.10 0.17 <0.001
416 15.82 dead OD III 26.4 2.50 0.14 <0.001
420 1.32 dead A II 17.4 N/A 0.06 <0.001
441 3.76 dead OA II 18.9 2.50 0.02 p=0.06
445 1.18 dead OA III 18.9 2.20 0.25 <0.001
446 0.45 dead A III 8.9 1.60 0.04 <0.001
467 0.05 dead A III 10.9 2.50 0.01 p=0.15
473 1.20 dead A III 22.7 2.50 0.20 <0.001
515 0.35 dead GBM 7.4 2.50 0.00 0.45
536 6.39 alive OA II 6.6 2.40 0.13 <0.001
565 2.79 dead GBM 14.2 1.90 0.23 <0.001
566 0.48 dead GBM 13.8 N/A 0.18 <0.001
568 16.31 alive OA III 16.5 2.60 0.20 <0.001
619 0.48 dead OD III 11.9 2.50 0.28 <0.001
628 7.52 dead A II 10.9 N/A 0.21 <0.001
629 2.22 dead GBM 10.8 2.50 0.08 <0.001
711 14.18 alive PA 14.3 1.30 0.10 <0.001
712 0.19 lost to follow up PA 13.9 2.60 0.17 <0.001
qPCR
We first aimed to determine whether differences identified using expression profiling on 
snap frozen tissue could be found on RNA isolated from FFPE samples. For this initial test, 
we selected for samples that were assigned to two distinct molecular clusters based on the 
fresh frozen expression data (Cluster 9 (n=5) and Cluster 18 (n=6)) (Gravendeel et al., 2009). 
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Cluster 9 shows a favorable prognosis compared to the other clusters, and is specific for loss 
of heterozygosity (LOH) of 1p and 19q, as well as a high frequency of IDH1 mutations. Cluster 
18 has poor prognosis and is characterized by EGFR amplifications and CDKN2A deletions. The 
RT-qPCR results showed that both direction and fold change of all four genes in all samples 
could be recapitulated on RNA isolated from FFPE samples. Overall correlation was relatively 
strong r2 =0.61 (p<0.001). Correlations (r2) and p values for individual genes EMP3, SUSD5, 
CSMD3 and SLC2A10 were 0.34 (p=0.024), 0.840 (p<0.001), 0.849 (p<0.001) and 0.255 (p=0.047) 
respectively. These results demonstrate that differences in gene expression are retained in RNA 
isolated from FFPE samples (figure 1). 
Exon array expression data & Molecular clustering analysis
After the hybridization of the exon 1.0 ST arrays, we compared the Robust Multichip Average 
(RMA) normalized expression data of the exon arrays (FFPE) with exon 1.0 ST arrays that were 
analyzed in earlier studies (FF tissue) (French et al., 2007; Schutte et al., 2008). The exon arrays 
with FF tissue showed expression of more probe sets, as well as higher expression levels than 
the exon arrays with FFPE material (supplementary figure 2). On Hu133 plus 2.0 arrays (using 
FF samples), 9261±117 (52.9%) probe sets are expressed at RMA levels > 6.5. On exon arrays, 
59618 ±20337 (20.7%) probe sets are detected at p < 0.01, using DABG values. It should be 
noted that significantly more probe sets are detected on exon arrays using fresh frozen tissue 
(141493±12924 [49.2%], see also supplementary figure 1. In addition, the distribution of the 
RMA expression histograms of the FFPE glioma tissue is shifted compared to the expression 
histograms of exon arrays with FF tissue (supplementary figure 3).
Figure 1. correlation of the expression of the rNA (FFPe) and the rNA (FF) of eleven matched 
FF-FFPe samples. The four genes (EMP3, SLC2A10, SUSD5, CSMD3) chosen are the most discriminating 
genes between two very distinct molecular subtypes. A) The correlation between the ΔCt of the qPCR 
results (FFPE material) and the expression data of the HU133plus 2.0 arrays (FF tissue). A high ΔCt value 
is indicative for a low expression value. The correlation plot shows a good correlation between the FF 
expression and the FFPE expression. B) This correlation view shows the correlation of the expression 
of the FF tissue (HU133 plus 2.0 array) and the expression of the FFPE tissue (qPCR). The green color 
represents high expression, red represents low expression. The molecular clusters can be identified using 
the RNA isolated from FFPE. 
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Exon arrays contain one or more probe sets per exon for each gene (287,329 core probe sets for 
22,011 genes), whereas only one data point per gene is generated on HU133plus2 arrays (17,583 genes, 
when using the alternative .cdf based on entrezgene) (Dai et al., 2005). We therefore first selected 
the probe sets on exon arrays that likely contain most of the biological information. Because genes 
that discriminate between molecular subtypes are by definition differentially expressed, and thus 
show a relatively high variance in expression, we selected the probe set with highest variance per 
gene (n=17,583 probe sets [6.2% of all “core” probe sets]) (log2 normalized data). Selecting the 
most variable probe set on exon arrays does not always identify those with highest correlation 
to expression on HU133plus2.0 arrays. However, selection based on variance approaches both 
datasets independently and avoids potential circular arguments. All further analysis was therefore 
done using the selection of exon-array probe sets based on variance as starting data set. 
In our previous study we performed molecular clustering with FF tissue based on the 5,000 
most variable genes (FF: 5,000). The overlap between the most variable probe sets in FF tissue and 
the most variable probe sets in FFPE tissue (FF: 5,000/ FFPE: 17,853) consisted of 4,620 matching 
probe sets (figure 2A).
The set of 17,853 probe sets assumes that all genes have at least one informative probe 
set per gene. It is however possible all probe sets that belong to the same gene perform 
Figure 2. Flow charts of the selection of probe sets containing the most informative gene expression 
data. A) We first selected the probe set with highest variance per gene (n=17,583 probe sets; FFPE: 17,583). In 
our previous study we performed molecular clustering with FF tissue based on the 5,000 most variable genes 
(FF: 5,000). The overlap between the most variable probe sets in FF tissue and the most variable probe sets in 
FFPE tissue (FF: 5,000/ FFPE: 17,853) consisted of 4,620 matching probe sets. Based on these 4,620 probe sets, 
samples were assigned to one of the seven molecular clusters using ClusterRepro. B) When using exon arrays, 
it is possible that no informative probe sets are available for a single gene, and such probe sets may be filtered 
out by selecting not only the most variable probe set per gene, but, of these, the most variable 5,000 probe 
sets (FF: 5,000/ FFPE:5,000). By using this filter, there are 1,827 overlapping probe sets. ClusterRepro was used 
to assign the samples to one of the seven molecular clusters based upon these overlapping probe sets.
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poorly. We therefore also performed a further selection of the 17,583 exon array probe sets, by 
selecting the 5000 most variable probe sets of these 17,583 (1.74% of the total number of “core” 
probe sets, figure 2B). Using the 5,000 most variable probe sets for both FF and FFPE material 
showed an overlap of 1,827 matching probe sets (FF: 5,000/ FFPE:5,000, 1,827 overlapping 
probe sets) (figure 2B).
We first compared the gene expression data (FF) of the genes used in the qPCR analysis 
(EMP3, SUSD5, CSMD3 and SLC2A10) with the expression data of the FFPE material. For 
this analysis we used the expression data of the same 11 samples that were also used in 
the qPCR analysis. Figure 3 shows the correlation of the qPCR genes (EMP3, CSMD3 and 
SLC2A10) between the expression of the FF RNA and the FFPE RNA. These results show a 
weak correlation between the FF and FFPE expressions for both EMP3 and SLC2A10 (r2=0.32; 
p=0.028; and r2= 0.21; p=0.067), and a good correlation for CSMD3 (r2= 0.97; p<0.001). There 
was no data available of SUSD5 since there were no probe sets of this gene on exon 1.0 ST 
arrays. These results highlight that exon arrays can show a concordance in gene expression 
compared to FF tissue, but that a selection of the biologically most informative probe sets is 
required.
Figure 3. correlation of the qPcr genes (EMP3, CSMD3 and SLC2A10) between the expression of 
the FF rNA and the FFPe rNA. We compared the gene expression data (FF; HU133 plus 2.0) of the four 
genes used in the qPCR analysis (EMP3, SUSD5, CSMD3 and SLC2A10) with the expression data of the FFPE 
material (Exon 1.0 ST). We used the expression data of the same 11 samples that were also used in the qPCR 
analysis. Panel 3A and panel 3B show a weak correlation for both EMP3 (r2= 0.32) SLC2A10 (r2= 0.21). A good 
correlation is seen for CSMD3 (r2= 0.97) (panel 3C). There was no data available of SUSD5 since there were 
no probe sets of this gene on exon 1.0 ST arrays.
We next compared the normalized expression data of the 5,000 most variable genes as used 
in our previous study, with the expression of the most variable exons (FF: 5,000/ FFPE: 17,583, 
4,620 matching probe sets) (Gravendeel et al., 2009). In general, the strength of correlation 
between FF and FFPE expression in a single sample (sample 8) was weak (r2= 0.24, p<0.001). 
It should be noted that part of the between FF and FFPE sample variability is biological: The 
snap frozen and FFPE tissues are not taken from exactly the same location within a tumor. For 
this analysis we compared differential gene expression between samples of cluster 9 and 18 
(separately for FF and FFPE). The correlation (r2) in differential gene expression between FF and 
FFPE was 0.38. 
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2We did the same analysis for the most variable 5,000 probe sets (FF: 5,000/ FFPE: 5,000, 
1,827 overlapping probe sets). Differential gene expression between samples of Cluster 9 and 
Cluster 18 then showed a relatively strong correlation between FF on HU133 plus 2.0 and FFPE on 
HuEx 1.0 ST arrays (R2 = 0.54; p<0.001 (figure 4). Our results demonstrate that differential gene 
expression between samples observed using RNA isolated from FF tissue is at least partially 
retained on RNA isolated from FFPE samples.
Figure 4. Differential gene expression between samples of cluster 9 and cluster 18. The differential 
gene expression between samples of two molecularly very distinct clusters (Cluster 9 and 18) showed a 
relatively good correlation between 18 FF samples on HU133 plus 2.0 and 18 FFPE samples on HuEx 1.0 ST 
arrays (R2= 0.54). For this analysis we used the 5,000 most variable probe sets of the exon expression data 
and subtracted the median expression of Cluster 18 from the median expression of Cluster 9.
Expression data of fresh frozen samples is performed HU133 Plus 2.0 arrays, a platform that 
is different from the platform used for FFPE samples (HuEx 1.0 st arrays). We have therefore 
compared expression of all probes (287,329) between FF and FFPE on exon arrays of eight 
matched samples (8, 40, 130, 206, 257, 259, 275, 293). In general, correlation between FF and 
FFPE samples on the same platform was reasonable (r2 = 0.315 ± 0.093 range 0.210-0.450, 
P<0.001). This correlation was much better than the overall correlation (also using 287,329 
probe sets) between FF on HU133 Plus 2.0 arrays and FFPE on HuEx 1.0 st arrays (0.034±0.023). 
The better correlation between FF and FFPE samples on the same platform therefore indicates 
that differential gene expression is better retained when using the same platform. 
Cluster assignment
Recently, we described the identification of seven molecular glioma subtypes based on gene 
expression profiling, which are a better predictor of survival than histology (Gravendeel et al., 
2009). Our final assessment to determine the suitability of RNA isolated from FFPE samples 
was to confirm sample assignment to individual molecular subtypes. Clustering results are 
represented in table 2. Overall, assignment to the correct cluster (e.g. assignment to the 
same molecular cluster as the FF tissue in the previous study) was seen in 76% (n=42) of the 
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Db no clustering rNA (FF)
clustering rNA FFPe 
17,853 most variable exons
clustering rNA FFPe 
5,000 most variable exons
8 9 9 9
40 9 9 9
55 9 9 9
63 0 17 0
77 0 23 23
92 18 18 18
98 22 22 22
99 23 17 0
104 23 23 23
105 23 23 23
112 23 23 23
119 22 22 22
123 17 17 17
130 9 9 9
134 17 17 17
143 0 0 0
174 23 23 23
183 23 23 23
194 18 18 18
198 17 17 17
199 18 18 18
206 22 0 0
209 17 17 17
227 22 17 17
253 18 18 18
256 18 18 18
257 9 9 9
258 18 23 23
259 9 23 23
286 17 17 17
291 18 18 18
293 0 9 9
315 17 17 17
336 22 9 0
353 22 22 22
380 9 23 23
387 22 22 17
393 23 23 23
416 17 17 17
420 22 0 0
441 9 0 0
445 18 18 18
446 16 23 23
467 22 22 22
table 2. Cluster assignment of samples. FF = fresh frozen; FFPE = fixed in formalin and embedded in paraffin. 
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2Db no clustering rNA (FF)
clustering rNA FFPe 
17,853 most variable exons
clustering rNA FFPe 
5,000 most variable exons
473 9 9 9
515 23 23 23
536 17 17 17
565 23 23 23
566 23 23 23
568 17 17 17
619 18 18 18
628 0 0 0
629 23 23 23
711 16 16 0
712 16 16 16
samples (FF: 5,000/ FFPE: 17,583). However, part of the variability between FF and FFPE samples 
is biological and may represent tumor heterogeneity. This heterogeneity is specifically notable 
for assignment to Cluster 0, as assignment to this cluster depends on the relative amount of 
non-neoplastic tissue present. Indeed, the overlap between FF and FFPE cluster assignment 
when excluding samples that are assigned to Cluster 0 is 86% (n=42/49). A total of 13 samples 
were assigned to a different molecular cluster, 7 without Cluster 0.
Similar performance in cluster assignment was observed when using the 5,000 most variable 
exon probe sets (FF: 5,000/ FFPE: 5,000) (figure 2B). Assignment to the identical cluster was 
seen in 75% (n=41) of the samples, 87% without Cluster 0 (n=41/47). 
Assignment to the same molecular cluster as the paired FF tissue did not have a significant 
correlation with the time in paraffin. The “wrongly” assigned blocks even showed a slightly 
shorter median time in paraffin than the “correctly” assigned samples (11.9 years vs. 14.3 years; 
p=0.07). The average RIN score of the incorrectly assigned samples was 2.18 ±0.40 and was not 
significantly different from the RIN scores of the correctly assigned samples 2.24±0.34, p=0.71). 
The high degree of overlap between FF and FFPE sample assignment (both FF: 5,000/ FFPE: 
17,583 and FF: 5,000/ FFPE: 5,000) is reflected in a highly similar patient survival curves (figure 5). 
However, FFPE survival curves also include three samples that originally were assigned to 
Cluster 0.
DISCUSSION
In this study, we describe a method that allows analysis of gene expression profiling of FFPE 
cancer tissue using HuEx 1.0 ST arrays. Our data show that expression data of RNA isolated from 
FFPE and FF tissues are comparable. However, a selection on the most informative probe sets 
(based on highest variance for each probe set/gene and highest variance between genes) is 
required. RIN score and the age of the FFPE tissue blocks do not influence the gene expression 
results. The average RIN score and the average time in paraffin of the incorrectly assigned 
samples were not significantly different from the RIN scores and time in paraffin of the correctly 
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Figure 5. Kaplan-Meier survival curves of the seven molecular clusters identified in FF and FFPe 
material show a high resemblance. A) This panel shows the survival of the seven molecular clusters 
identified, using FF material of the fifty-five patients included in this study (HU133 plus 2.0 arrays). B) Panel 
B shows the survival curves of the molecular clusters to which the FFPE tissue was assigned based on the 
17,852 most variable probe sets from the Exon 1.0 ST arrays. C) Panel C shows the survival curves of the 
molecular clusters to which the FFPE tissue was assigned by filtering the exon data on the 5,000 most 
variable probe sets. 
assigned samples. The probe sets identified in this study can be used in other profiling studies 
that lack paired FF samples. 
Differential gene expression between samples is well retained (figure 4). This is also illustrated 
by the identical assignment to intrinsic molecular subtypes for both FF and FFPE glioma tissue 
in up to 87% of the samples (table 2). It should be noted that FF and FFPE tissues are resected 
from different parts of the tumor. Therefore, tumor heterogeneity may also contribute to the 
differential assignment between FF and FFPE samples.
Previous studies demonstrated that FFPE samples can be used for gene expression profiling 
either using the Affymetrix (Exon 1.0 and HU133 plus 2.0) or Illumina (DASL) platforms (Hall et 
al., 2011; Hoshida et al., 2008; Linton et al., 2009; Linton et al., 2008; Mittempergher et al., 2011). 
However, these studies had limited sample size, lacked controlled experiments with paired 
FF-FFPE sample analysis, or were used to differentiate between very distinct cancers. Our study 
is the first to use a large cohort of paired FF-FFPE glioma samples for expression profiling with 
exon 1.0 ST arrays. We show that degraded RNA that is up to 25 years old, is suitable to identify 
subtle differences between subtypes within one specific cancer. 
Other genome wide techniques are also available that can perform expression profiling on 
FFPE samples, including the DASL platform (Illumina). The platform chosen for this study was 
based on reports from literature (Linton et al., 2009; Linton et al., 2008), and it is beyond the 
scope of this manuscript to compare performance of both platforms. Although it is possible 
other platforms perform better on FFPE samples, our study demonstrates that sufficient 
information is stored in FFPE samples so that it can be used for expression profiling using exon 
1.0 ST arrays. Our method allows molecular classification of archived clinical trial samples to 
evaluate the predictive and prognostic values of the molecular glioma clusters. Furthermore, 
it allows assignment of FFPE material of newly diagnosed patients to molecular clusters. Such 
assignment would allow clinicians to improve patients’ diagnosis and would contribute to 
treatment decisions. 
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3ABStRACt
Mutations in the gene encoding the isocitrate dehydrogenase 1 gene (IDH1) occur at a high 
frequency (up to 80%) in many different subtypes of glioma. In this study, we have screened for 
IDH1 mutations in a cohort of 496 gliomas. IDH1 mutations were most frequently observed in low 
grade gliomas with c.395G>A (p.R132H) representing >90% of all IDH1 mutations. Interestingly, 
non-p.R132H mutations segregate in distinct histological and molecular subtypes of glioma. 
Histologically, they occur sporadically in classic oligodendrogliomas and at significantly 
higher frequency in other grade II and III gliomas. Genetically, non-p.R132H mutations occur 
in tumors with TP53 mutation, are virtually absent in tumors with loss of heterozygosity on 
1p and 19q and accumulate in distinct (gene-expression profiling based) intrinsic molecular 
subtypes. The IDH1 mutation type does not affect patient survival. Our results were validated 
on an independent sample cohort, indicating that the IDH1 mutation spectrum may aid glioma 
subtype classification. Functional differences between p.R132H and non-p.R132H mutated IDH1 
may explain the segregation in distinct glioma subtypes. 
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INtRODUCtION
Approximately 200.000 people worldwide are diagnosed with primary brain cancer each 
year (1). The most common type of primary brain tumor (~40%) are gliomas. Based on their 
histological appearance, gliomas can be divided into three distinct types of tumors according 
to the standard WHO classification (2): Astrocytic tumors (75%), pure oligodendroglial tumors 
(ODs) and mixed oligoastrocytic tumors (MOAs) (25%). Tumors are further classified into 
grades II, III (anaplastic) and IV (Glioblastomas, GBMs) depending on the number of malignant 
features present. Despite advances in neurosurgery, chemotherapy and radiotherapy the 
prognosis for most glioma patients remains dismal (3).
Recently, a genetic screen identified somatic mutations in the isocitrate dehydrogenase 1 
gene (IDH1 [OMIM 147700],) in glioblastomas (4). IDH1 catalyzes the oxidative decarboxylation 
of isocitrate to a-ketoglutarate and uses NADP(+) as the electron acceptor (5-6). Additional 
analysis showed that IDH1 mutations occur at a very high frequency (up to 80%) in all grade II 
and III gliomas (astrocytic, oligodendrocytic and oligoastrocytic) and secondary GBMs (4, 7-13). 
IDH1 mutations do not occur at significant frequencies in other tumor types, with the notable 
exception of acute myeloid leukemia (AML) (12, 14-15). The reported mutations in IDH1 all result 
in a reduced enzymatic activity towards its native substrate, isocitrate (9, 12, 16).
Mutations in the IDH1 gene are heterozygous and virtually always affect only a single 
residue (arginine 132) which is replaced by a histidine in approximately 90% of tumors (c.395G>A 
resulting in p.R132H (7, 9-10, 12). However, non-p.R132H mutations in the IDH1 gene (e.g. 
p.R132C) have been reported to accumulate at higher frequencies in histological subtypes of 
glioma (17), in astrocytomas of Li-Fraumeni patients (18) and in patients with AML (15). Distinct 
mutations within the same gene but affecting the same codon therefore appear to segregate 
in distinct tumor subtypes. 
In this study, we demonstrate that non-p.R132H mutations specifically accumulate in distinct 
histological subtypes of glioma. Because histological classification of gliomas is subject to 
significant interobserver variability (19), we also used molecular markers (TP53 [OMIM 191170], 
1p/19q LOH and intrinsic molecular subtypes) to identify the glioma subtypes. Our results 
demonstrate that non-p.R132H mutations indeed segregate in distinct histological, genetic and 
molecular subtypes of gliomas 
MAtERIALS AND MEtHODS
Samples 
Glioma samples were collected from five hospitals in the Netherlands (Erasmus MC, Rotterdam; 
UMCU, Utrecht; NCI and VUMC, Amsterdam; RUNMC, Nijmegen) from patients, operated from 
1989-2009. Use of patient material was approved by the Institutional Review Board. All samples 
are listed in the supplementary data table 1. Histological diagnoses were made on formalin-fixed, 
paraffin-embedded Haematoxylin & Eosin sections and were reviewed by the neuropathologist 
(J.M.K.). Genomic DNA from snap frozen or formalin fixed, paraffin embedded tissue samples 
was isolated as described (20)2009; (21). Of the 496 glioma samples reported in this study, 
247 were derived from a series of gliomas of all histologies (set A) (20), 54 from a series of low 
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3grade astrocytomas (set B) (21), 24 were derived from samples operated in Rotterdam that were 
included in EORTC 26951 (set C) (22) and 171 novel glioma samples (set D). The IDH1 status of 297 
samples was described previously (20-21). IDH1 (NM_005896.2, GI:28178824) mutational status 
of the remaining 199 samples was determined as described (14), see also supplementary data 
table 2.
1p/19q status was determined in 317 samples. 1p19q LOH was determined by fluorescent 
in-situ hybridization (FISH) (23), inferred from genotyping arrays or by microsatellite analysis. 
Microsatellites were amplified by PCR on 20 nanogram genomic DNA, using a fluorescently 
labeled forward primer and a reversed primer. Allelic losses were statistically determined as 
described and scored by two independent researchers (24). TP53 (NM_000546.4, GI:187830767) 
status was determined in 169 samples. Primers and cycling conditions to determine the TP53 
mutation status are stated in the supplementary data table 2.
Statistical analysis 
Comparison between frequencies of different groups was assessed using the Fisher exact test. 
The significance of IDH1 mutation type was assessed by univariate and multivariate analysis 
using Cox Regression. Differences between Kaplan-Meyer survival curves were calculated by 
the Log-rank (Mantel-Cox) test. Survival time was defined as the period from date of surgery to 
date of death. If date of death was not available, date of last follow-up was used. 
RESULtS AND DISCUSSION
Dataset 
We have screened for mutations in IDH1 in a large cohort of 496 glioma samples. In this dataset, 
a total of 246 mutations in the IDH1 gene were identified (49.6%). The IDH1 mutation frequency 
for all grades II and III gliomas was high and ranged from 49% in anaplastic oligoastrocytic 
tumors to 79% in low grade oligodendrogliomas (table 1). The frequency of genetic changes 
in our sample cohort is similar to reported by others (7, 12-13, 17, 25). The frequency of IDH1 
mutations in grade II gliomas (76%, n=110/144) was higher than in grade III tumors (58%, 
table 1. The frequency of IDH1 (NM_005896.2, GI:28178824) mutations, LOH on 1p and 19q and mutations in 
TP53 (NM_000564.4, 187830767) in different histological. ODII/ODIII: grade II/III oligodendroglioma, OAII/OAIII: 
grade II/III oligoastrocytoma, AII/AIII: grade II/III astrocytoma, GBM: glioblastoma. nd: not determined.
  n p.r132H p.r132X IDH1 wt 1p/19 LoH no loss nd tP53 mut tP53 wt nd
ODII 43 34 0 9 21 9 13 0 6 37
ODIII 106 63 1 42 57 31 18 7 18 81
OAII 28 21 1 6 6 10 12 1 3 24
OAIII 39 15 4 20 3 23 13 8 2 29
AII 73 48 6 19 2 53 18 29 18 26
AIII 32 15 4 13 1 18 13 12 6 14
GBM 175 31 3 141 10 73 92 27 32 116
total 496 227 19 250 100 217   84 85  
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n=102/177, P<0.001) (see also (10)). More specifically, low grade oligodendrogliomas (79%, 
n=34/43) and oligoastrocytomas (79%, n=22/28) have a higher IDH1 mutation frequency then 
their corresponding grade III tumors (60%, n=64/106 and 49%, n=19/39 respectively P<0.05). 
A similar difference in frequency can also be extracted from at least two external sample 
cohorts (11, 17).
The observation of a higher mutation incidence in lower grade tumors has thusfar been 
described for only a few genes (see e.g. (26)). This differential frequency indicates that low 
grade tumors can accumulate distinct genetic changes and thus represent a different disease 
entity. Moreover, such differential frequency indicates that the IDH1 mutation status can, at 
least to some extent, serve as a marker for low grade gliomas (see also (27-28)).
Non-p.R132H mutations in IDH1 segregate in distinct glioma subtypes 
The majority of mutations (92.3%) in the IDH1 gene were heterozygous c.395G>A missense 
mutations that result in an arginine to histidine substitution on position 132 (p.R132H). However, 
19/246 mutations (7.7%) were non-p.R132H mutations: Single nucleotide changes that result in 
different amino acid substitutions albeit on the same position. Similar to reported, c.394C>T 
(p.R132C) was the second most common mutation type in our sample cohort and was identified 
in nine gliomas. Other non-p.R132H mutations were p.R132S (n=5), p.R132G (n=3), p.R132L (n=1) 
and p.R132P (n=1). 
When focusing on non-p.R132H IDH1 mutations in our dataset, we observed that in classical 
oligodendrogliomas (combined grades II and III), only one out of the total of 98 IDH1 mutations 
(1.0%) was non-p.R132H (figure 1). A significantly larger proportion of non-p.R132H mutations 
was present in oligoastrocytic tumors (5/41, P<0.01) and in astrocytic tumors (10/73, P<0.001). 
Significance remained within the different tumor grades (figure 1). These results indicate 
that, although non-p.R132H mutations are rare, they are not uniformly distributed across the 
different histological subtypes of glioma. 
Figure 1. Distribution of non-p.r132H 
mutations in IDH1 in different histological 
subtypes of glioma. Plotted is the relative 
frequency of non-p.R132H mutations 
in IDH1 mutated histological subtypes 
of glioma. Absolute numbers for each 
subtype is stated in/above individual bars. 
For example, IDH1 mutations are observed 
in 54 grade II astrocytomas. Of these, six 
are non-p.R132H. As can be seen, non-p.
R132H mutations are sporadically observed 
in oligodendrogliomas and more frequent 
in oligoastrocytomas and astrocytomas. 
*: P<0.05, **: P<0.01, Fishers’ exact test.
proportion of non-p.R132H mutations was present in oligoastrocytic tumors (5/41, 
P<0.01) and in astrocytic tumors (10/73, P<0.001). Significance remained within the 
different tumor grades (figure 1). These results indicate that, although non-p.R132H 
mutations are rare, they are not uniformly distributed across the different histological 
subtypes of glioma.  
We aimed to confirm the differential distribution of non-p.R132H mutations using 
objective molecular markers. We first screened for combined LOH on 1p and 19q; 
chromosomal losses that are freque tly observed in oligodendrogliomas and 
relatively rare in astrocytic tum rs 29-30)). These losses are caused by an
unbalanced translocation betwee  chromosom s 1 and 19 [t(1;19)(q10, 10)] (31-32). 
In our entire dataset, 1p/19q LOH was determined in 317 (63.9%) samples. Of the 
tumors with combined 1p/19q LOH (n=100), a mutation in the IDH1 gene was 
detected in 75 samples (75%). In these 75 samples, only one non-p.R132H mutation 
was identified (1.3%, figure 2). Conversely, in tumors that have retained 1p and/or 
19q (n=217), the proportion of non-p.R132H mutations was significantly higher, 
13/106 (12.3%, P<0.01). Non-p.R132H mutations therefore segregate in tumors that 
do not show combined 1p/19q LOH. 
 
 
 
Figure 1. Distribution of non-p.R132H mutations in IDH1 in different 
histological subtypes of glioma. Plotted is the relative frequency of non-
p.R132H mutations in IDH1 mutated histological subtypes of glioma. 
Absolute numbers for each subtype is stated in/above individual bars. For 
example, IDH1 mutations are observed in 54 grade II astrocytomas. Of 
these, six are non-p.R132H. As can be seen, non-p.R132H mutations are 
sporadically observed in oligodendrogliomas and more frequent in 
oligoastrocytomas and astrocytomas. *: P<0.05, **: P<0.01, Fishers’ exact 
test. 
 
We then correlated the type of IDH1 mutation to the TP53 mutation status. TP53 
mutations are frequently observed in astrocytomas and secondary glioblastomas but 
relatively rare in oligodendrogliomas and primary glioblastomas (29, 33). In our entire 
dataset, TP53 mutation status was determined in 169 samples (34.1 %). Of the 
tumors with a mutation in TP53 (n=84), a mutation in the IDH1 gene was detected in 
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We then correlated the type of IDH1 mutation to the TP53 mutation status. TP53 mutations 
are frequently observed in astrocytomas and secondary glioblastomas but relatively rare in 
oligodendrogliomas and primary glioblastomas (29, 33). In our entire dataset, TP53 mutation 
status was determined in 169 samples (34.1 %). Of the tumors with a mutation in TP53 (n=84), 
a mutation in the IDH1 gene was detected in 65 samples (77.4%). Non-p.R132H mutations were 
identified in 12 of these 65 samples (17.9%, figure 2). Conversely, in tumors with wt TP53 (n=85), 
the proportion of non-p.R132H mutations was significantly lower (3/54) (5.6%, P<0.05). Non-p.
R132H mutations therefore accumulate in tumors with a mutation in the TP53 gene.
Finally, we determined whether non-p.R132H mutations segregate in intrinsic, gene 
expression based-, molecular subtypes of glioma. In a recent study, we identified seven intrinsic 
glioma subtypes based on gene expression profiles of 276 gliomas of all histological subtypes 
and grades (20). As reported, IDH1 mutations were most frequently observed in clusters 9 and 
17 (27/40 and 22/32 respectively). When focusing on the non-p.R132H mutations (n=8) in this 
cohort, they were relatively rare in cluster 9 (n=1/27, 3.7%) and more frequent in cluster 17 (5/22, 
22.7%, P=0.05). Other non-R132 samples were identified in clusters that have relatively few IDH1 
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test.
65 samples (77.4%). Non-p.R132H mutations were identified in 12 of these 65 
samples (17.9%, figure 2). Conversely, in tumors with wt TP53 (n=85), the proportion 
of non-p.R132H mutations was significantly lower (3/54) (5.6%, P<0.05). Non-
p.R132H mutations therefore accumulate in tumors with a mutation in the TP53 gene. 
 
 
 
 
 
Figure 2. The frequency of non-p.R132H mutations in IDH1 is correlated to 
distinct genetic changes in gliomas. Non-p.R132H mutations are more 
prevalent in gliomas that do not show combined LOH on 1p and 19q (left) 
and in gliomas with a TP53 mutation (right). Absolute numbers for non-
p.R132H mutations/total number of IDH1 mutations are stated in/above the 
individual bars. *: P<0.05, **: P<0.01, Fishers’ exact test. 
 
Finally, we determined whether non-p.R132H mutations segregate in intrinsic, gene 
expression based-, molecular subtypes of glioma. In a recent study, we identified 
seven intrinsic glioma subtypes based on gene expression profiles of 276 gliomas of 
all histological subtypes and grades (20). As reported, IDH1 mutations were most 
frequently observed in clusters 9 and 17 (27/40 and 22/32 respectively). When 
focusing on the non-p.R132H mutations (n=8) in this cohort, they were relatively rare 
in cluster 9 (n=1/27, 3.7%) and more frequent in cluster 17 (5/22, 22.7%, P=0.05). 
Other non-R132 samples were identified in clusters that have relatively few IDH1 
mutations; one in cluster 0 and one in cluster 18 (20). Non-p.R132H mutations 
therefore appear not to be uniformly distributed across intrinsic molecular subtypes of 
glioma.  
 
Validation of non-p.R132H segregation. The segregation of non-p.R132H 
mutations into distinct molecular subtypes of gliomas was validated on a recently 
described independent cohort of glioma samples (25). In this study, a total of 119 
mutations in IDH1 were identified across various histological subtypes, nine of which 
were non-p.R132H. Non-p.R132H mutations are clearly more prevalent in IDH1 
mutated astrocytomas (7/45) compared to IDH1 mutated oligodendrogliomas (0/35, 
P<0.05). Furthermore, a significantly higher proportion of non-p.R132H mutations 
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mutations; one in cluster 0 and one in cluster 18 (20). Non-p.R132H mutations therefore appear 
not to be uniformly distributed across intrinsic molecular subtypes of glioma. 
Validation of non-p.R132H segregation 
The segregation of non-p.R132H mutations into distinct molecular subtypes of gliomas was 
validated on a recently described independent cohort of glioma samples (25). In this study, 
a total of 119 mutations in IDH1 were identified across various histological subtypes, nine 
of which were non-p.R132H. Non-p.R132H mutations are clearly more prevalent in IDH1 
mutated astrocytomas (7/45) compared to IDH1 mutated oligodendrogliomas (0/35, P<0.05). 
Furthermore, a significantly higher proportion of non-p.R132H mutations was observed 
in tumors with both IDH1 and TP53 mutation (8/65) compared to tumors with wt TP53 (1/52, 
P<0.05). Finally, all non-p.R132H mutations were identified in tumors that have retained 1p and 
19q (9/74 vs. 0/45, P<0.05). In summary, non-p.R132H mutations are more prevalent in IDH1 
mutated astrocytomas, gliomas with TP53 mutation and gliomas that have retained 1p and 19q in 
this external dataset. These data therefore confirm our hypothesis that non-p.R132H mutations 
in IDH1 are more prevalent in distinct subtypes of gliomas. 
IDH1  mutation and patient survival 
In gliomas, the presence of an IDH1 mutation has been associated with prolonged survival 
within gliomas of similar malignancy grade (4, 10). In our dataset, the IDH1 mutation status 
was also positively correlated to prolonged survival in the entire dataset (3.3 vs. 0.84 years, 
P<0.0001) and in glioblastomas (2.0 vs. 0.72 years, P<0.001). Survival of our sample cohort 
was similar to population based studies (see e.g. (34) and www.cbtrus.org). To determine 
whether the IDH1 mutation type affects patient prognosis, we performed survival analysis on 
p.R132H vs. non-p.R132H mutated samples. Univariate analysis indicates that the type of IDH1 
mutation does not affect patient survival (P=0.74). The IDH1 mutation type also does not affect 
patient survival within histological and/or molecular subtypes of glioma. For example, in the 
molecular glioma subtype that has a relatively large proportion of non-p.R132H mutations 
(Cluster 17) the median survival between p.R132H (n=17) and non-p.R132H (n=5) mutated 
samples is similar (3.2 and 3.7 years respectively). It should be noted that the low numbers 
of non-p.R132H mutations within defined subtypes may obscure relatively small differences. 
However, multivariate analysis (in which known prognostic factors tumor type, grade and 
age at diagnosis were included), also indicates that the type of IDH1 mutation does not affect 
patient survival (P=0.44). Therefore, the IDH1 mutation type does not largely affect patient 
survival within our sample cohort.
Non-p.R132H mutations in IDH1 have been reported to accumulate at higher frequencies 
in distinct histological subtypes of gliomas (17) and other tumor types (15, 18, 35). However, 
histological diagnosis of gliomas is subject to significant interobserver variability (19). This 
study therefore provides evidence for the preferential accumulation of distinct types of 
IDH1 mutations not only in histological subtypes of glioma but also using molecular markers 
such as TP53, 1p/19q LOH and intrinsic molecular subtypes. We demonstrate that non-p.
R132H mutations are relatively frequent in astrocytic tumors, tumors with mutation in TP53 
and gliomas that do not show combined LOH on 1p and 19q. Although our results indicate 
that non-p.R132H mutations occur preferentially in tumors with distinct molecular features, 
53
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increased frequency. The sequence in mutation events may also influence the type of IDH1 
mutation acquired.
There are two possible explanations for the differential distribution of non-p.R132H 
mutations in glioma subtypes. First, it is possible that (epi) genetic differences between tumor 
types (e.g. differences in DNA repair due to e.g. MGMT [OMIM 156569] promoter methylation) 
result in the preferential accumulation of distinct mutations (see e.g. (36)). For example, MGMT 
promoter methylation is associated with transition type mutations in TP53 in colorectal cancer 
and in gliomas (37-38). Indeed, a higher percentage of oligodendroglial tumors show MGMT 
promoter hypermethylation compared to astrocytic tumors (39-41). Differences in the MGMT 
promoter methylation status between glioma subtypes may therefore explain the differential 
distribution of non-p.R132H mutations in IDH1. However, the transition/transversion ratio in 
IDH1 (i.e. p.R132H, C/p.R132S, G, L, P) between GBMs, astrocytic tumors (AII/III), oligoastrocytic 
tumors (OAII/III) or oligodendrocytic tumors (ODII/III) is similar (2/32, 5/68, 2/39 and 1/97 
respectively). We also failed to observe a difference in transition/transversion ratio in the 
TP53 gene in the respective histological subgroups (14/12, 26/13, 8/1 and 5/2). The transition/
transversion ratio in the TP53 gene between R132H and non-R132H mutated samples is also 
similar (39/15 and 8/3 respectively). Any possible difference in DNA repair between tumor types 
therefore is not reflected by a difference in the type of mutations acquired. 
A second tentative possibility is that different mutations have different functional 
properties. For example, non-p.R132H mutations may show some residual activity towards 
isocitrate either in cis (activity of the mutated enzyme itself) or in trans (by influencing the 
activity of the remaining wt enzyme (16)). Alternatively, a recent study described that mutated 
IDH1 is able to convert a-ketoglutarate into 2-hydroxyglutarate (42). Interestingly, different 
IDH1 mutation types showed a differential activity towards a-ketoglutarate. Whether this 
differential activity can explain the differential distribution of specific types of IDH1 mutations 
requires further detailed analysis. 
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4ABStRACt
Purpose: The MGMT promoter methylation status has been suggested to be predictive for 
outcome totemozolomide chemotherapy in patients with glioblastoma (GBM). Subsequent 
studies indicated thatMGMT promoter methylation is a prognostic marker even in patients 
treated with radiotherapy alone, bothin GBMs and in grade III gliomas.
Experimental Design: To help determine the molecular mechanism behind this prognostic 
effect, we have conducted genome-wide methylation profiling and determined the MGMT 
promoter methylationstatus, 1p19q LOH, IDH1 mutation status, and expression profile on 
a series of oligodendroglial tumors[anaplastic oligodendrogliomas (AOD) and anaplastic 
oligoastrocytomas (AOA)] within EORTC study26951. The series was expanded with tumors of 
the same histology and treatment from our own archive.
Results: Methylation profiling identified two main subgroups of oligodendroglial brain 
tumors of whichsurvival in the CpG island hypermethylation phenotype (CIMP +) subgroup was 
markedly better than the survival of the unmethylated (CIMP-) subgroup (5.62 vs. 1.24 years; 
P <0.0001). CIMP status correlated with survival, MGMT promoter methylation, 1p19q LOH, 
and IDH1 mutation status. CIMP status stronglyincreases the predictive accuracy of survival in 
a model including known clinical prognostic factors such asage and performance score. We 
validated our results on an independent data set from the Cancer GenomeAtlas (TCGA).
Conclusion: The strong association between CIMP status and MGMT promoter methylation 
suggests that the MGMT promoter methylation status is part of a more general, prognostically 
favorable genome-wide methylation profile. Methylation profiling therefore may help identify 
AODs and AOAs with improved prognosis. 
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INtRODUCtION
Glioblastomas (GBM) are the most common and aggressive type of glial brain tumor (1, 2). 
GBMs in which the MGMT promoter is methylated show an improved survival when treated 
with temozolomide, a finding that has resulted in MGMT promoter methylation to serve as 
a predictive biomarker in GBMs (3, 4). The predictive effect of MGMT promoter methylation 
can be explained by a reduced ability to respond to DNA damage by alkylating agents for 
methylated tumors. 
Two large randomized controlled trials that focused on patients with grade III glioma 
unexpectedly also revealed a prognostic effect of MGMT promoter methylation in patients 
treated with radiotherapy only (5, 6). Similarly, a retrospective survey in GBM suggests that 
MGMT promoter methylation also has prognostic significance in patients with GBM treated 
with radiotherapy only (7). The current understanding of the function of the MGMT protein 
does not explain the observed prognostic effect of MGMT promoter methylation in patients 
treated with radiotherapy only. 
Methylation in cancer often occurs in the promoter regions of tumor suppressor genes 
(8, 9). Inactivation of gene expression by promoter methylation thus contributes to tumor 
formation as the second “hit” in tumor suppressor genes [Knudson 2-hit hypothesis (10)]. 
Several groups have therefore conducted genome-wide methylation profiling in GBMs (11) and 
astrocytomas (12). Importantly, whole-genome methylation profiling on GBMs can identify a 
subset of tumors that have a more favorable prognosis (11, 13). These tumors show an overall 
increase in DNA methylation at CpG sites (CIMP: CpG island methylator phenotype; ref. 13). 
Later studies showed that histologic subtype was associated with methylation class and IDH1 
mutation, and that GBMs generally show less overall CpG methylation than lower grade gliomas 
(14, 15). Identification of CpG methylation sites in gliomas may therefore identify genes involved 
in the initiation and/or progression of gliomas [see e.g., (16, 17)]. Moreover, an association 
between CIMP and MGMT promoter methylation may also provide an explanation for the 
prognostic effect of MGMT promoter methylation. 
In this study, we conducted methylation profiling on a set of 68 anaplastic 
oligodendrogliomas (AOD) and anaplastic oligoastrocytomas (AOA) and correlated the results 
to molecular (MGMT methylation, IDH1 mutation, LOH on 1p and 19q, and gene expression 
profiles) and clinical [overall survival (OS)] parameters. Fifty of these tumors were treated as 
part of the EORTC 26951 clinical trial of which the primary objective was to see if the addition 
of adjuvant PCV chemotherapy immediately after radiotherapy (59.4 Gy) would improve OS in 
patients with AOD or AOA (18, 19). Our results indicate that methylation profiling identified 2 
main subgroups of anaplastic oligodendroglial brain tumors that highly correlate with survival, 
MGMT promoter methylation, 1p19q LOH, and IDH1 mutation status. The strong association 
between CIMP status and MGMT promoter methylation suggests that the MGMT promoter 
methylation status in anaplastic glioma is part of a more general, prognostically favorable 
genome-wide methylation profile.
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4MAtERIALS AND MEtHODS
Samples
Glioma samples were collected from EORTC study 26951 (n = 50) or the Erasmus MC tumor 
archive (n = 18). One additional control sample (normal adult brain) was obtained from the Dutch 
Brain Bank. Samples were collected immediately after surgical resection, snap frozen, and stored 
at -80°C. Clinical data are summarized in Supplementary Table S1. The number of samples chosen 
was based on the availability of 50 fresh frozen samples from the EORTC study 26951. Additional 
samples with similar clinical and treatment characteristics were included to increase power of 
the study whilst maintaining the predominance of EORTC 26951 samples. Part of the molecular 
data of the EORTC 26951 samples was previously reported (5). Survival time was defined as the 
period from date of surgery to date of death. Patients were censored at the date of last follow-up. 
Patients were eligible for EORTC study 26951 if they had been diagnosed by the local pathologist 
with AOD or AOA with at least 25% oligodendroglial elements according to the 1994 edition 
of the WHO classification of brain tumors; had at least 3 of 5 anaplastic characteristics (high 
cellularity, mitoses, nuclear abnormalities, endothelial proliferation, or necrosis); were between 
16 and 70 years of age; had an Eastern Cooperative Oncology Group (ECOG) performance status 
of 0 to 2; and had not undergone prior chemotherapy or RT to the skull. Patients provided 
written informed consent according to national and local regulations for the clinical study and 
correlative tissue studies. For details of the EORTC study 26951 see reference (18). Additional 
samples from the Erasmus MC archive were selected on the basis of similar inclusion criteria 
as the EORTCstudy 26951: Histologic diagnosis AOA or AOD, age 16 to 70, and patients having 
undergone similar treatment as the patients in EORTC 26951 (radiotherapy with or without 
chemotherapy) and with similar clinical characteristics. For research on these samples approval 
has been obtained from the Erasmus MC institutional review board. Sample collection time 
for EORTC 26951 samples is from 1998 to 2002. Sample collection time for non-EORTC 26951 
samples is from 1989 to 2004. Mean follow-up time for all samples is 96.4 months. Survival data 
are collected till death or, for censored patients, either until lost to follow-up or to date.
Nucleic acid isolation, cDNA synthesis, and array hybridization
Genomic DNA was isolated from 5 to 40 cryostat sections of 40 mm thickness using the QIAamp 
DNA Mini Kit (Qiagen) according to the manufacturer’s instructions. Quality was assessed on 
agarose gel electrophoresis, in which a dominant high molecular weight DNA species should 
be present. For methylation profiling, 1 mg of genomic DNA was subjected to bisulphite 
modification using the EZ DNA methylation kit (Zymo research company). Bisulphite-converted 
DNA was then hybridized to Illumina Infinium Human Methylation27 arrays (Illumina) by Service 
XS (Leiden) according to standard Illumina protocols. Infinium Human Methylation27 arrays 
interrogate 27,578 Cp Gsites across 14,476 genes. Robustness of sample processing was assessed 
using 2 biological replicates, and resulted in replicates clustering very tightly to each other. 
These replicates were not included in any analysis. Data are available on request.
Unsupervised clustering analysis
Clustering was conducted using the hierarchical ordered partitioning and collapsing hybrid 
(HOPACH) algorithm (20). This clustering was used to identify molecular subgroups in gliomas 
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on 2,000 CpG sites with highest variance. Virtually identical clusters were identified using all or 
the 500, 1,000, 5,000, or 10,000 CpG sites with highest variance.
Nonparametric bootstrapping was used to estimate the probability that each sample 
belongs to a cluster (i.e., fuzzy clustering) and thus determine cluster stability. Samples were 
assigned to a cluster when at least 50% of bootstraps allocated the sample to that specific 
cluster.
Cluster validation was conducted by representing each of the molecular clusters in our 
data set by its centroid and classifying external samples to their nearest centroid. Samples 
belonging to the original data set that were not assigned to one of the 2 large clusters were 
similarly assigned to the nearest centroid. Robustness of external validation was estimated with 
the in-group proportion cluster quality measure (21).
Molecular analysis
The IDH1 mutation status was determined by direct sequencing as described (22, 23). 1p19q 
LOH was determined previously by FISH (19). Probes used were D1S32 (for 1p36), pUC1.77 (for 
centromere 1), equivalent amounts of bacterial artificial chromosome (BAC) RPCI 11-959O6, 
11-957I1, and 11-153P24 (for 19p), and BAC 426G3 (for 19q). Expression profiles were determined 
previously (20). The MGMT methylation status was determined on the snap-frozen DNA used 
for methylation profiling, using the methylation-specific multiplex ligation–dependent probe 
amplification (MS-MLPA) assay (ME011, MRC Holland) essentially as described (24). This assay 
uses a methylation-sensitive restriction enzyme (HhaI) and contains 3 probes within the MGMT 
promoter/gene. PCR products were separated by capillary gel electrophoresis (ABI Prism 
3130 x l; Applied Biosystems) and quantified by use of the GeneMarker Software version 1.7 
(SoftGenetics). 
The MS-MLPA results were normalized by dividing the peak height for each MGMT probe 
signal by the mean peak height for 8 control fragments within the same sample. The fraction 
of methylated MGMT promoter DNA was calculated by normalized values of each probe of 
HhaI-digested DNA divided by normalized values of corresponding undigested DNAs (24). A 
sample was considered to have a methylated MGMT promoter when the average fraction of the 
3 MGMT probes was more than 0.25.
Statistical analysis
Spearman correlation coefficient was used to assess the strength of the association between 
parameters. The Fisher exact test was used in the comparisons of patient and disease 
characteristics between subgroups. The Kaplan–Meier technique was used to assess OS and 
the log-rank test was computed to compare the survival of subgroups. The Cox regression 
was used for multivariate OS analysis including age, performance status, IDH1 mutation status, 
1p19q LOH, MGMT methylation status, and CIMP. The forward stepwise method was used to 
select variables with independent prognostic value. 
The models’ predictive accuracy was assessed by the Harrel c-index. The c-index is the 
probability that for 2 patients chosen at random, the patient who had the event first had a 
higher probability of having an event according to the model. C-index equal to 0.50 represents 
agreement by chance; c-index = 1.0 represents perfect discrimination. In the absence of an 
independent data set, the bootstrap technique was used to obtain a c-index corrected for 
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4optimism, that is, the model overfitting the data. No adjustment for multiple testing was 
conducted in this exploratory analysis. The power of multivariate analyses was limited and P 
values were presented to point out what the main effects or differences are, but not to provide 
definitive conclusions. The descriptive comparisons of the c-index among different multivariate 
models allow assessing the relative contribution of CIMP to the classification of patients for 
their survival. SAS version 9.2 (SAS Institute Inc.) was used for all statistical analyses except the 
computation of the c-index which was conducted with R software.
RESULtS
Samples
Methylation profiling was conducted on a total of 68 gliomas and 1 control brain. Two biological 
replicates (i.e., experiments carried out in parallel on independently isolated DNA) were 
also included. Patients and tumor characteristics are summarized in Table 1, and detailed in 
Supplementary Table S1. All glioma samples were diagnosed either with AOD or AOA by an 
expert neuropathologist (J.M. Kros). Fifty of the glioma samples were treated as part of the 
EORTC study 26951 (18), the remaining 18 samples were treated within the Erasmus Medical 
Centre. Sixteen of these patients received treatment paradigms similar to that used in the 
EORTC study 26951 (14 radiation therapy and 2 chemoradiation). One patient received PCV 
chemotherapy only. One patient refused further treatment after surgical resection; this sample 
was omitted from any analysis involving clinical parameters. 
Our cohort of samples both from EORTC 26951 and Erasmus Medical Centre did not differ 
from the entire EORTC 26951 cohort (368 patients) with respect to age, performance status, 
sex, diagnosis (AOD or AOA), IDH1 mutation, 1p19q LOH, and OS (Supplementary Table S2). 
MGMT promoter methylation was slightly less frequently observed (63.5% vs. 78.7%) in the 
present series than the entire EORTC data set.
Methylation profiling
A frequency distribution of the percentage of CpG methylation across our sample cohort shows 
an approximately bimodal distribution: predominantly unmethylated CpG sites (by far the 
most frequently observed) and predominantly methylated CpG sites (Supplementary Fig. S1). 
Few CpG sites show an intermediate percentage of methylation (between 10% and 75%). 
Unsupervised hierarchical clustering (HOPACH) using the 2,000 most variably methylated CpG 
loci identified 14 distinct molecular methylation subtypes (list available on request). Virtually 
identical subgroups were identified using all CpG loci, or the most variable 500, 1,000, 5,000, or 
10,000 CpG loci (data not shown). Nonparametric bootstrapping (Fuzzy clustering) confirmed 
that samples indeed belonged to a defined methylation cluster. 
We then focused our analysis on the 2 largest clusters that contain more than 10 samples and 
reassigned all samples to one of these 2 clusters. Cluster stability was shown as only 2 samples 
(samples 29 and 54) were assigned to a cluster that was different from the original cluster. 
The 2 large subgroups are defined by either predominantly methylated or unmethylated CpG 
islands (Fig. 1). Tumors with a high frequency of CpG island methylation are further referred to 
as CIMP+ tumors.
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CIMP status was strongly correlated to other molecular markers such as IDH1 mutation 
(rho = 0.75; P < 0.001), 1p19q LOH (rho = 0.54; P < 0.001), and MGMT promoter methylation 
(rho  = 0.61; P < 0.001; see also Supplementary Table S3). CIMP status was not correlated to 
clinical parameters such as age (rho = -0.06; P = 0.65), sex (rho = 0.23; P = 0.064), performance 
status (rho = 0.0008; P = 0.99), or histologic diagnosis (rho = - 0.01; P = 0.91).
Univariate analysis indicates that CIMP status [P < 0.0001; HR = 0.23 (0.12, 0.43)] is a strong 
prognostic factor for OS (Fig. 2). Other prognostic factors include IDH1 mutation status [P < 0.0001; 
HR = 0.30 (0.16, 0.57)], 1p19q LOH [P = 0.004; HR = 0.34 (0.16, 0.74)], MGMT promoter methylation 
[P = 0.016; 0.49 (0.27, 0.89)], and performance status [P = 0.032; HR = 1.55 (1.04, 2.33)]. In this series, 
age (P = 0.199) and histopathologic diagnosis (P = 0.67) are not correlated to OS. When stratified 
into the different treatment arms, CIMP+ tumors showed an increase in OS in RT-PCV–treated 
tumors compared with RT only (7.53 vs. 4.33 years, see also Supplementary Fig. S2). This increase in 
OS was, however, not significant (P = 0.45). No difference in OS can be observed in CIMP- tumors 
(1.0 vs. 1.21 years). Numbers are, however, too low to draw firm conclusions.
Multivariate analyses
Two models were fit with different variables grouping atentry and models were compared 
by their c-index. Final models of the predictive accuracy for patient survival are shown in 
Supplementary Table S4. Details of the full analysis are stated in Supplementary Table S5. Our 
first model included all biological factors (IDH1 mutation,1p19q LOH, and MGMT methylation) 
and histology. In this model, IDH1 mutation status (P = 0.0011) and 1p19q LOH (P = 0.06) were 
the most influential factors (c-index = 0.70). When CIMP was included in this model, CIMP status 
was the only factor selected (P < 0.0001; c-index = 0.71) with comparable predictive accuracy to 
the model with IDH1 mutation status and 1p19q LOH (0.71 vs. 0.70). 
Our second model included all biological factors (IDH1 mutation, 1p19q LOH, and MGMT 
methylation), clinical factors (age and performance status), and histology. In this model, 
performance status (P = 0.006), age (P = 0.002), IDH1 mutation status (P < 0.0001), and 1p19q 
LOH (P = 0.06) were selected (c-index = 0.74). When CIMP was included in this model, CIMP 
status was not selected for. 
Integrated analysis with expression profiling 
We next integrated our methylation data with gene expression profiles to determine the effect 
of methylation on gene expression. Expression and methylation data were available for 27 
samples included in this study and were integrated on the basis of “gene symbol” as indicated 
by the respective annotation files (20). Results are shown in Fig. 3. In general, few genes (994 
of 2,965, 33.5%) that are highly methylated (>75% methylation) are expressed (RMA levels > 6.5). 
In contrast, genes that are unmethylated (<10% methylation) show a much wider range in gene 
expression levels, though most (7,476 of 9,422, 79.3%) are expressed at RMA levels exceeding 6.5. 
The absence of methylation of genes therefore appears to be permissive for gene expression. 
An unmethylated gene is not necessarily expressed at high levels as a multitude of additional 
molecular mechanisms are involved in gene expression. 
We have recently conducted expression profiling on a large cohort of gliomas and 
identified  7 “intrinsic molecular subtypes” that correlate better with survival than histology 
(20). We determined whether these “intrinsic molecular subtypes” correlate with the tumors’ 
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4CIMP status. In our study, all but one CIMP+ tumors are in the prognostically favorable 
molecular clusters 9 (characterized by a high incidence of 1p19q LOH and IDH1 mutation) and 17 
(characterized by a high incidence of IDH1 and TP53 mutations). Conversely, tumors within the 
prognostically unfavorable molecular clusters 18 (characterized by a high frequency of EGFR 
amplification) and 23 (no clear molecular marker identified) are all CIMP- (P < 0.0001, the Fisher 
exact test). Only one sample was available of cluster 22 (secondary tumors and high frequency 
of IDH1 mutations), which clustered among the CIMP- tumors. Prognostically favorable tumors 
are therefore identified both by methylation profiling (CIMP+) and expression profiling (clusters 
9 and 17). However, methylation profiling does identify fewer prognostically relevant molecular 
subgroups than expression profiling (20, 25, 26).
Cluster validation
We next aimed to determine whether our CIMP+ and CIMP- methylation clusters can also 
be identified in anexternal data set. We therefore validated our methylation clusters on the 
Figure 1. Unsupervised clustering based on the 2000 most variably methylated cpG loci identifies 
two subgroups of gliomas. Subgroups can be separated based on predominantly unmethylated or 
methylated CpG loci. Sample numbers are shown above the graph. CIMP status as determined by HOPACH 
clustering (red= CIMP+, green= CIMP-), MGMT methylation status (red= MGMT methylated, green= 
unmethylated, white= not determined), 1p19qLOH (red= LOH, green = retention of either or both arms) 
and IDH1 mutation status (red= mutated, green= wildtype) is show below the figure. A second bar below 
the figure indicates sex (blue= males, pink= females), diagnosis (red= anaplastic oligoastrocytoma, green= 
anaplastic oligodendroglioma) and molecular cluster based on gene expression profiling (darkred= 
cl22; red= cl18; orange= cl23; yellow= cl17 and green= cl9). * denotes genes associated with gender (see 
supplementary figure 3).
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Figure 2. Kaplan Meyer survival curves based on ciMP status. Gliomas that are CIMP+ have a significantly 
better survival than CIMP- gliomas.
Figure 3. integrated analysis of cpG methylation and expression. As can be seen, most genes that are 
methylated are expressed at RMA levels <6.5 whereas genes that are unmethylated (<10% methylation) 
show a much wider range in gene expression levels. Values are +/- SE both for expression and methylation.
methylation data from the Cancer Genome Atlas (TCGA) external data set (assessed December 
2010) containing GBMs only (13). The “clusterRepro” R-package (see methods) was used to 
classify eachTCGAsample to one of the 2 clusters (CIMP+ or CIMP-) identified in the present 
study. Of the 269 samples included in this study, 245 were assigned to the CIMP- cluster, the 
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4remaining 24 samples were assigned to the CIMP+ cluster. Survival data were available for 190 
of these samples of which 176 wereassigned to the CIMP- cluster and 14 to the CIMP+ cluster. 
Similar to our data set, the CIMP+ tumors had a significantly better survival than the CIMP- 
tumors (Fig. 4; P = 0.0001).
Figure 4. Validation of the prognostic value of methylation subgroups on an external dataset. Of the 
269 samples included the TCGA study, 245 were assigned to the CIMP- cluster, the remaining 24 samples 
were assigned to the CIMP+ cluster. Survival data was available for 190 of these samples of which 176 were 
assigned to the CIMP- cluster and 14 to the CIMP+ cluster. Similar to our dataset, CIMP+ tumors had a 
significantly better survival compared to the CIMP- tumors
In summary, our CIMP+ and CIMP- methylation clusters can be identified in an external data 
set and, similar to our data set, these methylation clusters are prognostically relevant.
These results therefore validate our molecular clustering approach. 
CIMP statuswas originally defined in gliomas by the TCGA (13). We have therefore also 
assigned our data set according to the TCGA-defined CIMP status based on 1,503 CpG sites 
as reported (13). When the 68 samples of current study are assigned to one of these clusters, 
the CIMP status remained identical in 64 of 68 samples (Supplementary Table S1) with highly 
concordant survival (Supplementary Fig. S3). 
We next used samples of the TCGA to validate the association between CIMP status and 
“intrinsic molecular subtype.” For 217 samples of the TCGA data set, paired expression and 
methylation data are available. Each sample was assigned to a defined gene expression–based 
intrinsic subtype as described previously (20). When integrating the molecular expression 
clusters with methylation, all but one (8 of 9) samples within the CIMP+ subgroup were found in 
the prognostically favorable cluster 17 (IDH1 and TP53) and all but one 172 of 173 CIMP- tumors 
are within prognostically unfavorable tumors (clusters 18 and 23). Both CIMP+ (9 of 35) and 
CIMP- (26 of 35) tumors are found in cluster 22, which has unfavorable prognosis but contains 
secondary GBMs and a high percentage of tumors with IDH1 mutation. This observation largely 
confirms our hypothesis that prognostically favorable/unfavorable tumors can be identified 
both by methylation and expression profiling.
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DISCUSSION
In this study, we have identified 2 prognostically different molecular subgroups of anaplastic 
oligodendroglioma based on methylation profiling. These subgroups can be separated on 
overall CpG island methylation: CIMP+ tumors generally have a more favorable outcome than 
CIMP- tumors. CIMP was the only factor selected when all biological factors were included. 
Predictive accuracy was slightly higher in the model with CIMP alone. CIMP status was not 
selected in a model including all biological factors (IDH1 mutation, 1p19q LOH, and MGMT 
methylation), clinical factors (age and performance status), and histology. The prognostic 
value of CIMP status could be validated on an external data set from the TCGA.
Our results indicate that CIMP status is a strong predictor of survival in AODs and AOAs. 
Other prognostic markers in gliomas include 1p19q LOH (27), IDH1 mutation status (6, 28, 29), 
and MGMT methylation status (3, 6, 28) or whole-genome approaches such as gene expression 
profiling (20, 25, 26, 30) and, similar to reported in this study, methylation profiling (13–15). 
These prognostic markers may help classify gliomas as histologic classification is troublesome 
and subject to interobserver variation (31– 34). 
CIMP was first identified in colorectal cancer in 1999 (35). In this study, colorectal cancers 
could be distinguished on the basis of low or high levels of tumor-specific methylation, the latter 
being referred to as the CpG island methylator phenotype (CIMP). CIMP has been identified in 
several other cancer types including gastric, lung, liver, ovarian, and leukemias (36). Although 
CIMP+ gliomas are associated with a more favorable prognosis, a high methylation index is 
associated with a reduced progression free or OS in many other cancer subtypes, including 
bladder cancer, esophageal adenocarcinoma, neuroblastoma, ovarian cancers, and leukemia 
[see (36) and references therein]. Furthermore, in colorectal cancer, CIMP is associated with 
KRAS and BRAF mutations and negatively associated with TP53 mutations and chromosomal 
instability (37–39). In gliomas, CIMP status appears to be positively correlated with TP53 
mutations: astrocytic grade II and III tumors often are CIMP+, and these histologic subtypes 
have a high percentage of TP53 mutations (13, 40). Two recent papers have shown a more causal 
effect of IDH1 mutation on chromatin remodeling and CIMP status (41, 42). In thepresent study, 
however, not all IDH1 mutated tumors are CIMP+ (Fig. 1), which indicates that IDH1 mutation 
status is not the only determinant for CIMP status. 
CIMP has been associated with increased (protein) expression of DNA methyl transferase 
[DNMT; e.g., see ref. 43]. As a result, many genes involved in tumor initiation and or progression 
become methylated in CIMP+ tumors (44). Reversal of CIMP status may thus provide a potential 
method in the treatment of CIMP+ gliomas. Aberrant methylation in tumors may be reversed by 
treatment of DNMT1 inhibitors such as decitabine (9, 44). However, in our expression profiling 
data, the prognostically favorable tumors do not show an increase in DNMT1, 3A, or 3B (data 
not shown). It therefore remains to be determined whether DNMT1 inhibition is an effective 
treatment for gliomas. 
In summary, our data using mainly samples that were included in the large, prospective, 
randomized phase III EOTRC study 26951 show the association of CIMP status and prognosis in 
anaplastic oligodendroglial tumors, and their close association with 1p19q co-deletion, MGMT 
promoter association, and IDH1 mutations. The strong association between CIMP status 
and MGMT promoter methylation suggests that the MGMT promoter methylation status 
is part of a more general, prognostically favorable genome-wide methylation profile. This 
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4finding appears to explain the observations of the improved outcome in patients with MGMT 
promoter methylated tumors treated with radiotherapy only. Thus, in anaplastic glioma, 
MGMT promoter methylation may well be an epiphenomenon of genome-wide methylation. 
Methylation profiling may thus be helpful for identification of patients with AOD or AOAs with 
improved prognosis.
REFERENCES
1. Louis DN, Ohgaki H, Wiestler OD, Cavenee 
WK. WHO classification of tumours of the 
central nervous system. 4th ed. Lyon, France; 
2007.
2. Ohgaki H, Kleihues P. Epidemiology and eti-
ology of gliomas. Acta Neuropathol (Berl) 
2005;109:93–108.
3. Hegi ME, Diserens AC, Gorlia T, Hamou MF, 
de Tribolet N, Weller M, et al. MGMT gene si-
lencing and benefit from temozolomide in 
glioblastoma. N Engl J Med 2005;352:997–
1003.
4. Stupp R, Mason WP, van den Bent MJ, Weller 
M, Fisher B, Taphoorn MJ, et al. Radiother-
apy plus concomitant and adjuvant temo-
zolomide for glioblastoma. N Engl J Med 
2005;352:987–96.
5. van den Bent MJ, Dubbink HJ, Sanson M, van 
der Lee-Haarloo CR, Hegi M, Jeuken JW, et 
al. MGMT promoter methylation is prognos-
tic but not predictive for outcome to adju-
vant PCV chemotherapy in anaplastic oli-
godendroglial tumors: a report from EORTC 
Brain Tumor Group Study 26951. J Clin Oncol 
2009;27: 5881–86.
6. Wick W, Hartmann C, Engel C, Stoffels M, 
Felsberg J, Stockhammer F, et al. NOA-04 
randomized phase III trial of sequential ra-
diochemotherapy of anaplastic glioma with 
procarbazine, lomustine, and vincristine or 
temozolomide. J Clin Oncol 2009;27:5874–
80.
7. Rivera AL, Pelloski CE, Gilbert MR, Colman 
H, De La Cruz C, Sulman EP, et al. MGMT pro-
moter methylation is predictive of response 
to radiotherapy and prognostic in the ab-
sence of adjuvant alkylating chemotherapy 
for glioblastoma. Neuro Oncol 2010;12: 116–
21.
8. Esteller M. Epigenetics in cancer. N Engl J 
Med 2008;358:1148–59.
9. Taby R, Issa JP. Cancer epigenetics. CA Can-
cer J Clin 2010;60:376–92.
10. Knudson AG Jr. Mutation and cancer: statis-
tical study of retinoblastoma. Proc Natl Acad 
Sci U S A 1971;68:820–3.
11. Martinez R, Martin-Subero JI, Rohde V, Kir-
sch M, Alaminos M, Fernandez AF, et al. A 
microarray-based DNA methylation study 
of glioblastoma multiforme. Epigenetics 
2009;4:255–64.
12. WuX, Rauch TA, Zhong X, Bennett WP, Latif 
F, Krex D, et al. CpGislandhypermethyla-
tion in human astrocytomas. Cancer Res 
2010;70:2718–27.
13. Noushmehr H, Weisenberger DJ, Diefes K, 
Phillips HS, Pujara K, Berman BP, et al. Iden-
tification of a CpG island methylator pheno-
type that defines a distinct subgroup of glio-
ma. Cancer Cell 2010;17: 510–22.
14. Christensen BC, Smith AA, Zheng S, Koes-
tler DC, Houseman EA, Marsit CJ, et al. DNA 
methylation, isocitrate dehydrogenase mu-
tation, and survival in glioma. J Natl Cancer 
Inst 2011;103:143–53.
15. Laffaire J, Everhard S, Idbaih A, Criniere E, 
Marie Y, de Reynies A, et al. Methylation pro-
filing identifies 2 groups of gliomas accord-
ing to their tumorigenesis. Neuro Oncol 
2010;13:84–98.
16. Bagchi A, Mills AA. The quest for the 1p36 
tumor suppressor. Cancer Res 2008;68:2551–
6.
17. Bagchi A, Papazoglu C, Wu Y, Capurso D, 
Brodt M, Francis D, et al. CHD5 is a tumor sup-
pressor at human 1p36. Cell 2007;128:459–75.
18. van den Bent MJ, Carpentier AF, Brandes 
AA, Sanson M, Taphoorn MJ, Bernsen HJ, et 
al. Adjuvant procarbazine, lomustine, and 
vincristine improves progression-free sur-
vival but not overall survival in newly diag-
nosed anaplastic oligodendrogliomas and 
oligoastrocytomas: a randomized Euro-
pean Organisation for Research and Treat-
ment of Cancer phase III trial. J Clin Oncol 
2006;24:2715–22.
19. KouwenhovenMC, Gorlia T, Kros JM, Ibdaih 
A, Brandes AA, Bromberg JE, et al. Molecu-
lar analysis of anaplastic oligodendroglial tu-
mors in a prospective randomized study: a 
report from EORTC study 26951. Neuro Oncol 
2009;11:737–46.
70
A
 PRO
G
N
O
STIC
 M
ETH
Y
LA
TIO
N
 PH
EN
O
TY
PE IN
 O
LIG
O
D
EN
D
RO
G
LIO
M
A
S
4
20. Gravendeel LA, Kouwenhoven MC, Gevaert 
O, de Rooi JJ, Stubbs AP, Duijm JE, et al. In-
trinsic gene expression profiles of gliomas 
are a better predictor of survival than histol-
ogy. Cancer Res 2009;69:9065–72.
21. Kapp AV, Tibshirani R. Are clusters found in 
one dataset present in another dataset? Bi-
ostatistics 2007;8:9–31.
22. Gravendeel LA, Kloosterhof NK, Bralten LB, 
van Marion R, Dubbink HJ, Dinjens W, et al. 
Segregation of non-p.R132H mutations in 
IDH1 in distinct molecular subtypes of glio-
ma. Hum Mutat 2010;31:E1186–99.
23. van den Bent MJ, Dubbink HJ, Marie Y, 
Brandes AA, Taphoorn MJ, Wesseling P, et 
al. IDH1 and IDH2 mutations are prognostic 
but not predictive for outcome in anaplastic 
oligodendroglial tumors: a report of the Eu-
ropean Organization for Research and Treat-
ment of Cancer Brain Tumor Group. Clin Can-
cer Res 2010;16:1597–604.
24. Groenendijk FH, Taal W, Dubbink HJ, Haar-
loo CR, Kouwenhoven MC, van den Bent MJ, 
et al. MGMT promoter hypermethylation is a 
frequent, early, and consistent event in as-
trocytoma progression, and not correlated 
with TP53 mutation. J Neurooncol 2011;101: 
405–17.
25. Li A, Walling J, Ahn S, Kotliarov Y, Su Q, Que-
zado M, et al. Unsupervised analysis of tran-
scriptomic profiles reveals six glioma sub-
types. Cancer Res 2009;69:2091–9.
26. Phillips HS, Kharbanda S, Chen R, Forrest WF, 
Soriano RH, Wu TD, et al. Molecular subclass-
es of high-grade glioma predict prognosis, 
delineate a pattern of disease progression, 
and resemble stages in neurogenesis. Can-
cer Cell 2006;9:157–73.
27. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, 
Finkelstein DM, Hammond RR, et al. Specific 
genetic predictors of chemotherapeutic re-
sponse and survival in patients with anaplas-
tic oligodendrogliomas. J Natl Cancer Inst 
1998;90:1473–9.
28. Sanson M, Marie Y, Paris S, Idbaih A, Laffaire 
J, Ducray F, et al. Isocitrate dehydrogenase 
1 codon 132 mutation is an important prog-
nostic biomarker in gliomas. J Clin Oncol 
2009;27:4150–4.
29. Kloosterhof NK, Bralten LB, Dubbink HJ, 
French PJ, van den Bent MJ. Isocitrate de-
hydrogenase-1 mutations: a fundamentally 
new understanding of diffuse glioma? Lancet 
Oncol 2011;12:83–91.
30. Verhaak RG, Hoadley KA, Purdom E, Wang V, 
Qi Y, Wilkerson MD, et al. Integrated genom-
ic analysis identifies clinically relevant sub-
types of glioblastoma characterized by ab-
normalities in PDGFRA, IDH1, EGFR, and NF1. 
Cancer Cell 2010;17:98–110.
31. Scott CB, Nelson JS, Farnan NC, Curran WJ, 
Murray KJ, Fischbach AJ, et al. Central pa-
thology review in clinical trials for patients 
with malignant glioma. A report of Radia-
tion Therapy Oncology Group 83-02. Cancer 
1995;76:307–13.
32. Hildebrand J, Gorlia T, Kros JM, Afra D, Frenay 
M, Omuro A, et al. Adjuvant dibromodulcitol 
and BCNU chemotherapy in anaplastic astro-
cytoma: results of a randomised European 
Organisation for Research and Treatment of 
Cancer phase III study (EORTC study 26882). 
Eur J Cancer 2008;44:1210–6.
33. Kros JM, Gorlia T, Kouwenhoven MC, Zheng 
PP, Collins VP, Figarella- Branger D, et al. Panel 
review of anaplastic oligodendroglioma 
from European Organization For Research 
and Treatment of Cancer Trial 26951: assess-
ment of consensus in diagnosis, influence of 
1p/19q loss, and correlations with outcome. J 
Neuropathol Exp Neurol 2007;66:545–51.
34. Murphy M, Loosemore A, Ferrer I, Wesseling 
P, Wilkins PR, Bell BA. Neuropathologi-
cal diagnostic accuracy. Br JNeurosurg 
2002;16:461–4.
35. Toyota M, Ahuja N, Ohe-Toyota M, Herman 
JG, Baylin SB, Issa JP. CpG island methylator 
phenotype in colorectal cancer. Proc Natl 
Acad Sci U S A 1999;96:8681–6.
36. Teodoridis JM, Hardie C, Brown R. CpG is-
land methylator phenotype (CIMP) in can-
cer: causes and implications. Cancer Lett 
2008;268: 177–86.
37. Goel A, Nagasaka T, Arnold CN, Inoue T, 
Hamilton C, Niedzwiecki D, et al. The CpG 
island methylator phenotype and chromo-
somal instability are inversely correlated in 
sporadic colorectal cancer. Gastroenterol-
ogy 2007;132:127–38.
38. Shen L, Toyota M, Kondo Y, Lin E, Zhang L, 
Guo Y, et al. Integrated genetic and epige-
netic analysis identifies three different sub-
classes of colon cancer. Proc Natl Acad Sci U 
S A 2007;104:18654–9.
39. Toyota M, Ohe-Toyota M, Ahuja N, Issa JP. 
Distinct genetic profiles in colorectal tu-
mors with or without the CpG island meth-
ylator phenotype. Proc Natl Acad Sci U S A 
2000;97:710–5.
40. Collins VP. Brain tumours: classification 
and genes. J Neurol Neurosurg Psychiatry 
2004;75 Suppl 2:ii2–11.
41. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, 
Patel J, Shih A, et al. Leukemic IDH1 and IDH2 
mutations result in a hypermethylation phe-
notype, disrupt TET2 function, and impair 
71
4hematopoietic differentiation. Cancer Cell 
2010;18:553–67.
42. Xu W, Yang H, Liu Y, Yang Y, Wang P, KimSH, 
et al. Oncometabolite 2- hydroxyglutarate 
is a competitive inhibitor of alpha-ketoglu-
taratedependent dioxygenases. Cancer Cell 
2011;19:17–30.
43. Etoh T, Kanai Y, Ushijima S, Nakagawa T, Na-
kanishi Y, Sasako M, et al. Increased DNA 
methyltransferase 1 (DNMT1) protein ex-
pression correlates significantly with poor-
er tumor differentiation and frequentDNA 
hypermethylation of multiple CpG islands in 
gastric cancers. Am J Pathol 2004;164:689–
99.
44. Teodoridis JM, Strathdee G, Brown R. Epi-
genetic silencing mediated by CpG island 
methylation: potential as a therapeutic tar-
get and as a biomarker. Drug Resist Updat 
2004;7:267–78.
45. Berdasco M, Esteller M. Aberrant epigenet-
ic landscape in cancer: how cellular identity 
goes awry. Dev Cell 2010;19:698–711.
Supplementary Information accompanies the paper on the Clinical Cancer Research website 
(http://clincancerres.aacrjournals.org)
72


a Molecular subtype of glIoMa 
consIsts of two dIstInct 
tuMor entItIes wIth Markedly 
dIfferent clInIcal outcoMes 
Lonneke A.M. Gravendeel1, Nanne K. Kloosterhof1,4, 
Hein Sleddens2, Rutger Balvers3, Martine Lamfers3, 
Linda B.C. Bralten1, Peter A.E. Sillevis Smitt1, 
Martin J. van den Bent5, Pim J. French1.
Departments of 1Neurology, 2Pathology, and 3Neurosurgery, 
Erasmus University Medical Center, Rotterdam, the 
Netherlands; Department of 4Pediatric Oncology and 
Hematology, Sophia Children’s Hospital, Rotterdam, the 
Netherlands; 5Department of Neurology, Daniel Den Hoed 
Cancer Center, Rotterdam, the Netherlands.
Submitted.
5ABStRACt
Gene expression profiling is a powerful approach to identify molecular subtypes in cancer. It is 
generally believed that each “intrinsic subtype” represents a distinct tumor entity that requires 
its own unique treatment paradigm. Here, we demonstrate that a specific intrinsic subtype 
of glioma consists of two different tumor types with remarkably different outcomes. Tumors 
of this subtype can be separated by their genomic, but not by their epigenomic, aberrations: 
Patients that survive have a near diploid tumor genome apart from a tandem duplication on 
7q34. In contrast, most non-survivors are near tetraploid and a near tetraploid primary cell 
culture from one of these tumors has been established. All tumors are wt for IDH1, TP53 and 
BRAF. Eventhough pathology is also able to separate the two subtypes, classification based on 
histology is difficult as similar features are observed in both. Indeed, our screen for genomic 
aberrations has led us to identify at least one patient with highly favorable prognosis despite 
poor histological characteristics. The different outcomes (tetraploidy and long term survival) 
are confirmed in the TCGA and REMBRANDT external datasets. In summary, intrinsic tumor 
subtypes often mark molecularly similar tumors that have similar genetic changes and therefore 
may be clinically relevant. However, our study demonstrates that at least one intrinsic subtype 
is highly heterogeneous and thus that care should be taken when using intrinsic subtypes to 
screen for targeted therapies.
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INtRODUCtION
Unsupervised analysis of gene expression profiling in cancer is used to identify different 
molecular subtypes that sometimes are hard to separate by their histological characteristics 1-3. 
Often, these “intrinsic subtypes” share similar genetic aberrations, and therefore form a basis 
to screen for targeted therapies 3, 4.
In a previous study we performed expression profiling on a cohort of 276 gliomas of all 
histological subtypesin which we identified seven distinct subtypes of glioma 5. In general, the 
intrinsic molecular classification was a better predictor of survival than histology and genetic 
changes segregate in the different subtypes 5, 6. However, in one distinct molecular subtype 
(Cluster 16) pilocytic astrocytomas (PAs) clustered among gliomas of higher grades and with 
much poorer prognosis. This seems peculiar since PAs show a distinct biological behaviour with 
much longer survival times (5-year survival rate of 96% after surgical resection) than higher 
grade gliomas 7, 8. Indeed, all PA patients are still alive to date, while most patients diagnosed 
with other glioma subtypes died within a few years. Validation with external datasets (GSE12907) 
confirmed that PAs are virtually always assigned to this specific molecular cluster. However, 
the TCGA (The Cancer Genome Atlas 9) and REMBRANDT (the Repository for Molecular Brain 
Neoplasia Data 10) datasets also contained a small subset of higher grade gliomas that are also 
assigned to this subtype.
The aim of present study was to perform a detailed analysis this specific intrinsic subtype 
of glioma. Review of the pathological reports indicates that these tumors share similar 
characteristics; pilocytic features are recognized by the pathologist in many tumors of this 
intrinsic subtype, regardless of clinical outcome. However, tumors of this intrinsic subtype can 
be separated into two clinically relevant subtypes by their genomic aberrations. Such separation 
could not be made by genome-wide methylation profiling. Our results have implications for 
individual patients that have been diagnosed with a histologically malignant glioma subtype, 
but who can be identified as a long-term survivor using these molecular profiling techniques. 
Our data also indicate that tumors of the same intrinsic subtype can harbor different tumor 
subtypes and thus that intrinsic subtyping should be treated with caution when using it to 
screen for targeted therapies.
MAtERIALS AND MEtHODS
Patients and samples
Fresh frozen (FF) tumor samples from patients were collected from the Erasmus MC tumor 
archive from patients operated from 1989-2005. Samples were collected immediately after 
surgical resection, snap frozen, and stored at -80oC. Four matched formalin-fixed paraffin-
embedded (FFPE) tissue blocks were also included for Fluorescence In-Situ Hybridization 
(FISH) analysis and immunohistochemistry. Use of patient material was approved by the 
Institutional Review Board. The medical history of all patients in our dataset was available as 
described 5. Samples were assigned to molecular Cluster 16 using the cluster-repro package 
as described 11. 
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5Medical history from REMBRANDT(National Cancer Institute (2005), http://rembrandt.nci.
nih.gov, Assessed December 2008) and the TCGA samples were obtained via the respective 
repositories 5, 9, 10.
Molecular Cluster 16 is a relatively small intrinsic subtype of gliomas. It originally contains 
6 PAs, 1 astrocytoma (A) grade II, 1 A grade III, 1 oligodendroglioma (OD) grade III, and 1 GBM. 
In this study we also included one sample that was assigned to Cluster 16 (sample 17) derived 
a previous study 12 and one sample that was recently profiled (EGT 16). For survival analysis we 
also included four samples (242, 300, 628 and 631) that were originally assigned to Cluster 0 (a 
cluster containing all control samples), but are assigned to Cluster 16 when performing cluster-
repro without Cluster 0. This was done because lower grade samples are diffuse and often 
contain a significant proportion of control brain tissue. Omitting Cluster 0 therefore forces all 
tumor samples to cluster into its nearest subtype. It should be noted differences in survival time 
between PAs and non-PAs remain similar without these samples. This way, a total of 16 samples 
are assigned to Cluster 16. Patient characteristics are described in table 1.
table 1. Patients characteristics
Db No Histological diagnosis age at diagnosis survival status
451 astrocytoma grade II 24 9,5 alive
710 pilocytic astrocytoma 34 14,3 alive
711 pilocytic astrocytoma 37 14,4 alive
224 pilocytic astrocytoma 16 11,2 alive
300 pilocytic astrocytoma 22 6,5 alive
308 pilocytic astrocytoma 12 20,2 alive
709 pilocytic astrocytoma 18 17,2 alive
712 pilocytic astrocytoma 32 13,9 alive
362 glioblastoma 64 2,7 dead
351 oligodendroglioma grade III 79 1,6 dead
EGT 16 glioblastoma 68 1,3 dead
446 astrocytoma grade III 50 0,4 dead
17 mixed oligoastrocytoma grade III 47 1,0 dead
242 glioblastoma 65 0,4 dead
628 astrocytoma grade II 50 7,2 dead
631 glioblastoma 55 0,0 dead
Microarray data & SNP chip data
DNA and RNA were extracted from fresh frozen material using the Qiagen Allprep DNA/RNA 
mini Kit. Sample labeling and array hybridization on single-nucleotide polymorphism (SNP) 6.0 
arrays using the extracted DNA was performed by AROS Applied Biotechnology AS (Aarhus, 
Denmark) according to standard Affymetrix protocols. SNP 6.0 analysis was performed using 
Affymetrix Genotyping Console software. SNP 250k Nspl (Affymetrix) data of 21 samples that 
were included in previous studies were collected for analysis 5, 13.
Methylation profiling was performed as described 14. In brief, 1 mg of genomic DNA was 
subjected to bisulphite modification using the EZ DNA methylation kit (Zymo research company, 
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Orange, CA) and hybridized to IlluminaInfinium Human Methylation 27 arrays (Illumina, San 
Diego, CA). Arrays were hybridized by Service XS (Leiden, the Netherlands) according to 
standard Illumina protocols. Snap frozen DNA was available from eight Cluster 16 samples. 
A primary cell culture of a surgically resected tumor sample (EGT16) was established and 
propagated as described 15.
Molecular analysis
Detection of BRAF V600E mutations was performed by PCR analysis using primers as described 16. 
TP53 mutation status was determined using the primers and conditions as describedand by 
immunohistochemistry 12. To perform immunohistochemistry for TP53, sections of 10 μm thick 
were cut from each of the four FFPE blocks. TP53 immunohistochemistry was performed as 
described 17. FISH analysis was performed using probes for the centromeres of chromosome 1, 2 
and 7, and for EGFR (Kreatech Diagnostics) and performed as described 18. 
Statistical analysis
Differences between Kaplan-Meier survival curves were calculated by the log-rank (Mantel-
Cox) test. 
RESULtS
Cluster 16 samples contain pilocytic features
Molecular Cluster 16 is a relatively small intrinsic subtype of gliomas. Despite its small size a 
dramatic difference in survival between patients was observed: All seven patients with a PA were 
all still alive at the time of writing this article (survival 6.5-20.2 years), while 8/9 patients with 
non-PAs had died within 0.5-7.2 years (table 1). The only patient with a non-PA (an astrocytoma 
grade II) who remains alive has a survival time of 9.5 years (figure 1). The average age at 
diagnosis of Cluster 16 patients is 42 years. However, patients diagnosed with a PA are much 
younger (24 years, consistent with the age distribution of this tumor subtype) than patients 
with any other diagnosis in this cluster (56 years, P= 0.0012). Interestingly, the only patient not 
diagnosed with a PA that remains alive to date was diagnosed as a young adult (24 years). 
To further investigate this molecular subtype, we performed a detailed analysis of the original 
pathology reports. We observed that several of the non-PAs contained pilocytic features. The word 
“pilocytic” was in found in the pathology report in 3/8 of the non-PAs. One glioblastoma (GBM) was 
a recurrence from a PA diagnosed two years earlier, another tumor is described as a “reasonably 
characteristic image of a pilocytic astrocytoma” and the third as “astrocytoma with focal pilocytic 
features”. Pilocytic features were specific for tumors in Cluster 16; there were no pilocytic features 
identified in any of 60 samples of the other molecular subtypes. Tumors of Cluster 16 therefore are 
not only molecularly similar, many also share similar histological features.
Genotyping separates survivors from non-survivors
We performed genotyping to analyze the molecular differences between tumors of this cluster. 
Three of five of the examined survivors showed an amplification of chromosome 7q34, consistent 
with a tandem duplication which results in the KIAA1549-BRAF fusion gene (figure 2) 19. It should 
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5Figure 1. samples of a single molecular subtype show dramatic differences in overall survival when 
separated by histological diagnosis. Within a defined molecular subtype of glioma (Cluster 16), a large 
difference in survival between patients diagnosed with a PA or other diagnosis is observed. All patients 
with a PA were all still alive at the time of writing this article (survival 6.5-20.2 years) whereas 8/9 patients 
with non-PAs had died within 0.5-7.2 years.
Figure 2. Amplification of chromosome 7q34 in surviving patients. SNP 6.0 data of five survivors show 
an amplification of chromosome 7q34 in three. Amplification on 7q34 is associated with an increase in 
the smooth signal plots (bottom traces) and, on the allele difference plots (top traces) the appearance 
of a fourth ‘band’ (each band representing either AAA, AAB, ABB and BBB alleles) concomitant with a 
disappearance of a band on the ‘0’ line (the AB allele in a diploid situation). This amplification is consistent 
with a recurrent tandem duplication identified in PAs that results in a KIAA1549-BRAF fusion gene. This 
amplification is also reflected by the allele difference which is also aberrant for this exact location. 
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be noted that KIAA1549-BRAF fusion proteins are less frequent in adult than in child PAs 20. This 
amplification is common for PAs and was not seen in any of the non-survivors. Apart from this 
single genetic change, no other change was identified in any of the survivors. 
All of the examined non-survivors showed many genetic changes including EGFR 
amplification and deletion of the CDKN2A locus, but no amplification of 7q34 (supplementary 
figure 1). In addition, 3/4 of the non-survivors in this molecular cluster also showed near 
tetraploidy of virtually all chromosomes. Tetraploidy can be extracted from genotyping by 
analyzing the copy number plots with allele frequency plots: a loss of copy number is associated 
with an increase in the number of alleles. Tetraploidy was confirmed in the non-survivors by 
FISH analysis; all survivors were diploid (except for the tandem duplication on 7q34). Tetraploidy 
was not observed in samples that were assigned to other molecular clusters (SNP 6.0 and SNP 
250k Nspl data), which indicates that tetraploidy is specific for tumors in Cluster 16. All tumors 
of Cluster 16 were wild type (wt) for BRAF, IDH1 and TP53. No LOH on 1p19q was detected. 
Molecular data are shown in supplementary figure 1 and summarized in supplementary table 1.
Methylation profiling
Methylation profiling was performed on eight samples to further analyze molecular differences 
within this intrinsic subtype. In general, the methylation profiles of all Cluster 16 samples differs 
from those that have been reported, see e.g. 14, 21, 22. Unsupervised analysis based on the 1503 
most variable CpG sites in gliomas 22 does not discriminate survivors (samples 224, 308, 709, 711 
and 712) from the non-survivors (samples 17, 362 and 628, (figure 3). Recently, a genome-wide 
hypermethylation phenotype (CIMP+) was identified in gliomas that was associated with a more 
favorable prognosis 14, 21, 22. When assigning the methylation profiles of Cluster 16 samples, 2 and 
6 samples are assigned to the CIMP+ and CIMP- subtypes respectively. Interestingly, 2/3 of the 
non-survivors are assigned to the prognostically favorable CIMP+ subtype whereas all of the 
survivors are assigned to the prognostically poor CIMP- subtype. 
Validation on external datasets
As reported, two external datasets (REMBRANDT and the TCGA) without PAs also contained 
a minority of samples (1% and 2% respectively) in the that were assigned to Cluster 16 5. These 
samples were 2 oligodendrogliomas (OD) grade II, and 1 GBM in the REMBRANDT dataset and 
five GBM samples (2%) in the TCGA dataset. 
For this study, we obtained the original pathological reports of samples assigned to Cluster 
16 in the REMBRANDT dataset. We first noticed that, similar to our dataset all patients were 
diagnosed at relatively young age (18, 23, and 30 years). This is much younger than the median 
age of onset for grade II and III gliomas (CBTRUS statistical report, www.cbtrus.org) and 
molecular subtypes of glioma 5, 23. Interestingly, the two patients diagnosed with an OD remain 
alive to date (survival of 9.8 and 12.8 years respectively) whereas the GBM sample (survival 
0.65 years) was a recurrent tumor of a cerebellar astrocytoma (which often is indicative of a 
pilocytic astrocytoma) that was diagnosed two years earlier. Unfortunately, no tissue was 
available to genetically analyze these tumors for the presence of a KIAA1549-BRAF duplication 
or tetraploidy. Nevertheless, the remarkable long survival of the two OD patients confirm that 
our molecular profiling is able to identify patients who have a significant better prognosis than 
other higher grade gliomas, regardless of their histology. 
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5In the TCGA dataset, SNP 6.0 array data was available of 4/5 samples. All samples showed 
an amplification of EFGR and had a near tetraploid profile. Detailed analysis of SNP arrays 
from other clusters indicates that tetraploidy was not seen in TCGA glioma samples that were 
assigned to other molecular clusters. Patient survival was poor (0.5-1.7 years; survival available 
of four). These data confirm our observation that tumors with poor prognosis assigned to 
Cluster 16 are tetraploid. The patient characteristics of the external datasets are listed in table 2.
Figure 3. Methylation profiling of cluster 16 samples. A) Unsupervised analysis based on the 1503 most 
variable CpG sites in gliomas identifies two major subtypes and does not discriminate survivors from the 
non-survivors. In contrast to the more favorable prognosis associated with CIMP+ tumors, most ‘survivors’ 
are classified as CIMP-. Two samples with a prognostically poor tumor are classified as CIMP+. B) The 
median methylation % of CIMP- and CIMP+ samples are included for comparison 14. 
table 2. Patients characteristics external data sets
no Histological diagnosis age at diagnosis survival status dataset
HF-0897 oligodendroglioma grade II 30 12,78 alive Rembrandt
HF-1345 oligodendroglioma grade III 18 9,77 alive Rembrandt
HF-1357 glioblastoma 23 0,65 dead Rembrandt
TCGA-06-0132 glioblastoma 49,66 0,81 dead TCGA
TCGA-06-0142 glioblastoma N/A N/A dead TCGA
TCGA-02-0060 glioblastoma 66,17 0,50 dead TCGA
TCGA-06-0179 glioblastoma 64,25 1,69 dead TCGA
TCGA-02-0002 glioblastoma 55,50 0,56 dead TCGA
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Establishment of a polyploid cell line
One of the tetraploid samples was propagated in vitro under normal serum conditions. 
Genotypic analysis of passage 5 indicates that the genomic changes observed in the primary 
tumor are retained in the primary cell line. The cell line does contain several additional genetic 
changes that are not present in the primary tumor. In general, the cell line showed a tendency 
towards chromosomal loss and thus towards triploidy. Genetic changes include loss of a one 
allele on chromosome 4, 5, 11, 13, 15, 20 (all tumor tetraploid, cell line triploid) and 9q, 10, 
14q11-14q23.2, 17, 18, 19, 21 (all tumor triploid, cell line uniparentaldisomy). Cell line showed an 
additional homozygous deletion on 6q26. An example of the similarity and differences between 
the tumor and its matched primary cell line is shown in figure 4.
Figure 4. establishment of a polyploidy cell line. One of the tetraploid samples of Cluster 16 was 
propagated in vitro under normal serum conditions. Examples of three different chromosomes 
demonstrates that the genomic changes observed in the primary tumor are retained in the primary 
cell line. Note that the high copy amplicons on chromosome 19 are retained in tumor and cell line. On 
Chromosome 1, neither the allele difference plots nor the smooth signal can discriminate between a 
diploid or a tetraploid genome. 
DISCUSSION
In this study we demonstrate that a specific intrinsic subtype of glioma is not a homogenous 
tumor entity but consists of two different subtypes with remarkably different outcomes. 
Although expression profiling (nor methylation profiling) cannot separate the two tumor 
subtypes, they can be separated based on their histology (PA vs non-PA). However, many 
tumors within this intrinsic glioma subtype share the same histological characteristics (i.e. 
pilocytic features) and a tumor within Cluster 16 was diagnosed as an ODII but has the genetic 
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5aberration of PAs and remains alive to date without signs of tumor progression. Both the 
identification of long-term survivors and tetraploidy in non-survivors could be validated on 
independent datasets.
Gene expression profiling is a powerful technique that is used to identify “intrinsic” 
subtypes of tumors. Because these subtypes are molecularly similar, they form a basis to screen 
for targeted therapies. In fact, virtually all manuscripts that have identified intrinsic subtypes 
of tumors, argue they are relevant for targeted therapies, see e.g. 4, 5, 24-26. Indeed, intrinsic 
subtypes of glioma are clinically and biologically relevant: They predict survival better than 
histological diagnosis and distinct genetic changes segregate into defined intrinsic subtypes. 
Nevertheless, our study clearly demonstrates that not all intrinsic subtypes are homogeneous. 
Intrinsic subtyping of tumors therefore does not always identify a single defined subtype, and 
care should be taken when using intrinsic subtypes to screen for targeted therapies.
It has been reported that the histological distinction between PAs and low grade 
astrocytomas is difficult 27, 28. In should be noted however, that very few tumors within Cluster 16 
are diagnosed as low grade astrocytoma. In addition, IDH1 mutations are frequent (>70%) in low 
grade astrocytomas, but are noticeably absent in all Cluster 16 tumors 5, 29.
Relatively few studies have thusfarreported on tetraploidyin gliomas 30, 31. Mechanstically, 
tetraploidy in GBM U87 cells is associated with the expression of the dominant-negative PTN 
which leads to a less aggressive phenotype 32. A different study stated that the formation of a 
slower growing tetraploid cell population and astrocytic differentiation can be induced by high 
doses of specific alkylphosphocholines in rat glioma cells 33.
Tetraploidy has been observed in several other cancers (colon cancer, Barrett’s esophagus, 
breast cancer and cervical cancer) 34-38. A recent study demonstrated that tetraploidization 
occurs in a subset of human cancers with loss of function of the TP53 pathway as an early 
step 39. It also showed that persistent telomere damage can lead to tetraploidization and that 
telomere-driven tetraploidyis TP53 dependent. However, TP53 mutations were not observed 
in any of the samples in this study. Alternative mechanisms for tetraploidy include an excess 
of centrosomes, which generate aneuploid cells by producing multipolar spindles, or by 
misregulation or mutation for genes whose products mediate mitotic progression 40-42. Which 
mechanism leads to tetraploidy in Cluster 16 gliomas remains to be determined.
It remains to be determined why tetraploid gliomas share molecular features with PAs. A 
possible explanation may lie in the relatively few (when compared to other malignant glioma 
subtypes) genetic changes observed in tetraploidgliomas: Fewer genetic changes may result in 
a less aberrant gene expression pattern. Nevertheless, tetraploid tumors are a distinct subtype 
of glioma, and are likely to require a specific treatment paradigm. One interesting treatment 
pathway worth exploring is a therapy that can specifically target tetraploid cell lines as earlier 
described for aneuploid celllines 43.
In summary, we demonstrate that intrinsic subtyping of tumors does not always identify 
a single defined subtype. Our findings have implications when using intrinsic subtypes to 
screen for targeted therapies. Finally, we recommend all gliomas with pilocytic features and/or 
assigned to molecular Cluster 16, regardless of histological diagnosis, to be further molecularly 
analyzed for the 7q34 tandem duplication and/or tetraploidy using SNP arrays and/or FISH 
analysis. 
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6ABStRACt
Background: Intrinsic gliomasubtypes (IGS) are molecularly similar tumors that can be 
identified based on unsupervised gene-expression analysis. Here, we have evaluated the 
clinical relevance of these subtypes within EORTC26951, a randomized phase III clinical trial 
investigating adjuvant procarbazine, CCNU (lomustine) and vincristine (PCV) chemotherapy in 
anaplastic oligodendroglial tumors. Our study is the first to include gene-expression profiles of 
formalin-fixed and paraffin-embedded (FFPE) clinical trial samples. 
Methods: Gene-expression profiling was performed in 140 samples: 47 fresh frozen and 93 
FFPE, on HU133_Plus_2.0 and HuEx_1.0_st arrays (Affymetrix), respectively. 
Results: All previously identified six intrinsic glioma subtypes are present in EORTC26951. 
This confirms that different molecular subtypes are present within a well-defined histological 
subtype. Intrinsic subtypes are highly prognostic for overall- (OS) and progression-free survival 
(PFS). They are prognostic for PFS independent of clinical (age, performance, tumor location), 
molecular (1p19qLOH, IDH1 mutation, MGMT methylation) and histological parameters. 
Combining known molecular (1p19LOH, IDH1) prognostic parameters with intrinsic subtypes 
significantly improves outcome prediction (Proportion of Explained Variation 30% v 23%). 
Specific genetic changes (IDH1, 1p19qLOH and EGFR amplification) segregate into different 
subtypes. We identified one subtype, IGS-9 (characterized by a high percentage of 1p19qLOH 
and IDH1 mutations), that especially benefits from PCV chemotherapy. Median OS in this 
subtype was 5.5 years after radiotherapy (RT) alone v 12.8 years after RT/PCV; P=0.0349; HR 
2.181, 95% CI [1.057, 4.50]. 
Conclusion: Intrinsic subtypes are highly prognostic in EORTC26951 and improve outcome 
prediction when combined with other prognostic factors. Tumors assigned to IGS-9 benefit 
from adjuvant PCV. 
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INtRODUCtION
Unsupervised analysis of gene expression profiling identifies subgroups of tumors that 
are molecularly similar. This approach has been used to identify distinct ‘intrinsic’ subtypes 
of cancer and provides an objective method to classify tumors 1-4. In gliomas, the identified 
intrinsic subtypes reportedly correlate better with patient prognosis than histology 5-9. Intrinsic 
glioma subtypes are not only similar on the RNA level, specific genetic changes also segregate 
in distinct intrinsic subtypes 8,10. It is therefore likely that each molecular subtype will require its 
own treatment paradigm.
True validation of the prognostic relevance of the intrinsic glioma subtypes requires 
analysis on homogeneously and prospectively treated patients, ideally within a randomized 
clinical trial. One of the main problems in analysing clinical trial samples is that they are often 
of poor quality, most are formalin-fixed and embedded in paraffin (FFPE) 11. However, recent 
technological advances have enabled high-throughput analysis of FFPE material, including 
expression arrays 12-14. In a large cohort of paired FF-FFPE samples, we have recently demonstrated 
differences in mRNA expression are retained in FFPE samples. Importantly, the assignment to 
one of six intrinsic glioma subtypes (IGS) was identical between the FF-FFPE matched samples 
in 87% of cases 15 and the intrinsic subtypes remain highly prognostic for survival. These results 
demonstrate that FFPE material can be used for expression profiling. 
Not all glioma patients respond similarly to treatment. For example, glioblastomas with 
a methylated O6-methylguanine-methyltransferase (MGMT) promoter respond better to 
treatment with temozolomide 16,17. In oligodendrogliomas, uncontrolled trials indicated that 
loss of heterozygosity on 1p/19q is predictive for response to procarbazine, CCNU (lomustine) 
and vincristine (PCV) chemotherapy 18,19. Selection of patients that benefit most from particular 
therapeutic regimens helps to improve treatment efficacy and to potentially avoid toxicity in 
patients that are unlikely to benefit from that therapy anyway.
EORTC26951 is a randomized phase III clinical trial investigating whether the addition of PCV 
chemotherapy to RT would improve OS and PFS in patients with anaplastic oligodendroglioma 
(AOD) or anaplastic mixed oligoastrocytoma (AOA). This trial showed that the addition 
of 6 cycles PCV after 59.4 Gy RT increases OS and PFS in these tumors (van den Bent et al., 
submitted). However, some patients appeared to benefit more from the addition of PCV 
treatment than others 20. Here, we have evaluated the clinical relevance of intrinsic subtypes 
within EORTC26951. Our study is the first to use gene expression profiling on FFPE clinical 
trial samples. Our data validate that intrinsic subtypes of glioma are prognostic for survival. 
Intrinsic subtypes significantly improve outcome prediction when combined with other known 
prognostic parameters (1p19LOH, IDH1 mutation). Our data also indicate that patients with 
tumors assigned to a specific intrinsic subtype benefit from PCV treatment. 
MAtERIALS AND MEtHODS
Patient samples
Patients were considered eligible in the EORTC26951, if they had been diagnosed by the local 
pathologist with an AOD or a AOA according to the WHO classification of 1993, with at least 25% 
oligodendroglial elements; with at least three of five anaplastic characteristics (high cellularity, 
91
6mitoses, nuclear abnormalities, endothelial proliferation or necrosis); if they were between 
the 16 and 70 years of age; if they had an Eastern Cooperative Oncology Group (ECOG) status 
between the 0 and 2; if they had not undergone prior chemotherapy or RT to the skull; if they 
had no diseases interfering with follow-up; if they had adequate bone marrow, renal, and 
hepatic function and if written informed consent was obtained from all patients. All centers had 
to get approval of the study design from their local ethics committee prior to study activation 
according to local and national regulations 20. Study accrual was between August 13, 1995, and 
March 3, 2002. The consolidated standards on reporting trials (Consort) flow diagram has been 
reported previously 20, and is shown in supplementary figure 1.
RNA isolation and array hybridization
Total RNA extraction, purification and quantification from FF and FFPE material was reported 
previously 8,15. 150 ngRNA from FF and FFPE tissueswas used for expression profiling. FF samples 
(n=47) were profiled as described on HU133plus 2.0 arrays (Affymetrix, High Wycombe, UK)  8; 
FFPE samples (n=93) were profiled using HuEx_1.0_st arrays (Affymetrix) in combination with 
Nugen Ovation kits (Nugen, San Carlos, Ca) as reported 13,15.
Molecular assessments
Analysis of loss of heterozygosity on 1p/19q, EGFR amplification, IDH1 mutations and MGMT 
promoter methylation on EORTC26951 samples was described previously 20-22, see also paper by 
van den Bent et al. (submitted).
Statistical analysis
Samples were assigned to one of the six ‘intrinsic’ molecular subtypes of glioma using 
ClusterRepro (an R package) as described previously, omitting control cluster 08,23. In our 
previous manuscripts, these intrinsic subtypes were designated ‘cluster’ followed by the cluster 
number (0, 9, 16, 17, 18, 22 or 23). For clarity, we here annotate these ‘clusters’ as ‘intrinsic glioma 
subtype’ (IGS) followed by the same cluster number (e.g. IGS-9). 
Differences between the Kaplan-Meier survival curves were calculated by the Log-rank 
(Mantel-Cox) test using GraphPad Prism version 5.00 for Windows, GraphPad Software, San Diego, 
CA. Comparisons between frequencies were calculated by the Fisher’s exact test. In this exploratory 
analysisP<0.05 was considered to indicate significant differences. The significance of prognostic 
factors was determined with a multivariate analysis by Cox regression analysis using Stata version 
12.0 (Statacorp, College Station, TX). The importance of prognostic factors was compared in Cox 
and logistic regression using SAS macros (www.akh-wien.ac.at/imc/biometrie/relimp).
RESULtS
Patients and samples.
A total of 140 samples out of 368 patients within the EORTC26951 trial were available for the 
current study. Of these, 47 were FF and 93 FFPE. Seventy-three patients had been assigned to 
the RT plus PCV chemotherapy arm and 67 patients to the RT only arm. Our cohort of samples 
from the EORTC26951 study did not differ from the entire EORTC26951cohort (368 patients) with 
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respect to age, sex, performance status, diagnosis, tumor location, IDH1 mutation, 1p19qLOH, 
EGFR amplification, MGMT promoter methylation, OS and PFS (Table 1). However, OS within 
table 1. Comparison of baseline characteristics
Baseline characteristics  
 
 
included in the cluster analysis  
  No Yes total
P-value  N=228 (%) N=140 (%) N=368 (%)
Age 
Median 
range
49.5 
19.4 - 68.7
49.4
18.6 - 68.7 
49.5 
(18.6 - 68.7) 
0.57
  obs (o) 228 140 368  
sex Male  123 (53.9)  89 (63.6)  212 (57.6) 0.08
  Female  105 (46.1)  51 (36.4)  156 (42.4)  
Performance 
status 
0.  81 (35.5)  53 (37.9)  134 (36.4) 0.75
1.0  107 (46.9)  64 (45.7)  171 (46.5)  
2.0  36 (15.8)  22 (15.7)  58 (15.8)  
Histological 
diagnoses 
AoD  173 (75.9)  93 (66.4)  266 (72.3) 0.04
AoA>25% o  53 (23.2)  47 (33.6)  100 (27.2)  
central 
diagnosis
AoD  100 (43.9)  76 (54.3)  176 (47.8) 0.02
AoA  46 (20.2)  36 (25.7)  82 (22.3)  
LGG  28 (12.3)  11 (7.9)  39 (10.6)  
HGG  26 (11.4)  13 (9.3)  39 (10.6)  
other  10 (4.4)  0 (0.0)  10 (2.7)  
tumor 
location 
elsewhere  119 (52.2)  71 (50.7)  190 (51.6) 0.83
Frontal  109 (47.8)  69 (49.3)  178 (48.4)  
IDH1 
mutation 
Normal  40 (17.5)  57 (40.7)  97 (26.4) 0.37
Mutated  39 (17.1)  42 (30.0)  81 (22.0)  
1p19q LoH 
Non codeleted  141 (61.8)  95 (67.9)  236 (64.1) 0.51
codeleted  44 (19.3)  36 (25.7)  80 (21.7)  
EGFR 
mutation
Normal  111 (48.7)  82 (58.6)  193 (52.4) 0.76
Amplified  32 (14.0)  26 (18.6)  58 (15.8)  
MGMT 
promoter 
methylation 
Unmethylated  23 (10.1)  24 (17.1)  47 (12.8) 0.61
Methylated  60 (26.3)  76 (54.3)  136 (37.0)  
PFs 
obs (o); Hr (95% ci) 181; 1.00 117; 1.16 (0.92, 1.46)   0.21
Median (95% ci) 
(months)
19.65 (15.38, 33.35) 14.52 (9.63, 21.13)    
% at 2 Year(s) (95% ci) 48.02 (41.39, 54.34) 39.29 (31.20, 47.26)    
os
obs (o); 
Hr (95% ci)
168; 1.00 113; 1.25 (0.99, 1.59)   0.06
Median (95% ci) 
(months)
43.89 (30.03, 61.17) 26.87 (18.69, 38.31)    
% at 2 Year(s) (95% ci) 63.44 (56.81, 69.33) 51.43 (42.87, 59.33)    
Abbreviations: Obs: observation events; AOD: anaplastic oligodendroglioma; AOA: anaplastic oligoastrocytoma; 
LGG: low grade gliomas; HGG: high grade gliomas; HR: hazard ratio; CI: confidence interval; PFS: progression-free 
survival; OS: overall survival. P<0.01 is considered statistically significant. The missing values are not included in 
the tableand are the remaining percentages.
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6the RT-only treatment arm of included patients, was worse compared to OS in patients not 
included (OS: 1.59 v 3.70, P=0.009; HR: 1.59, 95% CI [1.121, 2.251], PFS: 0.77 v 1.43 years, P=0.012; 
HR: 1.548, 95% CI [1.103, 2.174], even when corrected for known clinical (age, extent of resection, 
sex and performance), molecular (1p19qLOH) and histological review diagnosis. There were no 
such differences in the RT-PCV arm. This effect is likely due to difference in patient selection in 
the hospitals but not related to tissue sampling. Of note, at the time of randomization patients 
were stratified per center. Of the included samples, there were no differences in clinical, 
molecular and histological characteristics between the two treatment arms (Supplementary 
Table 1). 
Intrinsic subtypes are prognostic for OS and PFS.
Expression profiling was performed on a total of 140 samples of patients treated within 
EORTC26951. All expression profiles were then assigned to one of six predefined intrinsic 
subtypes. These molecularly-similar ‘intrinsic subtypes’ were identified previously and are 
based on unsupervised gene expression analysis 8. All six intrinsic glioma subtypes were 
identified which shows that patients with different molecular subtypes were enrolled within this 
trial under the same histopathological diagnosis. After assignment IGS-9, IGS-16, IGS-17, IGS-18, 
IGS-22 and IGS-23 contained 50, 2, 26, 27, 8 and 27 patients respectively. These subtypes were 
highly prognostic for both OS and PFS. The median OS for IGS-9, IGS-17, IGS-18 and IGS-23 is 8.5, 
2.8, 1.2 and 1.0 years respectively; and the median PFS 5.7, 1.8, 0.5 and 0.5 years (Figure 1). IGS-16 
and IGS-22 contained too few samples to draw conclusions. The subtype-specific differences 
in survival were highly similar to previously reported differences using FF archival samples and 
confirms the prognostic power of intrinsic subtyping 8. 
In a multivariate analysis, intrinsic subtypes are a significant prognostic factor that is 
independent from clinical (age, sex, performance status and type of surgery), molecular 
(1p19qLOH) and histological (local diagnosis or review diagnosis) parameters (Table 2). When 
IDH1 mutation status is included in this analysis, intrinsic subtyping remains an independent 
Figure 1. Kaplan-Meier survival curves of the four intrinsic glioma subtypes for os and PFs. Overall 
survival (A) and progression free survival (B) of the four major intrinsic glioma subtypes to which the 
patients from EORTC26951 trial were assigned. The four intrinsic glioma subtypes were highly prognostic 
for both OS and PFS as patient prognosis is different for each intrinsic subtype. Only two and eight samples 
were assigned to IGS-16 and IGS-22 respectively (not shown).
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prognostic factor for PFS (P=0.003) but not OS (P=0.052). When MGMT promoter methylation is 
included, intrinsic subtyping remains an independent prognostic factor for both PFS (P<0.0001) 
and OS (P=0.008), though the number of patients analyzed becomes relatively small (n=80). Of 
note, even in the confirmed anaplastic oligodendroglial tumors at central pathology review, 
each histological subtype was found to contain several intrinsic subtypes. Within the AOD and 
AOA review diagnosis, intrinsic subtypes remain an independent prognostic factor.
1p19qLOH was significantly more frequently present in tumors assigned to IGS-9 (29/46, 
63%), compared to IGS-17 (6/25, 24%, P<0.01), 18 (0/26, 0%P<0.001) and IGS-23 (0/25, 0% 
P<0.001), (Figure 2). EGFR amplification was predominantly observed in IGS-18 (14/24, 58%) 
and, to a lesser extent, in IGS-23 (8/21, 38%). EGFR amplification was rarely observed in samples 
assigned to IGS-9 (3/39, 7.6%, P<0.001) and IGS-17 (0/19, 0%, P<0.001). IDH1 mutations were 
predominantly identified in patientsassigned to IGS-9 (23/33, 70%) and IGS-17 (14/22, 64%) 
compared to IGS-18 (2/19, 11%, P<0.001) and IGS-23 (4/21, 19%, P<0.001). MGMT promoter 
methylation was detected at high frequency in samples assigned to IGS-9 (27/28, 96%), and 
at somewhat lower frequencies in IGS-17 (16/20, 80%), IGS-18 (8/13, 62%, P<0.01 compared 
to IGS-9) and IGS-23 (10/13, 77%). This segregation was highly similar to that reported by us 
previously using archival samples and demonstrates that each intrinsic subtype has a different 
set of causal genetic changes 8.
Molecular (IDH1, 1p19qLOH) parameters 24 and intrinsic subtypes are both important 
prognostic factors. To assess the added predictive value of intrinsic subtyping, we combined 
molecular (IDH1, 1p19qLOH) data with intrinsic subtypes and performed an analysis of variance 
for the percentage of survival explained by the two models. Both molecular (IDH1, 1p19qLOH) 
parameters and intrinsic subtypes have similar ability to explain outcome as measured by 
the proportion of explained variation (PEV) (P=0.88) (Supplementary Table 2). However, the 
combined model has a larger PEV (30%) compared to 23% for each individual group of factors. 
A PEV>20% indicates a model providing sufficiently precise survival estimates 25,26. This does not 
mean that both models explain the same variability. Combining them significantly improves the 
power to predict outcome. 
table 2. Multivariate Cox’s regression prognostic analysis of intrinsic subtyping 
Number of observations  126
Number of failures  102
  P-value Hr 95% ci for Hr
Intrinsic subtype 0.002 1.072 1.025 - 1.120
Age 0.002 1.031 1.011 - 1.051
Sex 0.650 0.908 0.598 - 1.378
Type of surgery 0.023 0.685 0.495 - 0.949
Performance status 0.018 1.393 1.059 - 1.832
1p19qLOH 0.001 0.338 0.183 - 0.626
Review diagnosis 0.134 0.792 0.584 - 1.074
Abbreviations: HR: hazard ratio (compared to RT only arm); CI: confidence interval. Calculations are based on 
126 observations.
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6Prediction of benefit from adjuvant PCV
We then evaluated whether the benefit from adjuvant PCV chemotherapy is specific to selected 
intrinsic subtypes. The addition of adjuvant PCV improved OS in samples assigned to IGS-9 
(12.8 years in the RT-PCV arm v 5.5 years in the RT-only arm, P=0.035; HR 2.181, 95% CI[1.057, 
4.502]). An improvement was also observed for PFS (12.8 v 3.6 years, P=0.0018; HR 3.183,95% 
CI[1.537, 6.590]). Data are shown in Figure 3 and Table 3. PCV treatment also improved PFS, but 
not OS, in samples assigned to IGS-18(0.78v0.39 years P=0.028; HR 2.506, 95% CI[1.104, 5.687]). 
A trend towards an increase in both OS and PFS was observed between the two treatment arms 
Figure 2. Genetic differences between intrinsic molecular subtypes of gliomas. Specific genetic 
changes segregate into distinct intrinsic subtypes. 1p19q LOH was predominantly observed in tumors 
assigned to IGS-9 and to a lesser extent in IGS-17 and not seen in tumors assigned to IGS-18 and IGS-23. IDH1 
mutations were significantly more observed in samples assigned to IGS-9 and IGS-17 compared to IGS-18 
and IGS-23. EGFR amplification was predominantly identified in IGS-18 and IGS-23, but rarely identified in 
samples assigned to IGS-9 and IGS-17. Our data strongly suggest that each intrinsic subtype has a different 
set of causal genetic changes.
table 3. Median Overall and Progresson-free survival per treatment arm.
overall survival Progression-free survival
Median survival 
(years)
Hazard ratio, 
[95%ci] P-value
Median survival 
(years)
Hazard ratio, 
95% ci P-value
rt          rt/PcV rt            rt/PcV
IGS-9 5.52             12.77 2.18; [1.067, 4.502] 0.0349 3.62               12.77 3.18; [1.537, 6.590] 0.0018
IGS-17 1.83                5.42 2.21; [0.869, 5.597] 0.0962 1.05                2.21 2.12; [0.847, 5.301] 0.1086
IGS-18 1.13                1.38 1.43; [0.657, 3.123] 0.3669 0.39                0.78 2.51; [1.104, 5.687] 0.0280
IGS-22 1.49                3.19 1.92; [0.413, 8.954] 0.4051 0.88                1.25 3.12; [0.585, 16.600] 0.1829
IGS-23 1.14                0.97 0.89; [0.391, 2.020] 0.7771 0.61                0.49 0.98; [0.444, 2.180] 0.9678
Abbreviations: RT= radiotherapy; RT/PCV= radiotherapy followed by procarbazine, lomustine and vincristine 
chemotherapy.
96
IN
TRIN
SIC
 G
LIO
M
A
 SU
BTY
PES A
RE PRED
IC
TIV
E FO
R RESPO
N
SE TO
 PC
V
6
Figure 3. Kaplan-Meier survival curves of the four intrinsic glioma subtypes per treatment arm. (A) 
shows that adjuvant PCV chemotherapy improved OS and PFS in samples assigned to IGS-9 (B) shows a 
trend towards an increase in both OS and PFS between the two treatment arms in samples assigned to 
IGS-17 (C) Adjuvant PCV also improved PFS, but not OS in samples assigned to IGS-18. (D) No difference 
between the two treatment arms was observed in both OS and PFS in samples assigned to IGS-23. One 
specific intrinsic glioma subtype (IGS-9) seems to benefit from adjuvant PCV chemotherapy whereas 
patients with tumors assigned to IGS-23 do not.
in samples assigned to IGS-17 (OS: 5.42 v 1.82 years, P=0.096; HR 2.205, 95% CI[0.869, 5.597]; 
PFS: 2.21 v 1.05 years, P=0.109; HR 2.119, 95% CI[0.847, 5.301]). No difference in PFS or OS was 
observed between the treatment arms in samples assigned to IGS-23.
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6DISCUSSION
In this study, we have performed intrinsic subtyping within a prospective clinical trial, 
EORTC26951. Our data demonstrate that all six intrinsic glioma subtypes are present in 
EORTC26951, despite the fact that only AODs and AOAs (as diagnosed by the local pathologist) 
were included in this study. After central pathology review, each histological diagnosis still 
contains various intrinsic subtypes. Similarly to reported on archival samples, the intrinsic 
subtypes are an independent prognostic factor both for overall- (OS) and progression-free 
survival (PFS). Combining known molecular (1p19LOH, IDH1) prognostic parameters with 
intrinsic subtypes significantly improves outcome prediction (PEV 30% v 23%). Histological 
classification of gliomas is troublesome and subject to interobserver variation 27. In this study, we 
confirm that expression profiling, compared to the diagnoses made by the local pathologists, 
is a more accurate and objective method to classify gliomas 6-10,28-32. Also similar to reported on 
archival samples, specific genetic changes (IDH1, 1p19qLOH and EGFR amplification) segregate 
into different subtypes. Intrinsic subtypes therefore are not only similar in their RNA expression 
profile, but are also similar on the DNA level in their genetic aberrations. Our data validate 
the prognostic significance of intrinsic subtypes, and therefore can be used to determine the 
molecular heterogeneity of samples included in clinical trials.
As said, clinical trial samples are often of poor quality as most are formalin-fixed and embedded 
in paraffin 11. However, recent technological advances have indicated that expression profiling is 
feasible on FFPE material 12,13,15. Here, we demonstrate for the first time using clinical trial samples 
that FFPE material can be used for gene expression based, intrinsic subtyping of tumors. 
Long term follow up of this trial shows that adjuvant PCV improves OS in AOA and AODs (see 
accompanying paper). Here, we further demonstrate that not all patients benefit equally from 
this treatment. Samples assigned to IGS-9 (characterized by a high percentage of 1p19qLOH 
and IDH1 mutations) significantly benefit from PCV chemotherapy whereas samples assigned 
to IGS-23 do not show any improvement in outcome (neither PFS nor OS). This outcome for 
IGS-9 samples is remarkable as there was a large degree of crossover in the RT-only arm at time 
of progression 20.
Tumors with 1p19qLOH have been reported to show durable responses to chemotherapy 18,19,33. 
Independently, both the EORTC trial 26951 and its North-American counterpart RTOG9402 have 
shown that the addition of PCV to RT improved OS in 1p19q co-deleted oligodendrogliomas 34 
(Cairncross et al, submitted). Our data validate these observations as IGS-9 contains gliomas 
with the highest percentage 1p19qLOH. Moreover, the median survival time between the 
RT-PCV and RT-only arm is highly comparable to the median survival observed in RTOG9402 
(14.7 in the RT-PCV arm v 7.3 years in the RT only arm for the RTOG9402 trial and 12.8 in the 
RT-PCV arm v 5.5 years in the RT only arm for IGS-9 samples in the EORTC26951 trial). It should 
be noted that not all samples assigned to IGS-9 have 1p19qLOH, and that not all samples with 
1p19qLOH are assigned to IGS-9. Differences between the two classification methods should 
therefore be further examined, preferably on a larger cohort of samples. 
Identifying patients that do not benefit from PCV chemotherapy is of equal clinical 
relevance. In our study, samples assigned to IGS-18 or IGS-23 showed no benefit from PCV 
chemotherapy in OS (though an increase in PFS was observed for IGS-18). In RTOG9402, OS is 
not improved by PCV chemotherapy in AODs and AOAs that have retained either 1p and/or 19q. 
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Combined, these data indicate that patients harboring an AOD or AOA that have retained 1p 
and/or 19q, assigned to IGS-18 or IGS-23, do not show a benefit in OS from PCV chemotherapy.
Samples assigned to IGS-17 showed a trend towards improved outcome from PCV 
chemotherapy, both in PFS and OS. IGS-17 contains predominantly tumors that have retained 
1p19q but have IDH1 mutations. A similar trend towards improved outcome was observed in 
the entire EORTC26951 cohort tumors with retained 1p19q and mutated IDH1. Nevertheless, 
our sample cohort is relatively modest in size (140) and our analysis is post hoc (retrospective 
testing) which is hypothesis generating. Therefore our data should be validated in an 
additional independent cohort to firmly establish the predictive effect of these intrinsic 
molecular subtypes.
Interestingly, in a separate clinical trial (EORTC22981/26981) on glioblastoma, patients 
with tumors assigned to IGS-18 also failed to show a marked response to the addition of 
temozolomide to radiotherapy  8,35. In this study too few samples were assigned to other 
subtypes to draw firm conclusions. It should be noted that there are some important 
differences between EORTC26951 and EORTC22981/26981. For example, EORTC22981/26981 
examined the efficacy of temozolomide chemotherapy in combination with radiotherapy as 
opposed to PCV. However, PCV and temozolomide are both alkylating agents with similar 
mechanism of action. Another important difference is the histological subtype investigated: 
only glioblastomas (GBM) were included in EORTC22981/26981 whereas EORTC26951 made 
use of AOD and AOAs. However, intrinsic subtypes have similar molecular and clinical 
characteristics and are independent of histological diagnosis. We therefore hypothesize 
that samples assigned to a defined intrinsic subtype will show similar responses to similar 
chemotherapy regimens regardless of the histological diagnosis. 
In summary, our data demonstrate, on clinical trial samples and using FFPE material, that 
the intrinsic molecular subtypes are highly prognostic for OS and PFS. Our data also indicates 
that at least one intrinsic subtype of glioma responds favorably to PCV chemotherapy. 
Intrinsic subtypes are easily determined and therefore this approach provides a novel, 
straightforward and promising way to improve outcome prediction, also when combined 
with other prognostic factors.
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DISCUSSION
Molecular profiling
At present, treatment of gliomas is based on the histological typing and grading, with 
treatment paradigms based on large clinical studies using histological entry criteria. The 
histological typing and grading based on morphological similarities with similar outcome 
is however, especially in diffuse glioma, far from perfect with a classification that is subject 
to inter-observer variation 1-2. Slowly however, it has become clear that the presence or 
absence of specific molecular abnormalities contain much more information on the outcome 
of patients as compared to the classical histological diagnosis. Theoretically, a classification 
based on molecular abnormalities will be more rational, as tumors will be lumped based on the 
mechanism of the disease and not just on the phenotype that is the result of both genotype 
and environmental circumstances. Potentially, this may lead to more specific treatments, 
especially once the treatment is aimed at specific molecular alterations. Such a personalized 
medicine approach holds promise for a more rational treatment that may avoid both over and 
under treatment of tumors. Still, even in the absence of molecularly targeted approaches, 
classical treatment (e.g. with chemotherapy) may be more effective in certain molecularly 
defined subgroups. 
In this thesis several methods of the molecular profiling of gliomas have been investigated. 
The studies presented in this thesis demonstrate results of profiling using genome-wide 
expression analysis, methylation analysis, genotyping and by using additional specific molecular 
features such as IDH1 mutation, EFGR amplification, LOH of 1p19q, KIAA1549-BRAF, as well as 
FISH (to determine tetraploidy) 3-4. 
In chapter 1, we describe an RNA expression profiling study of a large series of snap frozen 
gliomas. This study was the first large unsupervised analysis which included all histological 
glioma subtypes, and showed an improved predictive effect on survival of tumor clustering 
based on expression analysis as compared to classical histology. A fundamental observation 
in this study was, that tumors with similar histologies were assigned to different clusters, 
suggesting that tumors with seemingly similar morphologic features may have completely 
different molecular backgrounds 3. Similarly, genome-wide methylation analysis of a series of 
anaplastic oligodendroglial tumors showed that this approach divided the tumors basically 
in two entities: those tumors that have a CpG Island Hypermethylated Phenotype (CIMP), 
and those without that phenotype 5. Moreover, tumors with a CIMP status had a much better 
prognosis. A similar widespread CpG island methylation phenomenon has been described in 
other tumors as well (leukemia, colorectal cancers), and was in these diseases also related 
to outcome. 
Still, that any of these techniques in itself also has limitations became clear from one of 
the RNA expression clusters, which contained both pilocytic astrocytomas (PA) (very favorable 
prognosis) and glioblastoma (GBM) (poor prognosis). Here, further analysis looking at 
chromosome copy numbers using SNP arrays showed a clear difference between these groups 
of tumors. This shows that any single technique may fail to distinguish between relevant glial 
subtypes, and warns against a too enthusiastic welcome for these novel tools. 
In the initial expression analysis of a glioma repository as described in chapter 1 we used 
snap frozen tissue samples. That has a major drawback however, as in many patients only 
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value of molecular based diagnostics, assays that can use FFPE to predict outcome to specific 
treatments are pivotal. We therefore analyzed whether expression analysis using RNA from 
FFPE material is possible. In chapter 2, we analyzed in a series of 55 tumors the correlation 
between expression analysis using snap frozen material and FFPE from the same surgery  6. 
In these paired samples a good correlation between expression analysis on snap frozen 
tumor samples and on FFPE samples was observed. This opens a whole new window in glioma 
research, since this implies FFPE material can be used to correlate treatment responses to 
the specific molecular subtypes as defined by RNA expression analysis. The possible role of 
expression analysis on FFPE and its relation to treatment outcome was further investigated 
on tumor material from patients that were included in multi-centered prospective phase 
III randomized controlled trial. This analysis using tumor specimens that were at least ten 
years old suggests that molecular subtypes as determined by RNA expression analysis may 
indeed respond differently to specific treatment protocols. This is a fascinating result, as 
the clinical trial was performed on a histologically homogeneous group of tumors, Even 
within those cases in which the oligodendroglial histology had been confirmed centrally, 
expression analysis of FFPE revealed major differences which were found to correlate with 
clinical outcome. 
This is obviously just the beginning, and at present not without limitations. Our studies 
have been performed retrospectively. Before they can be implemented in daily practice, 
both the prognostic and the predictive value of the molecular clusters must be validated in 
new prospective and properly controlled studies. In addition, the differences in treatment 
response between the clusters must be validated in independent datasets treated with 
similar regimens. Indeed, well defined classical treatments may be more effective in specific 
molecularly defined subtypes that are based on RNA expression, and a realistic scenario is 
that for each molecular subtype an optimal treatment paradigm is developed, even in the 
absence of molecularly targeted treatments. Ideally, specific molecular aberrations within 
the molecular clusters should be mechanistically linked to prognosis and treatment response. 
Although as expected, specific genetic aberrations are segregating into the molecular 
clusters, none of these are that specific and exclusive that it can be used for assignment to a 
specific molecular cluster. 
A relevant clinical question is whether the more comprehensive expression analysis 
(e.g., RNA expression, methylation profiling) contributes to assessment of specific, single, 
molecular abnormalities. In our series, analysis shows that the combination of molecular 
profiling using RNA expression and the determination of specific biomarkers such as IDH1, 
MGMT and LOH of 1p19q improves the prognostic and predictive value compared to using 
these profiling techniques separately. And importantly, the combination of these molecular 
profiling techniques gives a more accurate prognosis than histological classification. This also 
implies that expression analysis has added value to the basic of any of the more specific genetic 
aberrations. It also warns against placing too much confidence into one single technique or 
marker.
In conclusion, when validated in prospective studies, the molecular glioma profiles can 
be used to give patients the most accurate information about their diagnosis, prognosis, and 
treatment possibilities.
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Molecular biomarkers
As stated above, within the molecular glioma profiles identified, specific genetic aberrations 
and gene (co) expression signatures were seen, which supports the hypothesis that these 
molecularly defined glioma subtypes are fundamentally different. The individual molecular 
biomarkers investigated were all useful in improving diagnosis, prognosis and/or treatment 
strategy in comparison to classical histology alone. In this discussion we will further focus on 
several specific molecular biomarkers that are at present clinically relevant for adult patients 
with diffuse gliomas or GBMs. More sophisticated assays need to show added clinical value as 
compared to these markers. 
IDH1
In 2008, Parsons et al. identified mutations in a gene encoding isocitrate dehydrogenase (IDH1) 
in a subset (12%) of GBM samples 7. These mutations result in a reduced enzymatic activity towards 
the native substrate, isocitrate, and mutant IDH1catalyses the formation of 2-hydroxyglutarate 
(2HG) from a-ketoglutarate. Mutations in a homologous gene, IDH2, have also been 
identified, although they occur sporadically. The occurence of IDH1 and IDH2 mutations 
is mutually exclusive. The IDH1 mutations were most common in young patients with GBMs 
that had progressed from low-grade gliomas to secondary GBMs. Subsequently, other studies 
showed much higher frequencies (60-80%) of the IDH1 mutation in lower grade gliomas  7-10. 
Interestingly, the IDH1 mutations are detected in only a few tumor types: diffuse gliomas, acute 
myeloid leukemia (AML), in central and periosteal cartilaginous tumours and in intrahepatic 
cholangiocarcinoma  11-13. Sporadic mutations have been described in paragangliomas, 
pheochromocytomas, prostate carcinomas, and in a colon cancermetastasis  14-16. In gliomas, a 
very high prevalence (60-80%) of IDH1 mutations is found in diffuse low grade (grade II and III) 
gliomas and secondary gliomas. Since IDH1 mutations are rare in primary GBMs, IDH1 mutation 
status can help to distinguish between primary and secondary GBMs as well as in differentiating 
anaplastic (grade III) gliomas from GBMs. Also they can be used to distinguish diffuse gliomas 
from pilocytic astrocytomas (PA), since IDH1 mutations are virtually absent in the latter.
IDH1 mutations are associated both with the TP53 mutations and with LOH of 1p19q. 
Interestingly, TP53 mutations and LOH of 1p19q are mutually exclusive in glioma, occurring in 
astrocytomas and oligodendroglial tumors respectively. Therefore, a combination of testing 
these molecular markers can be used to differentiate between different glioma subtypes. 
In this thesis we showed that the IDH1 mutations are correlated with certain molecular 
profiles with a relatively good prognosis. The co-existence of IDH1 and either TP53 or LOH of 
1p19q in tumors was confirmed in our studies, as one expression cluster harbored gliomas with 
high frequencies of both IDH1 and LOH of 1p19q, while another other gliomas with both IDH1 
mutation and TP53 mutation were assigned to another cluster. 
There are several different hot spot mutations within the IDH1 gene. There is a some 
preponderance of IDH mutations for specific molecular glioma subtypes, confirming the 
genetic differences between the various subgroups 17. For example, the most common hot spot 
mutation (p.R132H) was found in gliomas with LOH of 1p19q, while non-p.R132H mutations were 
seen in gliomas harboring a TP53 mutation. This supports the hypothesis that the different IDH1 
mutations may cause different changes in different tumor pathways. The current data support 
the use of IDH1 and its mutational subtypes as a marker to identify glioma subtypes. 
107
7IDH1 is presumed to play a role in the early tumorigenesis, but the exact pathogenetic 
mechanism of the IDH1 mutation in gliomas remains unknown until now 18. Functional analysis 
of the R132H mutation showed a decreased proliferation in vitro as in vivo if introduced in a 
glioblastoma like cell line. A similar analysis of the non-132H mutations could reveal differences 
in proliferation rate between the mutational subtypes 19. If there are differences found between 
the mutational subtypes, this would be an explanation why the mutational IDH1 subtypes 
segregate into specific glioma subtypes.
Further studies have shown that mutated IDH1 inhibits histone demethylases and TET 
5-methylcytosine hydroxylases, leading to genome-wide histone and DNA methylation 
alterations 20. This finding reveals a relationship between the presence of IDH1 mutations and 
a hypermethylated tumor profile, including MGMT methylation. This “epigenetic control” 
function of the IDH1 mutation could be one of the first important events in the development 
of gliomas. Inhibition of the epigenetic effects of the IDH1 mutation, for example by trying to 
reduce the 2HG production, and/or by administration of mimic a-ketoglutarate could serve as 
a targeted therapy in IDH1 mutated tumors.
Several studies have analyzed the prognostic and predictive value of the IDH1 mutations 10,21-23. 
These studies conclude that there is a correlation in grade III tumors with prognosis, but any 
predictive effects on treatment response has not been shown yet. If a predictive effect can be 
shown in the future, the question is whether this is an effect of a specific metabolic change 
caused by IDH1 mutations, or a secondary effect by inducing (MGMT) methylation . As stated 
earlier, determination of the IDH1 mutation status can help to distinguish between the different 
subtypes of gliomas, and when histological morphology and/or other clinical factors give 
inconclusive information about the diagnosis. For examples, a recent study showed that all 
patients aged over sixty, diagnosed with an anaplastic astrocytoma lacking an IDH1 mutation, 
actually had an outcome that resembled outcome of GBM patients. This raises the question 
whether patients should be treated accordingly. Analysis of IDH status also allowed the 
distinction between reactive gliosis and tumor 23. 
Since IDH1 mutation status can give us valuable prognostic and diagnostic information in 
such cases, we recommend the determination of the IDH1 mutation status to be implemented 
in clinical practice.
MGMT and methylation profiling
O6-methylguanine-DNA methyltransferase (MGMT) is a DNA repair enzyme that is highly 
associated with resistance to alkylating and methylating agents (e.g., temozolomide, 
nitrosourea’s). The MGMT gene product reverses the alkylation caused by this type of 
chemotherapy, and thereby reduces the toxic effect. Epigenetic silencing of the MGMT 
gene by methylation of the CpG island located in the promoter region reduces the DNA-
repair function of the MGMT gene, and thereby induces an improved effect on alkylating 
chemotherapy. In the late nineties, the potential predictive value of MGMT protein levels in 
glioma patients was first described, and in 2000 the prognostic effect of MGMT methylation 
in BCNU treated GBM patients was shown by Esteller et al. 20. Five years later, Hegi et al. 
showed that MGMT methylation was predictive for response to additional temozolomide 
in GBM patients treated with radiotherapy. This confirmed the hypothesis that MGMT 
methylation predicts benefit from alkylating chemotherapies. This is further supported by 
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data from the German NOA-8 study, that suggest that in elderly glioblastoma patients the 
choice between RT and temozolomide should primarily be determined by MGMT status 24. To 
complicate this straight forward assumption, recent studies showed that MGMT promoter 
methylation in anaplastic gliomas is prognostic irrespective of initial treatment with 
radiotherapy or alkylating chemotherapy  25-29. This raises the question whether in grade III 
glioma MGMT promoter methylation isn’t merely an epiphenomenon of other biomarkers 
and/or part of a more general genome wide methylated profile. In the study presented in 
this thesis, we identified two main subgroups of oligodendroglial brain tumors by whole 
genome methylation profiling 30. The survival of the patients with a hypermethylated profile 
(CIMP+) was significantly better than the survival of the unmethylated (CIMP-) subgroup. 
CIMP+ status was seen almost exclusively in the molecular clusters with a favorable prognosis 
(also characterized by 1p-19q co-deletion and IDH mutations). As already mentioned in the 
section about IDH1, it is now assumed that IDH1 mutations induce genome wide methylation. 
In our study, the CIMP+ status indeed was highly associated with the IDH1 mutation status, 
In addition, the strong association between CIMP status and MGMT promoter methylation 
confirms the hypothesis that the MGMT promoter methylation status is part of a more general, 
prognostically favorable genome wide methylation profile. In future experiments, genes that 
are epigenetically altered in different glioma subtypes should be functionally analyzed to see 
whether they play a role in tumor formation, or may be a predictor of prognosis, and/or be 
predictive for response to therapy. 
LOH 1p19q
LOH of 1p19q was identified as the specific chromosomal lesion of oligodendroglioma by 
Reifenberger et al.31. Subsequently, Cairncross and Louis noted that this co-deletion predicted 
response to PCV chemotherapy in recurrent anaplastic oligodendrogliomas 32. Although initial 
reports of large randomized phase III trials failed to show that co-deletion of 1p/19q identifies 
newly diagnosed anaplastic oligodendroglial patients that benefit from adjuvant PCV, it clearly 
can serve as a prognostic marker in oligodendroglial tumors. However, very recent results 
of long term follow-up of these studies showed that LOH of 1p19q is predictive for treatment 
response in case of adjuvant chemotherapy (PCV) 33-34 Thus, the determination of 1p/19q status 
has now immediate therapeutic consequences. 
In this thesis we show that tumors that are assigned to molecular Cluster 9, regardless 
of their histological diagnosis, frequently show LOH of 1p19q and have a relatively good 
prognosis. Our data show that molecular profiling of gliomas (using RNA expression profiling 
and the determination of LOH 1p19q) identifies more patients with a relatively good prognosis 
than when only oligodendroglial tumors as determined by morphology are analyzed for 1p/19q 
loss. We would therefore propose as standard of care to determine the LOH 1p19q status in all 
tumors with oligodendroglial features . This identifies a subset of patients with a much better 
prognosis than their histological diagnosis would predict.
In 2011, inactivating mutations of the FUBP1 gene (chromosome 1p) and the CIC gene 
(chromosome 19q) were shown to be present in a substantial fraction of ODs with LOH of 
1p19q 35. Functional analysis of these genes is required to provide insights into the pathogenesis 
of these tumors, and to improve methods currently used for their diagnosis, prognosis, and 
treatment.
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KIAA1549-BRAF is an oncogenic fusion gene which was first described in 2008 by Jones 
et  al.  36-37. The mutation was specifically found in pilocytic astrocytomas. Korshunov et al. 
showed that combined analysis of IDH1 mutation status and for the KIAA1549-BRAF fusion gene 
could be used for distinguishing pilocytic astrocytomas from diffuse astrocytomas 38. IDH1 was 
exclusively seen in the diffuse astrocytomas, as the BRAF fusion gene was exclusive for pilocytic 
astrocytomas. In this thesis we showed that tumors with pilocytic features are all assigned to 
one specific molecular cluster, thereby sharing the same RNA expression profile. However, 
while sharing the same expression profile, these tumors segregated into two different entities, 
showing a dramatic difference in survival. All tumors harboring the BRAF fusion gene, regardless 
of their histological diagnosis, were long-term survivors. This illustrates that , a combination of 
different molecular profiling techniques can help to distinguish good-prognostic tumors from 
poor-prognostic tumors. In addition, these molecular biomarkers improve on genome wide 
profiling for this specific molecular cluster. Because of this strong prognostic and diagnostic 
value, we recommend all gliomas with pilocytic features (pilocytic morphology, located in the 
fossa posterior, young age at diagnosis) to be analyzed for the presence of the KIAA1549-BRAF 
fusion gene. 
EGFR mutation and amplification occurs in a distinct subset of gliomas. They are typically 
associated with GBMs . This could enable clinicians to refine histologic diagnosis in ambiguous 
cases. In this thesis, we confirmed that EGFR mutations only occurred in molecular clusters with 
poor prognosis.
The prognostic and predictive relevance of EGFR amplification and EGFRvIII mutation in 
GBMs remains controversial. The EGFR vIII mutation is the most common mutation of the EGFR 
receptor in GBMs. Because this genetic aberration is not found in normal tissue, it is a potential 
target for tumor-specific therapy. In 2005, it was suggested that coexpression of EGFRvIII by 
glioblastoma cells and PTEN is associated with responsiveness to EGFR kinase inhibitors  39. 
However, trials using EGFR tyrosine kinase inhibitors (erlotinib, imatinib and gefitinib) all had 
low response results even in subgroups that showed EGFRvIII variant and PTEN expression 40-42. 
Until now, there is not enough evidence to use EGFR as a prognostic or predictive marker in 
clinical practice.
The future of molecular profiling
In the past, classification of gliomas has been based on histopathological findings. In the near 
future, molecular profiling on various levels will become more and more important in addition 
to glioma morphology. Pathologists will have the possibility to make a selection of biomarkers 
which they can use to make the most accurate tumor classification. Biomarkers such as IDH1, 
LOH of 1p19q, MGMT, but also more comprehensive assays such as RNA expression profiling 
and methylation profiling could be useful to establish the most accurate diagnosis, to make a 
prediction of the prognosis and to determine the best treatment. The role of these markers to 
tailor treatments on the molecular profile of the tumor requires large prospective randomized 
trials to assess predictive value of specific markers. Preferably, analysis of these markers should 
be part of the prospective trial design, as post hoc analysis of identified markers are likely to 
remain on the level of exploratory subgroup analysis. 
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In the near future, we expect that next generation sequencing will make a large contribution 
to the profiling of gliomas. The exact single-base level information will provide more detailed 
insights in the tumorigenesis, and the specific genetic differences of the molecular glioma 
subtypes will lead to a further optimization of treatment.
The significance of the mutations found need however to be functionally analyzed in vitro 
and in vivo. Only then, these genetic data may also allow developing novel therapies to target 
vulnerable points embedded within the genetic blueprint of gliomas. This targeted therapy 
is currently a dream for the future of all cancer treatment. However, it remains a sobering 
fact that, until now, there are only few therapies available. Resection, radiation and classical 
chemotherapy have been the most important pillars for glioma treatment for decades, on which 
all clinical trials have been built. At present molecular assays may allow a more rational choice 
for of in particular chemotherapy, but we still use old treatment paradigms . The identification 
of new targets and the development of targeted therapies will take many more years before 
those can be implemented in daily practice. Which will be the only way to significantly improve 
the overall outcome of brain tumor patients .
Nowadays, large multi-centered networks such as The Cancer Genome Atlas (TCGA) 
are collecting large-scale data to provide a basis of complex diseases on a great variety of 
molecular levels  43. Especially in glioma, which represent a relatively small group of tumors, 
these extensive data sets allow researchers to investigate gliomas on a large scale. This will 
increase the possibilities of the identification new biomarkers and –more importantly- new 
targets and new treatments. That will be the only way to significantly improve outcome.
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Gliomas are the most common primary brain tumors in adults. Although improvements in 
treatment possibilities, almost every patient diagnosed with this tumor is facing a fatal disease. 
Currently, the diagnosis of gliomas is based on the histological morphology. This classification 
system discriminates between three distinct subtypes: astrocytomas (A), oligodendrogliomas 
(OD), and mixed oligoastrocytomas (OA). These subtypes are further separated into grades 
I to IV, with grade IV, the glioblastoma (GBM), being the most aggressive subtype. Prognosis 
and treatment decisions are strongly related to the histological subtype. Unfortunately, this 
histological classification is often difficult and subject to a lot of interobserver-variation. This 
can cause inaccuracy in diagnosis, prognosis and treatment decisions. Our hypothesis in this 
thesis was that molecular profiling of gliomas would provide a more objective and accurate 
classification system of gliomas.
In chapter 1 we describe the identification of seven intrinsic glioma clusters, which were 
indentified using whole genome expression profiling. The clustering was unsupervised, and 
all histological glioma subtypes were included in the study. The results showed that the seven 
clusters identified were a significant better predictor of prognosis than histology. Two clusters 
were a predictor of poor prognosis (median survival 0.67 and 0.68 years), two cluster were 
a predictor of intermediate prognosis (median survival 1.12 and 3.32 years), and two clusters 
predicted a favorable prognosis compared to the other clusters (median survival 6.06 and >4.7 
years). Several distinct genetic aberrations segregate into specific clusters. IDH1 mutations 
were specific for clusters with an intermediate prognosis including one cluster that was 
enriched for secondary GBMs and one of the clusters with good prognosis. LOH of 1p19q was 
specifically seen in one of the favorable prognostic clusters, and amplification of EGFR was seen 
in the clusters predicting a poor prognosis. 
All results were validated and confirmed in three large external datasets, thereby confirming 
our molecular cluster is a robust clustering method. We concluded that the intrinsic subtypes 
identified improve on histological classification of gliomas and are an accurate predictor of 
prognosis. Molecular classification can contribute to diagnosis and may form a rationale for 
clinical decision making and novel targeted therapies.
To see whether specific clusters show different responses to therapy, we require to analyze 
material of patients who were included in large randomized phase III trials. Unfortunately, 
tissue from these trials are most often formalin-fixed paraffin-embedded (FFPE) material. 
RNA isolated from FFPE material is notorious for being degraded and chemically modified. In 
chapter 2 we analyzed whether it is possible to reproduce our molecular clustering using RNA 
isolated from FFPE material. We used matched FFPE material of patients that were included in 
the study described in chapter 1. Affymetrix HuEx 1.0 “Exon” arrays were used as a platform to 
analyze the expression of RNA isolated from FFPE material. Our molecular clustering showed 
a reproducibility of ~85%. These results show that molecular profiling can be performed using 
RNA from FFPE which opens the possibility of using FFPE material from phase III clinical trials. 
In low grade gliomas mutations in the IDH1 gene are frequently seen. The R132H mutation is 
the most frequent mutation within this gene. Nevertheless, other point mutations do occur on 
the same position (non-p.R132H mutations e.g. p.R132C). chapter 3 describes the segregation 
of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma. We showed that 
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with LOH of 1p and 19q and accumulate in distinct (gene-expression profiling based) intrinsic 
molecular subtypes. The IDH1 mutation type does not affect patient survival. Our results were 
validated on an independent sample cohort, indicating that the IDH1 mutation spectrum may 
aid glioma subtype classification. Functional differences between p.R132H and non-p.R132H 
mutated IDH1 may explain the segregation in distinct glioma subtypes.
In chapter 4 another molecular profiling method is described, based on whole genome 
methylation profiling. Methylation is the addition of methyl groups to cytosines, which often 
ultimately results in inactivation of the gene. Methylation can occur in tumor suppressor genes 
and so may contribute to tumor formation. We performed genome wide methylation profiling 
on a series of oligodendroglial tumors within EORTC 26951. The series was expanded with tumors 
of the same histology and treatment from our own archive. Methylation profiling identified 
two main subgroups of which survival in the hypermethylated phenotype (CIMP+)” subgroup 
was markedly better than the survival of the unmethylated (CIMP-) subgroup. CIMP status 
correlated with survival, MGMT promoter methylation, 1p19q LOH and IDH1 mutation status. 
CIMP status strongly increases the predictive accuracy of survival in a model including known 
clinical prognostic factors such as age and performance score. We validated our results on an 
independent dataset from the cancer genome atlas (TCGA). The strong association between 
CIMP status and MGMT promoter methylation suggests that the MGMT promoter methylation 
status is part of a more general, prognostically favorable genome wide methylation profile. 
Methylation profiling therefore may help identify AODs and AOAs with improved prognosis.
In chapter 5 we described the molecular features of one particular cluster, Cluster 16 that 
contained all pilocytic astrocytomas (PAs). PAs have a good prognosis after resection of the 
tumor. However, within this molecular cluster, the PAs cluster together with glioma subtypes of 
higher grades. Remarkably, although these tumors that shared a similar molecular profile, PAs 
and non-PAs showed a dramatic difference in survival. The pathology reports showed that all 
gliomas within this cluster were characterized as having pilocytic features. Genotyping of these 
tumors resulted in two marked observations. We demonstrated that Cluster 16 marks tumors 
with long term survival (without signs of tumor progression), regardless of their histological 
subtype. Second, Cluster 16 marks tumors with poor survival that are near tetraploid. We are the 
first to identify this near tetraploid subtype of gliomas and it is likely that this subtype requires 
its own treatment paradigm. These two results were confirmed in independent external 
datasets. Our findings have major consequences for the patients that have been diagnosed with 
a histologically malignant glioma subtype, but who can be identified as a long-term survivor 
using these molecular profiling techniques. Based on the results we recommend all gliomas 
with pilocytic features, or tumors that are assigned to Cluster 16, to be molecularly analyzed 
on the presence of the KIAA1549-BRAF fusion gene and/or a tetraploid karyotype. Using this 
genetic information, the prognosis of the patient can be predicted accurately.
In chapter 6 we performed expression profiling on samples of a large European phase 3 
controlled trial (EORTC 26951) to evaluate the possible different treatment responses of the 
molecular subgroups identified in chapter 1. Both fresh frozen and paraffin embedded glioma 
material was analyzed, using the platforms and clustering methods for FF and FFPE material as 
described in chapter 1 and chapter 2 respectively. We found that all six glioma subtypes could 
be identified within the anaplastic oligodendrogliomas included in the EORTC 26951 trial. All 
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these molecular subtype were highly prognostic for progression free survival, as for overall 
survival. Also, the specific subtypes showed different treatment responses. Especially cluster 9 
showed to have a beneficial response to adjuvant PCV chemotherapy. With this study, we show 
that the intrinsic molecular glioma subtypes are both prognostic and predictive.
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Gliomen zijn de meest voorkomende primaire hersentumoren bij volwassenen. Ondanks 
verbeteringen in behandelingsmogelijkheden, hebben vrijwel alle patienten met dit type 
tumor een ongeneeselijke ziekte. Op dit moment wordt de diagnose van gliomen gebaseerd 
op de histologische morfologie. Dit classificatie systeem onderscheidt 3 verschillende subtypen: 
astrocytomen (A), oligodendrogliomen (OD), en gemengde oligoastrocytomen (OA). Deze 
subtypen worden verder onderscheiden met behulp van gradering (graad I-IV), waarbij graad IV, 
het glioblastoom (GBM), het meest aggressieve subtype is. De prognose en de behandeling van 
de patient is sterk gerelateerd aan het het histologische subtype. Helaas is het indelen van gliomen 
met behulp van de histologische classificatie vaak moeilijk en onderhevig aan veel interobserver 
variabiliteit. Dit kan een onnauwkeurig beeld geven van de diagnose en de prognose, en kan 
zorgen voor een suboptimale behandelingsstrategie. Onze hypothese bij het schrijven van 
dit proefschrift was dat door middel van het maken van moleculaire profielen in gliomen, een 
objectievere en nauwkeurigere classificatie van gliomen zou kunnen worden gecreëerd. 
In Hoofdstuk 1 beschrijven we zeven intrinsieke groepen (clusters) van gliomen, die 
werden geïdentificeerd op basis van de expressie van alle genen in het genoom (whole genome 
expression profiling). De clustering was niet gesuperviseerd, en alle histologische subtypes 
van gliomen werden geïncludeerd in de studie. De resultaten lieten zien dat de zeven clusters 
een significant betere voorspelling gaven van de prognose ten opzichte van de histologische 
classificatie. Twee clusters waren voorspellend voor een slechte prognose (mediane overleving 
0.67 en 0.68 jaar), twee clusters waren voorspellend voor een gemiddelde prognose (mediane 
overleving 1.12 en 3.32 jaar), en 2 clusters voorspelden een relatief goede prognose vergeleken 
met de andere clusters (6.06 en >4.7 jaar). Eén van deze goede prognostische clusters omvatte 
vrijwel alle pilocytaire astrocytomen (PA; graad 1) die in de studie waren geïncludeerd. Aan een 
ander cluster waren alle controle samples en alle tumor samples toegewezen die veel niet-
neoplastisch materiaal bevatten. Een aantal genetische afwijkingen waren specifiek voor de 
verschillende clusters. IDH1 mutaties werden specifiek gezien in de clusters met een gemiddelde 
of een goede prognose, waaronder ook een cluster waar veel secundaire glioblastomen in 
zaten. Verlies van 1p19q werd specifiek gezien in één van de clusters met een goede prognose, 
en amplificatie van EGFR werd gezien in de clusters met een slechte prognose.
Alle resultaten werden gevalideerd en bevestigd in drie grote externe datasets, waardoor 
werd bevestigd dat onze moleculaire clustering een robuuste manier is om gliomen van elkaar 
te onderscheiden. We concludeerden dat de geïdentificeerde groepen een verbetering zijn ten 
opzichte van de histologische classificatie van gliomen en dat zij een nauwkeurige voorspeller 
zijn van de prognose. Moleculaire classificatie kan bijdragen aan het stellen van een diagnose 
en zou een rol kunnen spelen bij het maken van klinische beslissingen, en bij het ontwikkelen 
van nieuwe, op specifieke tumortypes gerichte therapieën.
Om te zien of de specifieke clusters verschillend reageren op behandeling, moeten we 
tumor materiaal analyseren van patiënten die zijn geïncludeerd in grote gerandomiseerde fase 
3 trials. Helaas zijn deze trials bijna allemaal uitgevoerd door het gebruik van tumor materiaal 
dat is gefixeerd in paraffine (FFPE). RNA dat wordt geïsoleerd uit FFPE materiaal staat er om 
bekend dat het is afgebroken en chemische veranderingen heeft ondergaan, in tegenstelling 
tot RNA dat is geïsoleerd uit vers ingevroren tumor materiaal (FF).
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RNA te gebruiken dat is geïsoleerd uit FFPE materiaal. We hebben FFPE materiaal gebruikt 
van dezelfde patiënten waarvan het FF materiaal is gebruikt in Hoofdstuk 1. Affymetrix HuEx 
1.0 “Exon” arrays worden gebruikt als platform om de expressie van de het RNA uit het FFPE 
materiaal te analyseren. De moleculaire clustering kon in ongeveer 85% van de tumor samples 
gereproduceerd worden. Deze resultaten laten zien dat het maken van moleculaire profielen 
kan worden uitgevoerd met gebruik van RNA dat is geïsoleerd uit FFPE materiaal, wat de 
mogelijkheid creëert om FFPE materiaal uit grote fase 3 studies te gebruiken. 
In laaggradige gliomen worden zeer vaak mutaties in het IDH1 gen gezien. De meest 
voorkomende mutatie in dit gen is de R132H mutatie. Desalniettemin komen er ook andere 
puntmutaties voor op dezelfde positie (non-p.R132H mutaties, bijvoorbeeld p.R132C). 
Hoofdstuk 3 beschrijft het voorkomen van non-p.132H mutaties in het IDH1 gen in specifieke 
moleculaire subtypen van gliomen. Wij hebben laten zien dat non-p.R132H mutaties 
voorkomen in gliomen die ook een TP53 mutatie hebben, en dat de non-p.132H mutaties vrijwel 
altijd afwezig zijn in tumoren met verlies van 1p19q. De tumoren met een non-p.132H mutatie 
groeperen zich in specifieke moleculaire subtypen. Het type IDH1 mutatie heeft geen invloed 
op de overlevingsduur van patiënten. Onze resultaten zijn gevalideerd op een onafhankelijke 
dataset, en laten zien dat het de verschillende IDH1 mutaties mogelijk kunnen bijdragen aan de 
classificatie van tumoren in de moleculaire subtypes. Functionele verschillen tussen de p.R132H 
en de non-p.R132H mutaties zouden kunnen verklaren waarom de verschillende mutaties 
optreden in verschillende moleculaire clusters.
In Hoofdstuk 4 wordt een andere moleculaire methode beschreven om profielen van gliomen 
te maken. Deze methode is gebaseerd op het maken van profielen door naar de methylatie 
van het genoom te kijken. Methylatie is de toevoeging van methylgroepen aan cytosinen, wat 
vaak resulteert in deactivatie van een gen. Methylatie kan voorkomen in tumor suppressor 
genen en kan zo bijdragen aan tumorvorming. Wij hebben methylatie profielen gemaakt van 
een serie olidodendrogliale tumoren uit de EORTC 26951 studie. Deze serie is uitgebreid met 
oligodendrogliale tumoren die dezelfde behandeling hadden ondergaan uit ons eigen archief. 
Door het maken van methylatie profielen werden 2 hoofdgroepen onderscheiden, een groep 
met veel methylatie (CIMP+), en een groep met weinig methylatie (CIMP-). In de CIMP+ groep 
was de overleving opmerkelijk langer dan in de CIMP- groep. CIMP status correleerde dus met 
overleving, maar ook met MGMT promotor methylatie, met verlies van 1p19q en met IDH1 
mutaties. De CIMP status verbeterde de nauwkeurigheid van het voorspellen van de overleving 
van patiënten aanzienlijk, wanneer het werd gebruikt in een model waarin de bekende klinische 
factoren zoals leeftijd en de Karnofsky Performance Score werden meegenomen. We hebben 
onze resultaten gevalideerd op een onafhankelijke dataset van de Cancer Genome Atlas (TCGA). 
De sterke associatie tussen de CIMP status en de MGMT promotor methylatie suggereert dat de 
MGMT promotor methylatie onderdeel is van een meer algemeen, genome-wide methylatie 
profiel, dat prognostisch beter is. Het maken van glioom profielen door het bepalen van de 
methylatie status kan bijdragen aan het identificeren van anaplastische oligodendrogliomen en 
anaplastische oligoastrocytomen met een goede prognose.
In Hoofdstuk 5 beschrijven we de moleculaire kenmerken van een specifiek cluster, Cluster 
16, dat alle pilocytaire astrocytomen (PAs) die in de studie voorkwamen bevatte. Patienten met 
een PA hebben een goede prognose na resectie van de tumor. Opmerkelijk genoeg clusterden 
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deze PAs samen met gliomen met een hogere histologische graad. Ondanks dat ze hetzelfde 
moleculaire profiel deelden, lieten de PAs en de niet-PAs een dramatisch verschil in overleving 
zien. De pathologie verslagen van deze tumoren lieten zien dat alle gliomen in dit specifieke 
cluster werden gekenmerkt door het hebben van morfologische pilocytaire kenmerken. Het 
genotyperen van deze tumoren resulteerden in 2 opvallende observaties.
We hebben aangetoond dat Cluster 16 tumoren bevat met een lange overleving (zonder 
tekenen van tumor progressie), niet gerelateerd aan het histologische subtype en de graad van 
de tumoren. Alle tumoren van patiënten met een lange overleving hadden het KIAA1549-BRAF 
fusie gen. Ten tweede bevat Cluster 16 tumoren met een zeer korte overleving, die allemaal 
tetraploid zijn. Zo’n tetraploide subgroep is nooit eerder beschreven in gliomen en het is 
waarschijnlijk dat deze groep een eigen behandelingsstrategie vereist.
Deze resultaten werden bevestigd in onafhankelijke externe datasets.
Onze bevindingen kunen grote consequenties hebben voor patiënten die zijn 
gediagnosticeerd met een histologisch kwaadaardig glioom subtype, die kunnen worden 
geïdentificeerd als een lange-overlever met behulp van deze moleculaire technieken. Wij 
adviseren op basis van deze resultaten alle gliomen die pilocytaire kenmerken hebben en/of 
toegewezen zijn aan Cluster 16 moleculair te onderzoek op de aanwezigheid van het KIAA1549-
BRAF fusie gen en/of op de aanwezigheid van een tetraploïd karyotype. Met behulp van deze 
genetische informatie kan de prognose an patiënten nauwkeuriger worden bepaald.
In Hoofdstuk 6 hebben we expressie profielen gemaakt van tumor samples die 
geíncludeerd waren in een grote Europese fase 3 gecontroleerde trial (EORTC 26951), om te 
zien of de moleculaire clusters die we identificeerden in Hoofdstuk 1 verschillend reageren op 
behandeling met radio- en/of chemotherapie. Zowel FF als FFPE materiaal werd geïncludeerd, 
waarbij er gebruik werd gemaakt van de verschillende platformen en clustering methoden zoals 
beschreven in Hoofdstuk 1 en 2. Alle zes de glioom clusters konden worden geïdentificeerd in 
de groep tumoren uit de EORTC 26951 studie, waarin alleen anaplastische oligodendrogliale 
tumoren waren geïncludeerd. Alle moleculaire subtypen hadden een grote prognostische 
waarde voor zowel progressie-vrije overleving als voor algehele overleving. Tevens reageerden 
de specifieke subtypes anders op verschillende vormen van behandeling.
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A Astrocytoma
AA Anaplastic astrocytoma
AML Acute myeloid leukemia 
AOA Anaplastic oligoastrocytoma
AOD  Anaplastic oligodendroglioma
BAC Bacterial artificial chromosome
CBTRUS Central Brain Tumor Registry of the United States
CCNU Lomustine
CIMP CpG island methylator phenotype
DABG Detection Above BackGround
DASL cDNA-mediated Annealing, Selection, Extension, and Ligation 
DNA Deoxyribonucleic acid
ECOG Eastern Cooperative Oncology Group
EGFR Epidermal growth factor receptor
EORTC European Organisation for Research and Treatment of Cancer
FDR False discovery rate
FF Fresh frozen
FFPE Formalin-fixed paraffin-embedded
FISH Fluorescence in situ hybridization
GBM Glioblastoma
GSEA Gene set enrichment analysis
HOPACH Hierarchical ordered partitioning and collapsing hybrid
IDH1 Isocitrate dehydrogenase 1 gene
IDH2 Isocitrate dehydrogenase 2 gene
IGP In-group proportion
KPS Karnofsky performance score
LOH Loss of heterozygosity
MGMT O-6-methylguanine-DNA methyltransferase
MOA Mixed oligoastrocytoma
MS-MLPA methylation-specific multiplex ligation-dependent probe amplification
OA Oligoastrocytoma
OD  Oligodendroglioma
OS Overall survival
PA Pilocytic astrocytoma
PCR Polymerase chain reaction
PCV Procarbazine, Lomustine, and Vincristine chemotherapy
PFS Progression free survival
REMBRANDT Repository for Molecular Brain Neoplasia Data 
RIN score RNA integrity number score
RMA Robust Multi-array Average
RNA Ribonucleic acid
RT  Radiotherapy
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&SNP Single-nucleotide polymorphism
TCGA The Cancer Genome Atlas
TMZ Temozolomide
WHO World Health Organization
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